Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
27600.0 | 2013-05-22 00:00:00 UTC | Positive Data on Roche Candidate - Analyst Blog | ABBV | https://www.nasdaq.com/articles/positive-data-on-roche-candidate-analyst-blog-2013-05-22 | nan | nan | Roche ( RHHBY ) recently announced positive data on its ulcerative colitis (UC) candidate, etrolizumab (RG7413), from EUCALYPTUS, a phase II induction study (n=124).
The study is evaluating the efficacy and safety of etrolizumab for the treatment of moderate-to-severely active ulcerative colitis.
The study met its primary endpoint of clinical remission at week 10. Roche observed that patients suffering from moderate-to-severely active UC treated with etrolizumab showed significantly higher rates of clinical remission compared to placebo at week 10.
Moreover, it was observed that etrolizumab was well tolerated without any significant safety concerns.
According to the press release issued by Roche, approximately 0.9 million people suffer from UC in the US and Western Europe. Hence, the successful development and commercialization of etrolizumab bodes well for Roche given the sales potential.
However, the course might not be easy for Roche given the existing stiff competition. We note that Shire ( SHPG ) already has approved drugs like Lialda in the US for the treatment of patients with mild to moderately active UC.
Lialda was one of the best selling drugs for Shire in the first quarter of 2013 driven by an increased market share in the US.
Moreover, AbbVie 's ( ABBV ) Humira was approved by the European Commission and US Food and Drug Administration (FDA) in 2012 for the treatment of moderate to severe UC in adult patients, who responded inadequately to conventional therapy.
Nevertheless, we continue to be encouraged with the recent pipeline progress at Roche. Earlier in the month, Roche released positive initial results on its oncology candidate, obinutuzumab (GA101), from CLL11, a phase III study.
In addition, Roche obtained FDA approval for Tarceva (erlotinib) for the first-line treatment of patients suffering from metastatic non-small cell lung cancer.
Roche currently carries a Zacks Rank #3 (Hold). Right now, Salix Pharmaceuticals ( SLXP ) looks attractive with a Zacks Rank #1 (Strong Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ROCHE HLDG LTD (RHHBY): Get Free Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
SALIX PHARM-LTD (SLXP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Moreover, AbbVie 's ( ABBV ) Humira was approved by the European Commission and US Food and Drug Administration (FDA) in 2012 for the treatment of moderate to severe UC in adult patients, who responded inadequately to conventional therapy. ABBVIE INC (ABBV): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report To read this article on Zacks.com click here. Roche ( RHHBY ) recently announced positive data on its ulcerative colitis (UC) candidate, etrolizumab (RG7413), from EUCALYPTUS, a phase II induction study (n=124). | ABBVIE INC (ABBV): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, AbbVie 's ( ABBV ) Humira was approved by the European Commission and US Food and Drug Administration (FDA) in 2012 for the treatment of moderate to severe UC in adult patients, who responded inadequately to conventional therapy. Roche ( RHHBY ) recently announced positive data on its ulcerative colitis (UC) candidate, etrolizumab (RG7413), from EUCALYPTUS, a phase II induction study (n=124). | ABBVIE INC (ABBV): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, AbbVie 's ( ABBV ) Humira was approved by the European Commission and US Food and Drug Administration (FDA) in 2012 for the treatment of moderate to severe UC in adult patients, who responded inadequately to conventional therapy. Roche ( RHHBY ) recently announced positive data on its ulcerative colitis (UC) candidate, etrolizumab (RG7413), from EUCALYPTUS, a phase II induction study (n=124). | Moreover, AbbVie 's ( ABBV ) Humira was approved by the European Commission and US Food and Drug Administration (FDA) in 2012 for the treatment of moderate to severe UC in adult patients, who responded inadequately to conventional therapy. ABBVIE INC (ABBV): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report To read this article on Zacks.com click here. Roche ( RHHBY ) recently announced positive data on its ulcerative colitis (UC) candidate, etrolizumab (RG7413), from EUCALYPTUS, a phase II induction study (n=124). |
27601.0 | 2013-05-21 00:00:00 UTC | JNJ's Simponi Label Expanded - Analyst Blog | ABBV | https://www.nasdaq.com/articles/jnjs-simponi-label-expanded-analyst-blog-2013-05-21 | nan | nan | Johnson & Johnson's ( JNJ ) recently gained approval from the US Food and Drug Administration (FDA) for the expansion of Simponi's label. The FDA granted Simponi approval for the treatment of adults with moderately to severely active ulcerative colitis (UC) in case of corticosteroid dependence or when the patients have not responded sufficiently to or are intolerant to oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine.
This label expansion makes Simponi the first and only subcutaneously administered anti-tumor necrosis factor (TNF)-alpha therapy to gain approval for the induction and maintenance of clinical response and improvement of endoscopic appearance of the mucosa during induction.
As per the Crohn's & Colitis Foundation of America, about 700,000 people in the US suffer from UC.
Simponi is already approved for several indications like the treatment of moderate to severe rheumatoid arthritis (RA) with methotrexate, active psoriatic arthritis alone or with methotrexate and active ankylosing spondylitis in adults.
We believe Simponi, which posted sales $607 million in 2012 (up 48%), has blockbuster potential - approval for the UC indication should boost sales further.
Johnson & Johnson's Remicade is also approved for the treatment of moderately to severely active UC. Other treatments include AbbVie's ( ABBV ) Humira.
Johnson & Johnson currently carries a Zacks Rank #3 (Hold). While we expect Johnson & Johnson to continue facing headwinds in the form of pricing pressure, manufacturing issues, US healthcare reform and weak medical devices segment performance, we believe the diversified business model, lack of cyclicality, strong financial position will continue helping the company pave its way through tough situations.
Companies that currently look well-positioned include Salix Pharmaceuticals, Ltd. ( SLXP ) and Santarus, Inc. ( SNTS ). Both are Zacks Rank #1 (Strong Buy) stocks.
ABBVIE INC (ABBV): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
SALIX PHARM-LTD (SLXP): Free Stock Analysis Report
SANTARUS INC (SNTS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other treatments include AbbVie's ( ABBV ) Humira. ABBVIE INC (ABBV): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report SANTARUS INC (SNTS): Free Stock Analysis Report To read this article on Zacks.com click here. The FDA granted Simponi approval for the treatment of adults with moderately to severely active ulcerative colitis (UC) in case of corticosteroid dependence or when the patients have not responded sufficiently to or are intolerant to oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine. | ABBVIE INC (ABBV): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report SANTARUS INC (SNTS): Free Stock Analysis Report To read this article on Zacks.com click here. Other treatments include AbbVie's ( ABBV ) Humira. The FDA granted Simponi approval for the treatment of adults with moderately to severely active ulcerative colitis (UC) in case of corticosteroid dependence or when the patients have not responded sufficiently to or are intolerant to oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine. | ABBVIE INC (ABBV): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report SANTARUS INC (SNTS): Free Stock Analysis Report To read this article on Zacks.com click here. Other treatments include AbbVie's ( ABBV ) Humira. The FDA granted Simponi approval for the treatment of adults with moderately to severely active ulcerative colitis (UC) in case of corticosteroid dependence or when the patients have not responded sufficiently to or are intolerant to oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine. | Other treatments include AbbVie's ( ABBV ) Humira. ABBVIE INC (ABBV): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report SANTARUS INC (SNTS): Free Stock Analysis Report To read this article on Zacks.com click here. Johnson & Johnson's ( JNJ ) recently gained approval from the US Food and Drug Administration (FDA) for the expansion of Simponi's label. |
27602.0 | 2013-05-15 00:00:00 UTC | Mason Hawkins Gives Mickey Mouse the Boot, First Quarter Sells in Review | ABBV | https://www.nasdaq.com/articles/mason-hawkins-gives-mickey-mouse-boot-first-quarter-sells-review-2013-05-15 | nan | nan | Demonstrating once again that emotion can never get in the way of investing decisions, Guru Mason Hawkins of Southeastern Asset Management determined in the first quarter of 2013 that, as the Mickey Mouse Club once sang, "Now it's time to say goodbye." Hawkins let go of Mickey Mouse and other timeless icons of entertainment when he sold out his long-held stake in Walt Disney Co., as well as seven more companies.
Here's a review of the southern gentleman activist's sells as of March 31, 2013:
Sold Out: Walt Disney Co. ( DIS ) - Entertainment
Mason Hawkins sold out his long-time Disney holding, selling 18,216,229 shares at an average price of $54.48 for a 23.8% gain. GuruFocus shows his 20 consecutive quarters of gains trading DIS shares, with the highest gain of 252.7% in the first quarter of 2009.
This trade impacts his portfolio by -4%.
The current share price is $67.47.
DIS data by GuruFocus.com
His holding history:
Sold Out: Willis Group Holdings PLC ( WSH ) - Brokers & Exchanges
Hawkins also had a long-term relationship of positive gains with WSH, starting in the second quarter of 2008, with 20 consecutive quarters of trading since that time. The trading history shows that Hawkins has always gained on this holding, with no losses. The first quarter of 2009 was his highest gaining quarter for 78.8%. Selling out 5,462,500 shares in the first quarter of 2013 at an average price of $36.53, he made a 13% gain. This trade impacts his portfolio by -0.8%.
Sold Out: AbbVie Inc. ( ABBV ) - Pharmaceutical
First buying AbbVie Inc. in the fourth quarter of 2012, Mason Hawkins sold out his ABBV holding in the first quarter of 2013, selling 6,000 shares at an average price of $37.02 for a 22.2% gain. The current share price is $45.23.
Sold Out: General Motors ( GM ) - Autos
Another short-timer stock: Hawkins first bought GM for 28,000 shares in the fourth quarter of 2012 at the average price of $25.20, for a 25.2% gain. Mason Hawkins sold out his GM holding, selling 28,000 shares at an average price of $28.41 for an 11.1% gain. This trade impacts his portfolio by -0.0035%.
The current share price is $31.55.
GM data by GuruFocus.com
Sold Out: Microsoft Corporation ( MSFT ) - Application Software
Another short-timer stock: Hawkins first bought MSFT for 51,295 shares in the fourth quarter of 2012 at the average price of $27.96, for an 18.8% gain. Mason Hawkins sold out his Microsoft holding in the first quarter of 2013, selling 51,295 shares at an average price of $27.69 for a 20% gain. This trade impacts his portfolio by -0.006%.
The current share price is $33.23.
MSFT data by GuruFocus.com
Sold Out: American International Group Inc. ( AIG ) - Insurance
Mason Hawkins also sold out his position with AIG, a position he had initiated in the first quarter of 2012, buying 20,600 shares at an average price of $27.11 for a 68.8% gain. When Hawkins sold out his remaining 80,075 shares at $37.65 per share, he saw a gain of 21.5%. This trade impacts his portfolio by -0.012%.
Sold Out: Potlatch Corp. ( PCH ) - REITs
Mason Hawkins sold out his PCH position as of first quarter 2013, selling off 1,365,200 shares at $43.72 per share for a 13.3% gain.
Sold Out: Franklin Resources Inc. ( BEN ) - Asset Management
Mason Hawkins sold out his BEN position as of first quarter 2013, selling off a little more than 4 million shares at $140.91 per share for a 15.7% gain. His highest gain was in the fourth quarter of 2011 when he first bought 1,097,393 shares at an average price of $99.60, making a 64.1% gain. This trade impacts his portfolio by -2.2%.
Guru Mason Hawkins has been the chairman and CEO of Southeastern Asset Management since 1975, and he and his partners manage the Longleaf Partners Funds. The Southeastern Asset Management portfolio currently lists 37 stocks and a total value of $22.2 billion, with a quarter-over-quarter turnover of 4%.
Here is a summary of activity at Southeastern Asset Management:
If you are not yet a Premium Member, we invite you for a7-day Free Trial.
Use the GuruFocus Value Screen to find52-Week Lowsand discover potentially deep value stocks held by billionaire Guru investors.
GuruFocus "Real Time Picks" reports the stock purchases and sales that Gurus have made within the prior 2 weeks. The report time lag can be as short as 2 days after the date of the transaction. This feature is for Premium Members only.
GuruFocus'Score Board of Gurusshows which investors produced the largest average returns in the past 6 and 12 months, as well as on a historical basis. About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Sold Out: AbbVie Inc. ( ABBV ) - Pharmaceutical First buying AbbVie Inc. in the fourth quarter of 2012, Mason Hawkins sold out his ABBV holding in the first quarter of 2013, selling 6,000 shares at an average price of $37.02 for a 22.2% gain. Demonstrating once again that emotion can never get in the way of investing decisions, Guru Mason Hawkins of Southeastern Asset Management determined in the first quarter of 2013 that, as the Mickey Mouse Club once sang, "Now it's time to say goodbye." Hawkins let go of Mickey Mouse and other timeless icons of entertainment when he sold out his long-held stake in Walt Disney Co., as well as seven more companies. | Sold Out: AbbVie Inc. ( ABBV ) - Pharmaceutical First buying AbbVie Inc. in the fourth quarter of 2012, Mason Hawkins sold out his ABBV holding in the first quarter of 2013, selling 6,000 shares at an average price of $37.02 for a 22.2% gain. Here's a review of the southern gentleman activist's sells as of March 31, 2013: Sold Out: Walt Disney Co. ( DIS ) - Entertainment Mason Hawkins sold out his long-time Disney holding, selling 18,216,229 shares at an average price of $54.48 for a 23.8% gain. GM data by GuruFocus.com Sold Out: Microsoft Corporation ( MSFT ) - Application Software Another short-timer stock: Hawkins first bought MSFT for 51,295 shares in the fourth quarter of 2012 at the average price of $27.96, for an 18.8% gain. | Sold Out: AbbVie Inc. ( ABBV ) - Pharmaceutical First buying AbbVie Inc. in the fourth quarter of 2012, Mason Hawkins sold out his ABBV holding in the first quarter of 2013, selling 6,000 shares at an average price of $37.02 for a 22.2% gain. Sold Out: Potlatch Corp. ( PCH ) - REITs Mason Hawkins sold out his PCH position as of first quarter 2013, selling off 1,365,200 shares at $43.72 per share for a 13.3% gain. Sold Out: Franklin Resources Inc. ( BEN ) - Asset Management Mason Hawkins sold out his BEN position as of first quarter 2013, selling off a little more than 4 million shares at $140.91 per share for a 15.7% gain. | Sold Out: AbbVie Inc. ( ABBV ) - Pharmaceutical First buying AbbVie Inc. in the fourth quarter of 2012, Mason Hawkins sold out his ABBV holding in the first quarter of 2013, selling 6,000 shares at an average price of $37.02 for a 22.2% gain. Selling out 5,462,500 shares in the first quarter of 2013 at an average price of $36.53, he made a 13% gain. Mason Hawkins sold out his Microsoft holding in the first quarter of 2013, selling 51,295 shares at an average price of $27.69 for a 20% gain. |
27603.0 | 2013-05-14 00:00:00 UTC | Dodge & Cox Buys Kraft and AbbVie | ABBV | https://www.nasdaq.com/articles/dodge-cox-buys-kraft-and-abbvie-2013-05-14 | nan | nan | Classic value investors Dodge & Cox scour markets for the best bargains, and in the first quarter, they found only two to their liking: Kraft Foods Group Inc. ( KRFT ) and AbbVie Inc. ( ABBV ). Their $81.34 billion portfolio experienced a 3% quarter-over-quarter turnover and ended the quarter with 163 holdings.
Last year, Dodge & Cox returned 22% to investors in its Stock Fund, though it is near even with the market over the past 10 years, with a 102.4% cumulative return compared to 99.7% for the S&P500. Long term, over the past 15 years, it performed much better, returning 191.7% cumulatively, compared to 93.8% for the index.
The New Buys
Dodge & Cox bought 3,946 shares of Kraft Foods Group Inc. ( KRFT ) in the first quarter for $48 per share on average. They expended just $203,000 for this 0.0002% portfolio weighting. Kraft shares have increased 14% from the average purchase price to date.
Kraft Foods, a North American grocery business, was spun off of Mondelez International Inc., an international snack foods business, in October 2012. Dodge & Cox has 11,840 shares of Mondelez International Inc. ( MDZ ), a 0.0004% portfolio weighting.
Kraft Foods Group Inc. has a market cap of $32.46 billion; its shares were traded at around $54.77 with a P/E ratio of 20.20 and P/S ratio of 1.80. The dividend yield of Kraft Foods Group Inc. stocks is 1.80%.
The larger new buy is AbbVie Inc. ( ABBV ) . Dodge & Cox bought 37,865 shares of the company for $37 per share on average, giving it a 0.0019% portfolio weighting. AbbVie shares gained 22% since from the average purchase price.
AbbVie is a pharmaceutical company working on advanced therapies in HUMIRA, metabolic, virology, endocrinology, dyslipidemia and many other areas. Abbvie Inc. has a market cap of $70.59 billion; its shares were traded around $45.35 with a P/E ratio of 13.60 and P/S ratio of 3.80. The dividend yield of Abbvie Inc. stocks is 1.80%.
See Dodge & Cox's portfolio here. Also check out the Undervalued Stocks, Top Growth Companies and High Yield stocks of Dodge & Cox.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Classic value investors Dodge & Cox scour markets for the best bargains, and in the first quarter, they found only two to their liking: Kraft Foods Group Inc. ( KRFT ) and AbbVie Inc. ( ABBV ). AbbVie is a pharmaceutical company working on advanced therapies in HUMIRA, metabolic, virology, endocrinology, dyslipidemia and many other areas. The larger new buy is AbbVie Inc. ( ABBV ) . | Classic value investors Dodge & Cox scour markets for the best bargains, and in the first quarter, they found only two to their liking: Kraft Foods Group Inc. ( KRFT ) and AbbVie Inc. ( ABBV ). The larger new buy is AbbVie Inc. ( ABBV ) . AbbVie shares gained 22% since from the average purchase price. | Classic value investors Dodge & Cox scour markets for the best bargains, and in the first quarter, they found only two to their liking: Kraft Foods Group Inc. ( KRFT ) and AbbVie Inc. ( ABBV ). The larger new buy is AbbVie Inc. ( ABBV ) . AbbVie shares gained 22% since from the average purchase price. | Classic value investors Dodge & Cox scour markets for the best bargains, and in the first quarter, they found only two to their liking: Kraft Foods Group Inc. ( KRFT ) and AbbVie Inc. ( ABBV ). The larger new buy is AbbVie Inc. ( ABBV ) . AbbVie shares gained 22% since from the average purchase price. |
27604.0 | 2013-05-07 00:00:00 UTC | Merck's Liptruzet Approved in the US - Analyst Blog | ABBV | https://www.nasdaq.com/articles/mercks-liptruzet-approved-in-the-us-analyst-blog-2013-05-07 | nan | nan | Merck ( MRK ) recently gained US Food and Drug Administration (FDA) approval for its combination cholesterol treatment, Liptruzet. The FDA granted approval to Liptruzet for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.
Liptruzet is basically a combination of two drugs - Merck's Zetia (ezetimibe) and Pfizer's ( PFE ) Lipitor (atorvastatin). While ezetimibe will help inhibit the absorption of cholesterol in the digestive tract, atorvastatin will inhibit the production of cholesterol in the liver.
However, Liptruzet is yet to show any additional benefit compared to Lipitor where cardiovascular morbidity and mortality are concerned.
We note that Merck has another Zetia/statin combination in its portfolio in the form of Vytorin. Vytorin is a combination of Zetia and Zocor (simvastatin). Merck's cardiovascular franchise currently consists of Vytorin and Zetia. While Zetia sales increased 5.7% to $2.6 billion in 2012, Vytorin sales declined 7.2% to $1.7 billion.
Merck has entered a challenging period with erstwhile blockbuster drug, Singulair, losing exclusivity in the US as well as the EU. With Singulair and a few other products facing generic competition, we expect the top- and bottom-line to remain under pressure. Other headwinds remain in the form of unfavorable currency movement and pipeline setbacks.
Merck has another FDA decision coming up later this year. The company, which submitted an NDA for its insomnia candidate - suvorexant, should receive a response from the FDA regarding the approvability of the candidate in mid-13.
Once it is approved, the Drug Enforcement Administration (DEA) will assess and assign the schedule for the drug before it is launched.
Suvorexant belongs to a new class of medicines called orexin receptor antagonists which target and block orexins. However, we note that the insomnia market is highly competitive and genericized especially given the presence of generic versions of Sanofi's ( SNY ) Ambien.
Merck, Pfizer and Sanofi are all Zacks Rank #3 (Hold) stocks. Currently, AbbVie ( ABBV ) looks attractive with a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Currently, AbbVie ( ABBV ) looks attractive with a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Merck ( MRK ) recently gained US Food and Drug Administration (FDA) approval for its combination cholesterol treatment, Liptruzet. | ABBVIE INC (ABBV): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, AbbVie ( ABBV ) looks attractive with a Zacks Rank #2 (Buy). Merck ( MRK ) recently gained US Food and Drug Administration (FDA) approval for its combination cholesterol treatment, Liptruzet. | ABBVIE INC (ABBV): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, AbbVie ( ABBV ) looks attractive with a Zacks Rank #2 (Buy). Merck ( MRK ) recently gained US Food and Drug Administration (FDA) approval for its combination cholesterol treatment, Liptruzet. | Currently, AbbVie ( ABBV ) looks attractive with a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Merck ( MRK ) recently gained US Food and Drug Administration (FDA) approval for its combination cholesterol treatment, Liptruzet. |
27605.0 | 2013-05-06 00:00:00 UTC | Bayer Discontinues Hemophilia Study - Analyst Blog | ABBV | https://www.nasdaq.com/articles/bayer-discontinues-hemophilia-study-analyst-blog-2013-05-06 | nan | nan | Bayer 's ( BAYRY ) HealthCare segment recently decided to discontinue the phase II/III TRUST (TReatment with Unique recombinant rFVIIa STudy) study on BAY 86-6150. The study was evaluating the efficacy and safety of the candidate in patients suffering from hemophilia A or hemophilia B with inhibitors.
Bayer stated that a neutralizing antibody was detected during the course of the study. Since patient safety was the primary objective of the study, the company discontinued the BAY 86-6150 trial as a precautionary measure.
Bayer already has Kogenate in its product portfolio for the treatment of haemophilia. The drug generated around €1.2 billion in revenues during 2012. Bayer also has BAY 94-9027 (rFVIII mutein) in its pipeline targeting hemophilia A. The candidate is currently in phase III development.
We note that companies like Biogen Idec Inc. ( BIIB ) are also developing therapies targeting the hemophilia market.
Bayer was recently in the news when it inked a deal to buy Conceptus Inc. ( CPTS ) for $31.00 per share or approximately $1.1 billion in cash. Bayer intends to launch a public tender soon to acquire all shares of Conceptus. The transaction is expected to close by mid-2013.
Bayer's impending acquisition of Conceptus will add the Essure permanent (non-surgical) birth control system to its product portfolio. We note that Conceptus' Essure procedure was approved in 2002 in the US and is well accepted in the market.
Bayer, a large cap pharma company, presently carries a Zacks Rank #4 (Sell). Other large cap pharma companies such as Abbvie Inc. ( ABBV ) currently look more attractive. Abbvie carries a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
CONCEPTUS INC (CPTS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other large cap pharma companies such as Abbvie Inc. ( ABBV ) currently look more attractive. Abbvie carries a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CONCEPTUS INC (CPTS): Free Stock Analysis Report To read this article on Zacks.com click here. | ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CONCEPTUS INC (CPTS): Free Stock Analysis Report To read this article on Zacks.com click here. Other large cap pharma companies such as Abbvie Inc. ( ABBV ) currently look more attractive. Abbvie carries a Zacks Rank #2 (Buy). | ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CONCEPTUS INC (CPTS): Free Stock Analysis Report To read this article on Zacks.com click here. Other large cap pharma companies such as Abbvie Inc. ( ABBV ) currently look more attractive. Abbvie carries a Zacks Rank #2 (Buy). | Other large cap pharma companies such as Abbvie Inc. ( ABBV ) currently look more attractive. Abbvie carries a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CONCEPTUS INC (CPTS): Free Stock Analysis Report To read this article on Zacks.com click here. |
27606.0 | 2013-05-06 00:00:00 UTC | Good News for Bristol-Myers - Analyst Blog | ABBV | https://www.nasdaq.com/articles/good-news-for-bristol-myers-analyst-blog-2013-05-06 | nan | nan | Bristol-Myers Squibb Company ( BMY ) recently received positive news from the US Food and Drug Administration (FDA) when the US regulatory authority approved the pharma major's HIV drug Sustiva for treating children between three months and three years. The body weight of the children should not exceed 3.5 kilograms.
The approval provides a once-daily option as part of a regimen for HIV infected children between three months and three years. Moreover, the "capsule sprinkle" administration procedure is beneficial for children who cannot swallow capsules or tablets.
We note that Sustiva is already approved for treating HIV infected patients aged three years and above and weighing not less than 10 kilograms. The FDA decision has expanded the patient population for Sustiva. This will boost the drug's sales potential.
The FDA decided to expand the patient population for Sustiva on the basis of data from three open-label studies, which evaluated the pharmacokinetics, safety and antiretroviral activity of the drug combined with other antiretroviral agents in 182 antiretroviral-naïve and - experienced patients infected with HIV. The studies evaluated patients aged between three months and 21 years for a median of 123 weeks.
The FDA's decision to broaden Sustiva's target population is encouraging for Bristol-Myers, which has entered a challenging phase following the genericization of Plavix. Plavix, co-developed with Sanofi ( SNY ), went off patent in the US in May 2012. The drug's genericization has resulted in the loss of significant revenues for Bristol-Myers.
Bristol-Myers is looking to combat the challenges confronting it through partnering deals and acquisitions and introducing new products to augment its product portfolio.
Bristol-Myers, a large cap pharma stock, carries a Zacks Rank # 3 (Hold). AbbVie (ABBV ) appears to be more favorably placed in the large cap pharma space with a Zacks Rank # 2 (Buy). Meanwhile, CelgeneCorporation ( CELG ) too carries a Zacks Rank # 2.
ABBVIE INC (ABBV): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (ABBV ) appears to be more favorably placed in the large cap pharma space with a Zacks Rank # 2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Sustiva is already approved for treating HIV infected patients aged three years and above and weighing not less than 10 kilograms. | ABBVIE INC (ABBV): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV ) appears to be more favorably placed in the large cap pharma space with a Zacks Rank # 2 (Buy). Bristol-Myers Squibb Company ( BMY ) recently received positive news from the US Food and Drug Administration (FDA) when the US regulatory authority approved the pharma major's HIV drug Sustiva for treating children between three months and three years. | ABBVIE INC (ABBV): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV ) appears to be more favorably placed in the large cap pharma space with a Zacks Rank # 2 (Buy). Bristol-Myers Squibb Company ( BMY ) recently received positive news from the US Food and Drug Administration (FDA) when the US regulatory authority approved the pharma major's HIV drug Sustiva for treating children between three months and three years. | AbbVie (ABBV ) appears to be more favorably placed in the large cap pharma space with a Zacks Rank # 2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Sustiva is already approved for treating HIV infected patients aged three years and above and weighing not less than 10 kilograms. |
27607.0 | 2013-05-06 00:00:00 UTC | Positive Opinion on Allergan Candidate - Analyst Blog | ABBV | https://www.nasdaq.com/articles/positive-opinion-on-allergan-candidate-analyst-blog-2013-05-06 | nan | nan | Allergan, Inc. ( AGN ) recently received encouraging news when the US Food and Drug Administration's (FDA) General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee unanimously recommended the approval of Juvéderm Voluma XC.
The company is looking to get Juvéderm Voluma XC, its injectable hyaluronic acid dermal filler, approved for cheek augmentation to correct age-related volume deficit in the mid-face.
Although the FDA is not bound to accept the recommendation of the advisory panel it does pay heed when reviewing new drug applications. The company noted that if approved Juvéderm Voluma XC will be the first and only dermal filler in the US for the above mentioned indication. The company expects to launch the drug in late 2013.
A few days back Allergan reported first quarter 2013 earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. While earnings increased 18.1% from the year-ago quarter, revenues increased 8.3% to $1,459.6 million, above the Zacks Consensus Estimate of $1,443 million. Allergan now expects 2013 earnings of $4.70 - $4.76 per share as compared to the previous guidance of $4.75 - $4.83 per share. The latest guidance includes the impact of the acquisition of MAP Pharmaceutical.
Allergan currently carries a Zacks Rank #3 (Hold). Stocks that look better positioned at present include AbbVie ( ABBV ) and Onyx Pharmaceuticals, Inc. ( ONXX ). Both the stocks carry a Zacks Rank #2 (Buy). Isis Pharmaceuticals, Inc. ( ISIS ) also looks well-positioned with a Zacks Rank #1 (Strong Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
ISIS PHARMACEUT (ISIS): Free Stock Analysis Report
ONYX PHARMA INC (ONXX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks that look better positioned at present include AbbVie ( ABBV ) and Onyx Pharmaceuticals, Inc. ( ONXX ). ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report To read this article on Zacks.com click here. Allergan, Inc. ( AGN ) recently received encouraging news when the US Food and Drug Administration's (FDA) General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee unanimously recommended the approval of Juvéderm Voluma XC. | Stocks that look better positioned at present include AbbVie ( ABBV ) and Onyx Pharmaceuticals, Inc. ( ONXX ). ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report To read this article on Zacks.com click here. Allergan, Inc. ( AGN ) recently received encouraging news when the US Food and Drug Administration's (FDA) General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee unanimously recommended the approval of Juvéderm Voluma XC. | ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks that look better positioned at present include AbbVie ( ABBV ) and Onyx Pharmaceuticals, Inc. ( ONXX ). Allergan, Inc. ( AGN ) recently received encouraging news when the US Food and Drug Administration's (FDA) General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee unanimously recommended the approval of Juvéderm Voluma XC. | Stocks that look better positioned at present include AbbVie ( ABBV ) and Onyx Pharmaceuticals, Inc. ( ONXX ). ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report To read this article on Zacks.com click here. Allergan, Inc. ( AGN ) recently received encouraging news when the US Food and Drug Administration's (FDA) General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee unanimously recommended the approval of Juvéderm Voluma XC. |
27608.0 | 2013-05-03 00:00:00 UTC | AbbVie pullback draws bullish action | ABBV | https://www.nasdaq.com/articles/abbvie-pullback-draws-bullish-action-2013-05-03 | nan | nan | AbbVie pulled back yesterday, but the bulls quickly jumped in.
optionMONSTER's Heat Seeker monitoring system detected the purchase of 14,500 August 47.50 calls for $1.05 and the sale of an equal number of August 40 puts for $0.80. Volume was more than 5 times the previous open interest at each strike, indicating that new money was put to work.
The investor paid $0.25 to open the position and now stands to profit from stock gains in the drug maker, which was spun off from Abbott Laboratories on Jan. 1. The long calls will appreciate and the puts sold short will lose value should shares push higher, while the opposite will happen to the downside.
The benefit of the strategy is that it provides inexpensive long exposure to the stock, while programming a buy order on a drop to $40. (See our Education section for more on how options can be used to manage trades.)
ABBV is down 3.42 percent to $43.99 yesterday but is up 29 percent so far this year. It's been climbing along with other pharmaceutical names and as the company blends existing medicines in hope of curing Hepatitis-C. It fell yesterday after Gilead Sciences raced ahead in the competition to launch a cure for the disease, which infects hundreds of millions of people globally.
Total option volume in ABBV was 4 times greater than average in yesterday's session.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright © 2010 OptionMonster® Holdings, Inc. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie pulled back yesterday, but the bulls quickly jumped in. ABBV is down 3.42 percent to $43.99 yesterday but is up 29 percent so far this year. Total option volume in ABBV was 4 times greater than average in yesterday's session. | Total option volume in ABBV was 4 times greater than average in yesterday's session. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie pulled back yesterday, but the bulls quickly jumped in. | Total option volume in ABBV was 4 times greater than average in yesterday's session. AbbVie pulled back yesterday, but the bulls quickly jumped in. ABBV is down 3.42 percent to $43.99 yesterday but is up 29 percent so far this year. | AbbVie pulled back yesterday, but the bulls quickly jumped in. Total option volume in ABBV was 4 times greater than average in yesterday's session. ABBV is down 3.42 percent to $43.99 yesterday but is up 29 percent so far this year. |
27609.0 | 2013-05-03 00:00:00 UTC | Earnings Plummet, Outlook Maintained at Sanofi - Analyst Blog | ABBV | https://www.nasdaq.com/articles/earnings-plummet-outlook-maintained-at-sanofi-analyst-blog-2013-05-03 | nan | nan | Sanofi ( SNY ) reported first quarter 2013 business earnings of 81 cents per American Depository Share (ADS), below the Zacks Consensus Estimate of 89 cents. Earnings were down 29.0% at constant exchange rates (CER) from the year-ago period.
First quarter net sales decreased 5.3% on a reported basis and 2.8% at CER. The strong performance of growth platforms was more than offset by generic competition.
Segmental Performance
Sanofi operates through the following segments: Pharmaceuticals, Human Vaccines and Animal Health. All growth rates mentioned below are on a year-on-year basis and at CER.
Pharmaceutical segment sales decreased 4.4% to €6.8 billion. Weaker revenues were primarily due to generic competition (€553 million) and European pricing pressure. The diabetes franchise (up 19.6% to €1.5 billion) continued to perform well with growth driven by Lantus (up 21.3% to €1.3 billion). Apidra sales went up 30.8% to €66 million in the first quarter of 2013.
We note that several of Sanofi's key products are facing generic competition. In the first quarter of 2013, Eloxatin sales nosedived 84.6% to €59 million due to generic competition. The product went off patent in the US on Aug 9, 2012.
Generic competition also affected Plavix revenues, down 5.0% to €450 million and Aprovel/Avapro/Karvea/Avalide revenues, down 20.8% to €241 million. We remind investors that Plavix and Avapro went off patent in the US in May 2012 and Mar 2012, respectively.
Lovenox (down 17.7% to €428 million) also performed disappointingly due to generic competition in the US.
Newly launched multiple sclerosis drug, Aubagio, generated sales of €20 million in the first quarter of 2013 as compared to €7 million in fourth quarter 2012.
Genzyme sales increased 25.5% to €493 million. Cerezyme sales increased 16.8% to €171 million. Myozyme/Lumizyme sales increased 4.5% to €116 million.
Fabrazyme sales were €92 million, up 100% benefiting from patients switching to Fabrazyme from Shire 's ( SHPG ) Replagal.
Sales in the consumer health care business climbed 3.1% to €811 million. In Jan 2013, Sanofi acquired worldwide rights of an over-the-counter antacid Rolaids from McNeil Consumer Healthcare, a subsidiary of Johnson and Johnson ( JNJ ).
Rolaids, initially launched in 1954, is used to relieve heartburn and acid indigestion. Sanofi plans to re-launch the drug and make it available in late 2013.
The Generics sub-group at Sanofi continued with its disappointing performance in the first quarter of 2013 with sales declining 1.8% to €423 million. Reduced sales of the authorized generic versions of Lovenox and Taxotere in the US coupled with lower sales in Brazil hurt results during the quarter.
First quarter 2013 Human Vaccines revenues were €697 million, up 15.9%. Sales of the Animal Health segment decreased 3.1% to €554 million in the first quarter of 2013.
Outlook Maintained
The company continues to expect 2013 business earnings per share to remain flat to down 5% from 2012 levels (at CER).
Business net income will be impacted by around €800 million in the first half of 2013 due to Plavix and Avapro genericization. Sanofi expects to return to growth from the second half of 2013.
Sanofi is looking to combat the generic threat confronting most of its key drugs by signing deals and making acquisitions. We are pleased with Sanofi's efforts to develop its pipeline and believe that newly approved products in Sanofi's portfolio hold huge commercial potential.
Since the start of 2013, several of Sanofi's pipeline candidates gained approval including approval of diabetes candidate, Lyxumia (lixisenatide) and oncology drug, Zaltrap (aflibercept) in Europe and Kynamro for homozygous familial hypercholesterolemia (HoFH) in the US. Hexyon/Hexacima, a 6-in-1 pediatric vaccine also received approval in Europe.
Sanofi carries a Zacks Rank #3 (Hold). Stocks that look better placed at present include AbbVie ( ABBV ), which carries a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks that look better placed at present include AbbVie ( ABBV ), which carries a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. The Generics sub-group at Sanofi continued with its disappointing performance in the first quarter of 2013 with sales declining 1.8% to €423 million. | ABBVIE INC (ABBV): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks that look better placed at present include AbbVie ( ABBV ), which carries a Zacks Rank #2 (Buy). Segmental Performance Sanofi operates through the following segments: Pharmaceuticals, Human Vaccines and Animal Health. | ABBVIE INC (ABBV): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks that look better placed at present include AbbVie ( ABBV ), which carries a Zacks Rank #2 (Buy). Newly launched multiple sclerosis drug, Aubagio, generated sales of €20 million in the first quarter of 2013 as compared to €7 million in fourth quarter 2012. | Stocks that look better placed at present include AbbVie ( ABBV ), which carries a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. First quarter net sales decreased 5.3% on a reported basis and 2.8% at CER. |
27610.0 | 2013-05-02 00:00:00 UTC | Actavis Beats on Earnings, Raises View - Analyst Blog | ABBV | https://www.nasdaq.com/articles/actavis-beats-on-earnings-raises-view-analyst-blog-2013-05-02 | nan | nan | Actavis, Inc.'s ( ACT ) first quarter 2013 earnings of $1.99 per share beat the Zacks Consensus Estimate of $1.87 and increased 21% from the year-ago earnings.
Revenues for the reported quarter came in at approximately $1,895.5 million, up 24% from the year-ago figure, but below the Zacks Consensus Estimate of $1,995 million.
Quarterly Details
Actavis operates through three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution.
The Actavis Pharma segment posted sales of $1.5 billion, up 37%. The upside was driven by new product launches including the generic versions of Suboxone sublingual tablets and Singulair in several EU markets. International revenues were strong at $608.6 million, up 254%, reflecting the inclusion of legacy Actavis products.
Actavis Pharma revenues are expected in the range of $6.3 billion - $6.5 billion in 2013. This segment should benefit from the launch of its authorized generic version of Zovirax ointment 5% in April. The company was also very active on the patent settlement front and signed agreements for generic versions of Crestor, Exalgo, Ziana, Zyclara, Intuniv and the abuse deterrent version of OxyContin.
Actavis Specialty Brands revenues came in at $130.7 million, up 19%. Increased contributions from products like Rapaflo, Crinone, Androderm and Generess Fe and the inclusion of Kadian revenues as a result of the Actavis acquisition aided the performance of the segment. Actavis Specialty Brands is slated to post revenues of $550 million - $600 million in 2013.
Net revenues from the Anda Distribution segment decreased 23% during the quarter to $231.0 million reflecting lower chain sales and new third party product launches. This segment consists of only third-party product sales and is expected to post revenues of $1.0 billion - $1.2 billion in 2013.
Raises Earnings Outlook
Following the release of first quarter results, Actavis raised its earnings guidance for 2013 and now expects to earn $8.10 - $8.50 per share. The company was earlier expecting to earn $7.70 - $8.10 per share. Total revenues guidance remained unchanged at $8.1 billion. The Zacks Consensus Estimate for earnings currently stands below the revised guidance range at $8.09 per share. Meanwhile, the Zacks Consensus Estimate for revenues is $8.1 billion.
Actavis currently carries a Zacks Rank #2 (Buy). We view the company's acquisition of Actavis Group as a smart strategic move. We believe the company should be able to achieve its guidance easily. With fewer major patent expiries slated to occur in the next few years, we are encouraged by Actavis' focus on building its branded and biosimilars pipeline.
Companies in the pharma space that currently look well-positioned include UCB ( UCBJF ), Catalyst Pharmaceuticals Partners Inc. ( CPRX ) and AbbVie ( ABBV ). While UCB and Catalyst Pharma are Zacks Rank #1 (Strong Buy) stocks, AbbVie is a Zacks Rank #2 stock.
ABBVIE INC (ABBV): Free Stock Analysis Report
ACTAVIS INC (ACT): Free Stock Analysis Report
CATALYST PHARMA (CPRX): Free Stock Analysis Report
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Companies in the pharma space that currently look well-positioned include UCB ( UCBJF ), Catalyst Pharmaceuticals Partners Inc. ( CPRX ) and AbbVie ( ABBV ). While UCB and Catalyst Pharma are Zacks Rank #1 (Strong Buy) stocks, AbbVie is a Zacks Rank #2 stock. ABBVIE INC (ABBV): Free Stock Analysis Report ACTAVIS INC (ACT): Free Stock Analysis Report CATALYST PHARMA (CPRX): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. | While UCB and Catalyst Pharma are Zacks Rank #1 (Strong Buy) stocks, AbbVie is a Zacks Rank #2 stock. ABBVIE INC (ABBV): Free Stock Analysis Report ACTAVIS INC (ACT): Free Stock Analysis Report CATALYST PHARMA (CPRX): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Companies in the pharma space that currently look well-positioned include UCB ( UCBJF ), Catalyst Pharmaceuticals Partners Inc. ( CPRX ) and AbbVie ( ABBV ). | ABBVIE INC (ABBV): Free Stock Analysis Report ACTAVIS INC (ACT): Free Stock Analysis Report CATALYST PHARMA (CPRX): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Companies in the pharma space that currently look well-positioned include UCB ( UCBJF ), Catalyst Pharmaceuticals Partners Inc. ( CPRX ) and AbbVie ( ABBV ). While UCB and Catalyst Pharma are Zacks Rank #1 (Strong Buy) stocks, AbbVie is a Zacks Rank #2 stock. | While UCB and Catalyst Pharma are Zacks Rank #1 (Strong Buy) stocks, AbbVie is a Zacks Rank #2 stock. Companies in the pharma space that currently look well-positioned include UCB ( UCBJF ), Catalyst Pharmaceuticals Partners Inc. ( CPRX ) and AbbVie ( ABBV ). ABBVIE INC (ABBV): Free Stock Analysis Report ACTAVIS INC (ACT): Free Stock Analysis Report CATALYST PHARMA (CPRX): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. |
27611.0 | 2013-05-02 00:00:00 UTC | Earnings and Sales Rise at Novo Nordisk - Analyst Blog | ABBV | https://www.nasdaq.com/articles/earnings-and-sales-rise-at-novo-nordisk-analyst-blog-2013-05-02 | nan | nan | Novo Nordisk ( NVO ) reported first quarter 2013 earnings of $1.94 per American Depository Receipt (ADR), up 32.5% from the year-ago period. Revenues in the first quarter of 2013 increased 14% in local currencies year over year.
All growth rates mentioned below are on a year-over-year and local currency basis.
Quarter Highlights
In the reported quarter, total revenues grew 14% driven by strong sales in North America (up 24%) and International Operations (up 17%). Key sales drivers were modern insulins and Victoza.
Geographically, North America was the largest contributor (68% share of growth) to total revenues followed by International Operations (19%), China (10%) and Europe (6%). Timing of shipments in the US and International Operations had a positive impact on sales growth.
Novo Nordisk's Diabetes Care segment recorded growth of 15%. Modern insulins generated strong revenues (up 16%) driven by NovoRapid (up 16%) and Levemir (19%). Novo Nordisk's key drug, Victoza, is a once-daily human glucagon-like peptide 1 (GLP-1) analogue approved for improving blood sugar (glucose) levels in adult type II diabetes patients. The drug witnessed sales growth of 36%. Victoza witnessed growth in North America, Europe and International Operations. Protein-related product sales were flat. Oral antidiabetic product sales and human insulins sales were down 3%.
Sales in the Biopharmaceuticals segment of Novo Nordisk increased 12%. Strong sales of Norditropin (up 18%), NovoSeven (up 7%) and other products (up 9%) contributed to the increase.
Modern insulins contributed 50% to total sales growth whereas Victoza contributed 28%.
Novo Nordisk's research and development (R&D) costs and sales and distribution costs increased 6% and 15%, respectively. Novo Nordisk's efforts to develop its pipeline, primarily the ongoing phase IIIa study on the once-weekly GLP-1 analogue semaglutide and liraglutide in obesity, drove R&D expenses in the reported quarter. Increase in sales and distribution cost was primarily driven by the expansion of the US sales force and costs for the launch of Tresiba in Europe and Japan.
2013 Guidance
In local currencies, operating profit is expected to grow 10% despite including the impact of significant costs related to the expected launch of Tresiba outside the US, investments in the modern insulins portfolio and Victoza in the US, the expanded US sales force as well as sales and marketing investments in China.
In local currencies, sales growth is expected to be in the range of 9-11%, above the previous expectations of 8-11%. This guidance is mainly driven by robust penetration of modern insulins, steady Victoza growth and sales contribution from Tresiba. These positives are expected to be partly offset by the challenging pricing environment in major markets, generic competition for oral anti-diabetic products, intensifying competition within Diabetes Care as well as Biopharmaceuticals.
Novo Nordisk carries a Zacks Rank #3 (Hold). Currently, companies like Catalyst Pharmaceutical Partners Inc. ( CPRX ) and UCB ( UCBJF ) look more attractive with a Zacks Rank #1 (Strong Buy). AbbVie Inc. ( ABBV ) is also well positioned with a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
CATALYST PHARMA (CPRX): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ( ABBV ) is also well positioned with a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report CATALYST PHARMA (CPRX): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Geographically, North America was the largest contributor (68% share of growth) to total revenues followed by International Operations (19%), China (10%) and Europe (6%). | ABBVIE INC (ABBV): Free Stock Analysis Report CATALYST PHARMA (CPRX): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. AbbVie Inc. ( ABBV ) is also well positioned with a Zacks Rank #2 (Buy). Quarter Highlights In the reported quarter, total revenues grew 14% driven by strong sales in North America (up 24%) and International Operations (up 17%). | ABBVIE INC (ABBV): Free Stock Analysis Report CATALYST PHARMA (CPRX): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. AbbVie Inc. ( ABBV ) is also well positioned with a Zacks Rank #2 (Buy). Increase in sales and distribution cost was primarily driven by the expansion of the US sales force and costs for the launch of Tresiba in Europe and Japan. | AbbVie Inc. ( ABBV ) is also well positioned with a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report CATALYST PHARMA (CPRX): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Quarter Highlights In the reported quarter, total revenues grew 14% driven by strong sales in North America (up 24%) and International Operations (up 17%). |
27612.0 | 2013-05-02 00:00:00 UTC | Top Fund Buys Focus On Defensive Stocks, Housing | ABBV | https://www.nasdaq.com/articles/top-fund-buys-focus-defensive-stocks-housing-2013-05-02 | nan | nan | April notched another month of gains for the stock market. That's four straight months so far this year.
But this market rally is getting long in the tooth and top fund managers have been cautious in their buying.
The nation's top-performing funds the past three months have been adding medical stocks to their portfolios, such as big biotech firmsCelgene ( CELG ),Biogen Idec ( BIIB ) andAmgen ( AMGN ) andRegeneron Pharmaceuticals ( REGN ), in their latest reporting periods. DrugmakerAbbVie ( ABBV ) drew heavy buying from top funds.
Media giants,Time Warner (TWX) andNews Corp. (NWSA), have been solid performers. Leading funds invested an estimated $14.3 million in News Corp., as of their latest reporting periods.
As the housing market starts to recover, building supply retailer Home Depot (HD) and self-storage facility REITExtra Space Storage (EXR), have garnered buying interest by leading funds.
IBD spotted two best-performing funds buyingPulte Group (PHM). The $3.1 billion DWS Core Equity Fund added the stock to its holdings.
The Bloomfield Hills, Mich.-based Pulte builds single-family homes, townhouses, condos and duplexes for first-time homebuyers as well as repeat buyers. Its financial services segment handles the mortgage banking and title operations.
Pulte is back on track as housing rebounds. But inventory of homes for sale is still tight, as well as buildable land. Low mortgage rates have also fueled buying.
The stock has been consolidating since running up to a 52-week high of 21.97.
Analysts see Q2 earnings rising 123%.
The Sell Side
The country's leading funds have been unloading a handful of drug giants, such asPfizer (PFE) andBristol-Myers Squibb (BMY), in their latest reporting periods.
These two stocks have had strong run-ups so far this year, notching fresh 52-week highs. But they've hit a wall in recent weeks.
Pfizer reported disappointing first-quarter earnings results, missing analysts' expectations on both earnings and revenue.
It cited lost sales to generic versions of its best-selling cholesterol-lowering drug, Lipitor. Overseas revenue was also hurt by a strong dollar.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | DrugmakerAbbVie ( ABBV ) drew heavy buying from top funds. The nation's top-performing funds the past three months have been adding medical stocks to their portfolios, such as big biotech firmsCelgene ( CELG ),Biogen Idec ( BIIB ) andAmgen ( AMGN ) andRegeneron Pharmaceuticals ( REGN ), in their latest reporting periods. As the housing market starts to recover, building supply retailer Home Depot (HD) and self-storage facility REITExtra Space Storage (EXR), have garnered buying interest by leading funds. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. DrugmakerAbbVie ( ABBV ) drew heavy buying from top funds. The nation's top-performing funds the past three months have been adding medical stocks to their portfolios, such as big biotech firmsCelgene ( CELG ),Biogen Idec ( BIIB ) andAmgen ( AMGN ) andRegeneron Pharmaceuticals ( REGN ), in their latest reporting periods. | DrugmakerAbbVie ( ABBV ) drew heavy buying from top funds. The nation's top-performing funds the past three months have been adding medical stocks to their portfolios, such as big biotech firmsCelgene ( CELG ),Biogen Idec ( BIIB ) andAmgen ( AMGN ) andRegeneron Pharmaceuticals ( REGN ), in their latest reporting periods. As the housing market starts to recover, building supply retailer Home Depot (HD) and self-storage facility REITExtra Space Storage (EXR), have garnered buying interest by leading funds. | DrugmakerAbbVie ( ABBV ) drew heavy buying from top funds. But this market rally is getting long in the tooth and top fund managers have been cautious in their buying. The nation's top-performing funds the past three months have been adding medical stocks to their portfolios, such as big biotech firmsCelgene ( CELG ),Biogen Idec ( BIIB ) andAmgen ( AMGN ) andRegeneron Pharmaceuticals ( REGN ), in their latest reporting periods. |
27613.0 | 2013-05-01 00:00:00 UTC | Merck Earnings Decline Y/Y, Cuts Outlook - Analyst Blog | ABBV | https://www.nasdaq.com/articles/merck-earnings-decline-y-y-cuts-outlook-analyst-blog-2013-05-01 | nan | nan | Merck & Co . ( MRK ) reported first quarter 2013 earnings of 85 cents per share, well above the Zacks Consensus Estimate of 78 cents. Tax benefits boosted first quarter 2013 earnings by 6 cents. Earnings, however, declined 14.1% from the year-ago period.
Revenues for the quarter fell 9.0% to $10,671 million and missed the Zacks Consensus Estimate of $10,997 million. Revenues were hit by the genericization of Singulair and a few other products and negative currency fluctuation (2%).
Including one-time items, first quarter 2013 earnings declined 7.1% to 52 cents per share.
The Quarter in Details
Merck's Pharmaceutical segment posted sales of $8.9 billion, down 12%. Negative currency movement impacted Pharmaceutical segment sales by 2%. Products like Remicade, Simponi, Isentress, Zostavax and Gardasil performed well.
However, the strong performance of these products was offset by lower sales of Singulair, Maxalt, and Clarinex.
Singulair sales experienced a severe decline following its US patent expiry in Aug 2012. Sales fell 75% from the year-ago period to $337 million. We note that Singulair lost exclusivity in the EU in Feb 2013 and is experiencing a sharp decline in sales. The drug retains exclusivity in Japan until 2016.
Meanwhile, Remicade and Simponi combined sales increased 11% to $657 million. We expect Merck to focus on improving penetration rates and drive growth in Europe, Russia and Turkey.
Isentress, the company's product for HIV infection, recorded sales of $362 million, up 8%, in the reported quarter mainly due to strong growth in Europe and emerging markets.
The diabetes franchise, consisting of Januvia and Janumet, witnessed a 1% decline in sales which came in at $1.3 billion. The lower sales reflect a 2% negative impact of currency movement as well as lower sales in the US (down 5%) due to lower customer inventory levels. While Januvia sales declined 4% to $884 million, Janumet sales grew 4% to $409 million.
Gardasil, Merck's cervical cancer vaccine, recorded sales of $390 million, up 37% year over year. Sales were driven by increased vaccination of males in the US, higher public sector purchases and strong performance in emerging markets.
Zostavax sales came in at $168 million, up 121.1%, in response to the company's promotional efforts and the availability of supply. The company reported strong demand in the US.
Zostavax should continue to be a strong growth driver considering that a large part of the US population is yet to receive the vaccine. Moreover, Merck intends to launch Zostavax outside the US later this year.
Meanwhile, Merck's ProQuad, MMR II and Varivax vaccines recorded combined sales of $272 million, up 7%. Vytorin sales declined 11% to $394 million during the quarter.
Merck's hepatitis C treatment, Victrelis posted sales of $110 million, down 1% from the year-ago period.
Emerging markets accounted for 21% of pharmaceutical sales in the first quarter of 2013 with China continuing to put in a strong performance.
Merck's animal health segment posted sales of $840 million, up 2%. Results were driven by growth in companion animal products and poultry.
Consumer Care sales increased 3% to $571 million in the first quarter of 2013, mainly due to Dr. Claritin and Coppertone suncare products.
Marketing and administrative expenses declined 1.7% to $2.9 billion in the first quarter of 2013 due to productivity measures undertaken by the company. R&D spend increased 3% to $1.9 billion in the first quarter of 2013.
Cuts 2013 Guidance
Merck lowered its outlook for 2013 to reflect higher-than-expected pressure on sales including the impact of foreign exchange. Merck now expects adjusted earnings in the range of $3.45 and $3.55, down from its earlier guidance of $3.60 - $3.70 per share. The Zacks Consensus Estimate currently stands at $3.64 per share, well above the new guidance range. The new guidance also takes into account the revised tax rate of 22% - 23% (old guidance: 21% - 23%).
Revenues are now expected to decline 3% - 4% from 2012 levels instead of remaining flat as expected earlier.
Merck expects R&D spend to increase slightly from 2012 levels instead of remaining flat. The company spent $7.9 billion on R&D in 2012.
In addition to reporting first-quarter 2013 results, Merck announced a new share buyback program under which the company will use up to $15 billion to buy back shares. While half the authorized amount will be used for repurchasing shares over the next 12 months, the remaining $7.5 billion will not have any time limit.
Our Take
Merck has entered a challenging period with erstwhile blockbuster drug, Singulair, losing exclusivity in the US in early Aug 2012 and in the EU in Feb 2013. Merck's first quarter results were disappointing with generics eating into sales. The decline in Januvia sales is also a matter of concern. Even though earnings exceeded expectations, the company cut its outlook for 2013 based on higher-than-expected pressure on sales.
With Singulair and a few other products facing generic competition, we expect the top- and bottom-line to remain under pressure. Other headwinds remain in the form of unfavorable currency movement, and pipeline setbacks. We believe the company will look towards cost-cutting initiatives and share buybacks to drive the bottom-line.
Merck currently carries a Zacks Rank #3 (Hold). Shares were down in pre-market trading. Merck's results come a day after pharma major, Pfizer ( PFE ), reported first quarter results. Pfizer's first quarter performance was also a letdown with the company missing on both earnings and revenues. Pfizer's results were also hit by genericization and unfavorable currency movement and the company lowered its outlook for 2013.
Companies that currently look better-positioned include AbbVie ( ABBV ) and UCB ( UCBJF ). While UCB is a Zacks Rank #1 (Strong Buy) stock, AbbVie holds a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Companies that currently look better-positioned include AbbVie ( ABBV ) and UCB ( UCBJF ). While UCB is a Zacks Rank #1 (Strong Buy) stock, AbbVie holds a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. | While UCB is a Zacks Rank #1 (Strong Buy) stock, AbbVie holds a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Companies that currently look better-positioned include AbbVie ( ABBV ) and UCB ( UCBJF ). | Companies that currently look better-positioned include AbbVie ( ABBV ) and UCB ( UCBJF ). While UCB is a Zacks Rank #1 (Strong Buy) stock, AbbVie holds a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. | Companies that currently look better-positioned include AbbVie ( ABBV ) and UCB ( UCBJF ). While UCB is a Zacks Rank #1 (Strong Buy) stock, AbbVie holds a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. |
27614.0 | 2013-05-01 00:00:00 UTC | Allergan Beats on Earnings - Analyst Blog | ABBV | https://www.nasdaq.com/articles/allergan-beats-on-earnings-analyst-blog-2013-05-01 | nan | nan | Allergan, Inc. ( AGN ) reported first quarter 2013 earnings of 98 cents per share, beating the Zacks Consensus Estimate of 96 cents per share by 2 cents.
While earnings increased 18.1% from the year-ago quarter, revenues increased 8.3% to $1,459.6 million, above the Zacks Consensus Estimate of $1,443 million.
The Quarter in Detail
Specialty pharmaceuticals sales increased 8.1% to $1,231.8 million, with eye-care, pharmaceutical, Botox and skin-care sales driving growth.
Eye-care pharmaceutical sales increased 2.5% to $668.6 million with products like Restasis (up 11.3%), Alphagan franchise (up 4.1%) and the Latisse (up 6.9%) contributing to growth.
Allergan continues to expect Lumigan franchise sales to increase to $630 million - $660 million in 2013. Meanwhile, Alphagan franchise sales are still expected in the range of $440 - $470 million in 2013.
Restasis sales are expected to increase to $850 million - $890 million in 2013 (previous guidance: $830 million - $870 million). Allergan continues to expect Latisse sales to increase to $110 million in 2013.
Botox sales increased 14.8% year over year to $457.9 million. In Jan 2013, the Food and Drug Administration (FDA) approved Botox for the treatment of patients suffering from overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency. The drug can be used in adults with OAB, who have not responded adequately to, or, are intolerant to anticholinergic medication.
Allergan increased the lower end of its 2013 Botox sales guidance by $20 million and now expects 2013 Botox sales in the range of $1,920 million - $2,000 million (previous guidance: $1,900 million - $2,000 million).
Meanwhile, Allergan's medical devices segment posted sales of $200.7 million, up 10.2%. While breast aesthetics sales decreased 8.9% to $89.6 million, facial aesthetics sales increased 32.6% to $111.1 million.
Allergan is looking to sell the obesity intervention segment and expects to do the same in mid-2013. We note that the obesity intervention unit is treated as discontinued operations from the first quarter of 2013.
Other Details
Selling, general and administrative (SG&A) expenses increased 5.9% during the quarter to $586.9 million. Research and development (R&D) expenses amounted to $248.8 million, up 13.2%.
2013 Earnings Guidance
Allergan now expects 2013 earnings of $4.70 - $4.76 per share as compared to previous guidance of $4.75 - $4.83 per share. The guidance excludes the impact of the R&D tax credit signed into law earlier this year. The Zacks Consensus Estimate currently standing at $4.76 per share.
The company expects product net sales to range from $5,975 - $6,200 million in 2013 (previous guidance: $5,900 million - $6,200 million).
For 2013, Allergan expects total specialty pharmaceuticals net sales of $5,175 million - $5,340 million (previous guidance: $5,100 million - $5,340 million).
The company continues to expect medical devices net sales of $800 million - $860 million. Here, performance will be driven mainly by facial aesthetics. Facial aesthetics sales are still expected in the range of $410 million - $440 million.
Breast aesthetics sales are continued to be expected in the range of $390 million - $420 million.
For 2013, Allergan reiterated its cost guidance and expects cost of sales to product net sales ratio of about 13.5%, SG&A expenses to product net sales ratio of 37% - 38% and R&D expenses to product net sales ratio of 16.5%.
Allergan expects second quarter earnings in the range of $1.18 - $1.20 per share on product net sales of $1,500 million and $1,575 million. We note that Allergan's guidance includes the dilutive impact of MAP Pharmaceuticals acquisition. The Zacks Consensus Estimate currently stands at $1.23 per share, above the company's guidance range.
Allergan currently carries a Zacks Rank #3 (Hold). While we believe Allergan's presence across different segments will help maintain growth going forward. Stocks that look better at present include AbbVie ( ABBV ) which carries a Zacks Rank #2 (Buy). UCB ( UCBJF ) and Onyx Pharmaceuticals, Inc. ( ONXX ) also look well-positioned with a Zacks Rank #1 (Strong Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
ONYX PHARMA INC (ONXX): Free Stock Analysis Report
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks that look better at present include AbbVie ( ABBV ) which carries a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Eye-care pharmaceutical sales increased 2.5% to $668.6 million with products like Restasis (up 11.3%), Alphagan franchise (up 4.1%) and the Latisse (up 6.9%) contributing to growth. | ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Stocks that look better at present include AbbVie ( ABBV ) which carries a Zacks Rank #2 (Buy). For 2013, Allergan expects total specialty pharmaceuticals net sales of $5,175 million - $5,340 million (previous guidance: $5,100 million - $5,340 million). | Stocks that look better at present include AbbVie ( ABBV ) which carries a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Restasis sales are expected to increase to $850 million - $890 million in 2013 (previous guidance: $830 million - $870 million). | Stocks that look better at present include AbbVie ( ABBV ) which carries a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Restasis sales are expected to increase to $850 million - $890 million in 2013 (previous guidance: $830 million - $870 million). |
27615.0 | 2013-04-30 00:00:00 UTC | Merck - Pfizer in Diabetes Deal - Analyst Blog | ABBV | https://www.nasdaq.com/articles/merck-pfizer-in-diabetes-deal-analyst-blog-2013-04-30 | nan | nan | Merck & Co., Inc. ( MRK ) recently announced a strategic deal with Pfizer Inc. ( PFE ) for the development and commercialization of Pfizer's ertugliflozin. The companies will also evaluate fixed dose combinations of ertugliflozin with metformin and Merck's Januvia.
The Candidate
Ertugliflozin is an investigational oral sodium glucose cotransporter (SGLT2) inhibitor which is being developed for the treatment of type II diabetes. Phase III studies on ertugliflozin are expected to commence later this year.
We note that Pfizer and Merck are not the only companies pursuing the development of SLGT2 inhibitors. While Invokana is approved in the US, Forxiga is approved in the EU. Meanwhile, empagliflozin is under development.
Terms of the Deal
Under this deal, Pfizer got $60 million in the form of upfront and milestones payments from Merck. Additionally, Pfizer is eligible for payments on the achievement of pre-specified clinical, regulatory and commercial milestones. Revenues and a few cost items will be shared between Merck and Pfizer in the ratio of 3:2.
Our Take
This collaboration signifies Merck's efforts to strengthen its diabetes franchise. Merck's diabetes franchise has Januvia and Janumet for the treatment of type II diabetes. Januvia, a DPP-IV (dipeptidyl peptidase) inhibitor for type II diabetes, was approved in Oct 2006. Since then, the product has done very well. Sales have leapfrogged from $42.9 million in 2006 to $4,086 million in 2012. Merck combined Januvia and metformin (an oral diabetes drug) into a single pill called Janumet. Combined sales of the two drugs were $5.7 billion in 2012, up 22.6%. Currently, Merck has a phase III type II diabetes candidate, MK-3102, in its pipeline.
Merck and Pfizer carry a Zacks Rank #3 (Hold). Currently, companies like Cleveland BioLabs, Inc. ( CBLI ) and AbbVie Inc. ( ABBV ), carrying Zacks Rank #1 (Strong Buy) and Zacks Rank #2 (Buy) respectively, appear more attractive.
ABBVIE INC (ABBV): Free Stock Analysis Report
CLEVELAND BIOLB (CBLI): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Currently, companies like Cleveland BioLabs, Inc. ( CBLI ) and AbbVie Inc. ( ABBV ), carrying Zacks Rank #1 (Strong Buy) and Zacks Rank #2 (Buy) respectively, appear more attractive. ABBVIE INC (ABBV): Free Stock Analysis Report CLEVELAND BIOLB (CBLI): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. The Candidate Ertugliflozin is an investigational oral sodium glucose cotransporter (SGLT2) inhibitor which is being developed for the treatment of type II diabetes. | Currently, companies like Cleveland BioLabs, Inc. ( CBLI ) and AbbVie Inc. ( ABBV ), carrying Zacks Rank #1 (Strong Buy) and Zacks Rank #2 (Buy) respectively, appear more attractive. ABBVIE INC (ABBV): Free Stock Analysis Report CLEVELAND BIOLB (CBLI): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Merck's diabetes franchise has Januvia and Janumet for the treatment of type II diabetes. | ABBVIE INC (ABBV): Free Stock Analysis Report CLEVELAND BIOLB (CBLI): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, companies like Cleveland BioLabs, Inc. ( CBLI ) and AbbVie Inc. ( ABBV ), carrying Zacks Rank #1 (Strong Buy) and Zacks Rank #2 (Buy) respectively, appear more attractive. Merck & Co., Inc. ( MRK ) recently announced a strategic deal with Pfizer Inc. ( PFE ) for the development and commercialization of Pfizer's ertugliflozin. | Currently, companies like Cleveland BioLabs, Inc. ( CBLI ) and AbbVie Inc. ( ABBV ), carrying Zacks Rank #1 (Strong Buy) and Zacks Rank #2 (Buy) respectively, appear more attractive. ABBVIE INC (ABBV): Free Stock Analysis Report CLEVELAND BIOLB (CBLI): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. The Candidate Ertugliflozin is an investigational oral sodium glucose cotransporter (SGLT2) inhibitor which is being developed for the treatment of type II diabetes. |
27616.0 | 2013-04-30 00:00:00 UTC | Bayer Aims to Expand HealthCare Portfolio - Analyst Blog | ABBV | https://www.nasdaq.com/articles/bayer-aims-to-expand-healthcare-portfolio-analyst-blog-2013-04-30 | nan | nan | In a bid to strengthen its contraceptive portfolio Bayer ( BAYRY ) inked a deal to buy Conceptus Inc. ( CPTS ) for $31.00 per share or approximately $1.1 billion in cash. Conceptus focuses on developing and commercializing innovative device-based solutions in permanent birth control.
Bayer intends to launch a public tender offer to acquire all shares of Conceptus within the next 10 days. The transaction is expected to close by mid-2013.
Bayer's impending acquisition of Conceptus will add the Essure permanent (non-surgical) birth control system to its product portfolio. We note that Conceptus' Essure procedure was approved in 2002 in the US and is well accepted in the market. Bayer's contraceptive portfolio currently includes drugs like Yasmin/Yaz and Mirena among others.
Successful completion of the acquisition would ensure the presence of short-term, long-term and permanent contraceptive choices for women in Bayer's portfolio. The Essure procedure is a strategic fit in Bayer's HealthCare business.
Bayer mentioned in its press release that more than 700,000 women around the world have already undergone this procedure. Conceptus reported net sales of $141 million for the year 2012.
The HealthCare segment recorded revenues of €4.4 billion in the first quarter of 2013, up 2.3% year over year. Bayer expects revenues from the HealthCare segment to come in at around €19 billion in 2013.
We remind investors that the contraceptive market has players like Teva Pharmaceutical Industries Ltd. ( TEVA ).
Bayer, a large cap pharma company, presently carries a Zacks Rank #4 (Sell). Other large cap pharma companies such as Abbvie Inc. ( ABBV ) currently look more attractive. Abbvie carries a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
CONCEPTUS INC (CPTS): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other large cap pharma companies such as Abbvie Inc. ( ABBV ) currently look more attractive. Abbvie carries a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report CONCEPTUS INC (CPTS): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. | Other large cap pharma companies such as Abbvie Inc. ( ABBV ) currently look more attractive. ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report CONCEPTUS INC (CPTS): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbvie carries a Zacks Rank #2 (Buy). | ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report CONCEPTUS INC (CPTS): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Other large cap pharma companies such as Abbvie Inc. ( ABBV ) currently look more attractive. Abbvie carries a Zacks Rank #2 (Buy). | Other large cap pharma companies such as Abbvie Inc. ( ABBV ) currently look more attractive. Abbvie carries a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report CONCEPTUS INC (CPTS): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. |
27617.0 | 2013-04-29 00:00:00 UTC | Company News for April 29, 2013 - Corporate Summary | ABBV | https://www.nasdaq.com/articles/company-news-for-april-29-2013-corporate-summary-2013-04-29 | nan | nan | • Amazon.com, Inc. (NASDAQ: AMZN ) reported first quarter earnings per share of $0.18, beating the Zacks Consensus Estimate of $0.10
• Starbucks Corporation (NASDAQ: SBUX ) posted second quarter earnings per share of $0.48, in line with the Zacks Consensus Estimate
• AbbVie Inc. (NYSE: ABBV ) reported first quarter earnings per share of $0.68, higher than the Zacks Consensus Estimate of $0.66
• American Electric Power Company, Inc. (NYSE: AEP ) posted first quarter earnings per share of $0.80, in line with the Zacks Consensus Estimate
• Covidien plc (NYSE: COV ) reported second quarter earnings per share of $1.12, ahead of the Zacks Consensus Estimate of $1.10
• Weyerhaeuser Company (NYSE: WY ) posted first quarter earnings per share of $0.26, surpassing the Zacks Consensus Estimate of $0.22
• Aon PLC (NYSE: AON ) reported first quarter earnings per share of $1.11, in line with the Zacks Consensus Estimate
• Autoliv Inc. (NYSE: ALV ) posted first quarter earnings per share of $1.29, beating the Zacks Consensus Estimate of $1.27
ABBVIE INC (ABBV): Free Stock Analysis Report
AMER ELEC PWR (AEP): Free Stock Analysis Report
AUTOLIV INC (ALV): Free Stock Analysis Report
AMAZON.COM INC (AMZN): Free Stock Analysis Report
AON PLC (AON): Free Stock Analysis Report
COVIDIEN PLC (COV): Free Stock Analysis Report
STARBUCKS CORP (SBUX): Free Stock Analysis Report
WEYERHAEUSER CO (WY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Amazon.com, Inc. (NASDAQ: AMZN ) reported first quarter earnings per share of $0.18, beating the Zacks Consensus Estimate of $0.10 • Starbucks Corporation (NASDAQ: SBUX ) posted second quarter earnings per share of $0.48, in line with the Zacks Consensus Estimate • AbbVie Inc. (NYSE: ABBV ) reported first quarter earnings per share of $0.68, higher than the Zacks Consensus Estimate of $0.66 • American Electric Power Company, Inc. (NYSE: AEP ) posted first quarter earnings per share of $0.80, in line with the Zacks Consensus Estimate • Covidien plc (NYSE: COV ) reported second quarter earnings per share of $1.12, ahead of the Zacks Consensus Estimate of $1.10 • Weyerhaeuser Company (NYSE: WY ) posted first quarter earnings per share of $0.26, surpassing the Zacks Consensus Estimate of $0.22 • Aon PLC (NYSE: AON ) reported first quarter earnings per share of $1.11, in line with the Zacks Consensus Estimate • Autoliv Inc. (NYSE: ALV ) posted first quarter earnings per share of $1.29, beating the Zacks Consensus Estimate of $1.27 ABBVIE INC (ABBV): Free Stock Analysis Report AMER ELEC PWR (AEP): Free Stock Analysis Report AUTOLIV INC (ALV): Free Stock Analysis Report AMAZON.COM INC (AMZN): Free Stock Analysis Report AON PLC (AON): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report STARBUCKS CORP (SBUX): Free Stock Analysis Report WEYERHAEUSER CO (WY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Amazon.com, Inc. (NASDAQ: AMZN ) reported first quarter earnings per share of $0.18, beating the Zacks Consensus Estimate of $0.10 • Starbucks Corporation (NASDAQ: SBUX ) posted second quarter earnings per share of $0.48, in line with the Zacks Consensus Estimate • AbbVie Inc. (NYSE: ABBV ) reported first quarter earnings per share of $0.68, higher than the Zacks Consensus Estimate of $0.66 • American Electric Power Company, Inc. (NYSE: AEP ) posted first quarter earnings per share of $0.80, in line with the Zacks Consensus Estimate • Covidien plc (NYSE: COV ) reported second quarter earnings per share of $1.12, ahead of the Zacks Consensus Estimate of $1.10 • Weyerhaeuser Company (NYSE: WY ) posted first quarter earnings per share of $0.26, surpassing the Zacks Consensus Estimate of $0.22 • Aon PLC (NYSE: AON ) reported first quarter earnings per share of $1.11, in line with the Zacks Consensus Estimate • Autoliv Inc. (NYSE: ALV ) posted first quarter earnings per share of $1.29, beating the Zacks Consensus Estimate of $1.27 ABBVIE INC (ABBV): Free Stock Analysis Report AMER ELEC PWR (AEP): Free Stock Analysis Report AUTOLIV INC (ALV): Free Stock Analysis Report AMAZON.COM INC (AMZN): Free Stock Analysis Report AON PLC (AON): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report STARBUCKS CORP (SBUX): Free Stock Analysis Report WEYERHAEUSER CO (WY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Amazon.com, Inc. (NASDAQ: AMZN ) reported first quarter earnings per share of $0.18, beating the Zacks Consensus Estimate of $0.10 • Starbucks Corporation (NASDAQ: SBUX ) posted second quarter earnings per share of $0.48, in line with the Zacks Consensus Estimate • AbbVie Inc. (NYSE: ABBV ) reported first quarter earnings per share of $0.68, higher than the Zacks Consensus Estimate of $0.66 • American Electric Power Company, Inc. (NYSE: AEP ) posted first quarter earnings per share of $0.80, in line with the Zacks Consensus Estimate • Covidien plc (NYSE: COV ) reported second quarter earnings per share of $1.12, ahead of the Zacks Consensus Estimate of $1.10 • Weyerhaeuser Company (NYSE: WY ) posted first quarter earnings per share of $0.26, surpassing the Zacks Consensus Estimate of $0.22 • Aon PLC (NYSE: AON ) reported first quarter earnings per share of $1.11, in line with the Zacks Consensus Estimate • Autoliv Inc. (NYSE: ALV ) posted first quarter earnings per share of $1.29, beating the Zacks Consensus Estimate of $1.27 ABBVIE INC (ABBV): Free Stock Analysis Report AMER ELEC PWR (AEP): Free Stock Analysis Report AUTOLIV INC (ALV): Free Stock Analysis Report AMAZON.COM INC (AMZN): Free Stock Analysis Report AON PLC (AON): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report STARBUCKS CORP (SBUX): Free Stock Analysis Report WEYERHAEUSER CO (WY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Amazon.com, Inc. (NASDAQ: AMZN ) reported first quarter earnings per share of $0.18, beating the Zacks Consensus Estimate of $0.10 • Starbucks Corporation (NASDAQ: SBUX ) posted second quarter earnings per share of $0.48, in line with the Zacks Consensus Estimate • AbbVie Inc. (NYSE: ABBV ) reported first quarter earnings per share of $0.68, higher than the Zacks Consensus Estimate of $0.66 • American Electric Power Company, Inc. (NYSE: AEP ) posted first quarter earnings per share of $0.80, in line with the Zacks Consensus Estimate • Covidien plc (NYSE: COV ) reported second quarter earnings per share of $1.12, ahead of the Zacks Consensus Estimate of $1.10 • Weyerhaeuser Company (NYSE: WY ) posted first quarter earnings per share of $0.26, surpassing the Zacks Consensus Estimate of $0.22 • Aon PLC (NYSE: AON ) reported first quarter earnings per share of $1.11, in line with the Zacks Consensus Estimate • Autoliv Inc. (NYSE: ALV ) posted first quarter earnings per share of $1.29, beating the Zacks Consensus Estimate of $1.27 ABBVIE INC (ABBV): Free Stock Analysis Report AMER ELEC PWR (AEP): Free Stock Analysis Report AUTOLIV INC (ALV): Free Stock Analysis Report AMAZON.COM INC (AMZN): Free Stock Analysis Report AON PLC (AON): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report STARBUCKS CORP (SBUX): Free Stock Analysis Report WEYERHAEUSER CO (WY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
27618.0 | 2013-04-22 00:00:00 UTC | New Product from Abbott Labs - Analyst Blog | ABBV | https://www.nasdaq.com/articles/new-product-from-abbott-labs-analyst-blog-2013-04-22 | nan | nan | Abbott Laboratories ( ABT ) recently announced that the company has gained approval from the US Food and Drug Administration (FDA) for its TECNIS Toric 1-Piece intraocular lens (IOL). The company gained approval for treating cataract patients with pre-existing corneal astigmatism.
Abbott Labs has launched the product following the approval.
Corneal astigmatism results in blurred vision as it prevents light rays from focusing clearly on the retina. We note that the new product from Abbott Labs is superior to conventional IOLs since it has the ability to correct the loss of focus due to pre-existing corneal astigmatism of one diopter or greater.
As per Abbott Labs, the number of surgeries is expected to grow nearly 3% each year driven by an aging US population which should fuel patient demand for improved, precise visual outcomes and independence from glasses.
We note that cataract sales accounted for 60% of the company's total medical optics in the first quarter of 2013 driven by solid growth of its TECNIS brand of intraocular lenses. In particular, growth was strong in emerging markets. Meanwhile, sales of Medical Optics were down 0.6% in the first quarter of 2013 as growth in cataract sales was partially offset by a modest decline in refractive sales driven by continued soft market conditions.
Going forward, Abbott Labs expects to launch several products in the cataract segment such as TECNIS Preloaded IOLs in 2013. In addition, the Japanese launch of Tecnis OptiBlue IOL in the first quarter of 2013 should further propel growth of cataract sales.
Abbott Labs expects low-single digit sales growth in its vision care business in the second quarter of 2013 (excluding the impact of foreign exchange).
We remind investors that in Jan 2013, Abbott Labs separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ).
Following the move, Abbott Labs became a diversified medical products company with a presence in branded generic pharmaceutical, devices, diagnostic and nutritional businesses.
Abbott intends to increase its presence in emerging markets, which provide a substantial opportunity for growth, given the rise in middle-class income and aging population. The diversification should enable Abbott to penetrate these markets and capture market share.
Abbott Labs currently carries a Zacks Rank #3 (Hold). As of now, Nuvasive ( NUVA ) looks attractive with a Zacks Rank #1 (Strong Buy). Exactech ( EXAC ) also looks well placed with a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
EXACTECH INC (EXAC): Free Stock Analysis Report
NUVASIVE INC (NUVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We remind investors that in Jan 2013, Abbott Labs separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) recently announced that the company has gained approval from the US Food and Drug Administration (FDA) for its TECNIS Toric 1-Piece intraocular lens (IOL). | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that in Jan 2013, Abbott Labs separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). The company gained approval for treating cataract patients with pre-existing corneal astigmatism. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that in Jan 2013, Abbott Labs separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). Meanwhile, sales of Medical Optics were down 0.6% in the first quarter of 2013 as growth in cataract sales was partially offset by a modest decline in refractive sales driven by continued soft market conditions. | We remind investors that in Jan 2013, Abbott Labs separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs has launched the product following the approval. |
27619.0 | 2013-04-19 00:00:00 UTC | Abbott Labs Recalls Glucose Meter - Analyst Blog | ABBV | https://www.nasdaq.com/articles/abbott-labs-recalls-glucose-meter-analyst-blog-2013-04-19 | nan | nan | Abbott Laboratories ( ABT ) recently announced that the company is initiating a voluntary recall of its FreeStyle InsuLinx Blood Glucose Meters in the US.
Abbott Labs decided to recall the its FreeStyle InsuLinx Blood Glucose Meters as it found that the device displayed and stored wrong test results in patients with extremely high blood glucose levels.
Abbott Labs estimates that there are approximately 50,000 active FreeStyle InsuLinx Meter users in the US and asked them to take appropriate measures.
Following the identification of the deficiency, the company has started the process of informing the concerned persons about the same.
Abbott Labs has also notified the US Food and Drug Administration (FDA) and all relevant healthcare authorities in the other countries about the defect.
We note that Abbott Labs obtained U.S. regulatory approval for its FreeStyle InsuLinx Meter in the first quarter of 2013. Earlier in 2011, the company obtained CE mark and Health Canada approval for ts FreeStyle InsuLinx Blood Glucose Meters. The CE mark is a mandatory confirmation for products placed in the European markets.
We remind investors that in Jan 2013, Abbott Labs separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). The decision to spin off the business was taken in Oct 2011 when Abbott decided to separate its business into two publicly traded companies - one in diversified medical products and the other in research-based pharmaceuticals.
Following the move, Abbott Labs became a diversified medical products company including branded generic pharmaceutical, devices, diagnostic and nutritional businesses.
Abbott intends to increase its presence in emerging markets, which provide a substantial opportunity for growth, given the rise in middle-class income and aging population. The diversification should enable Abbott to penetrate these markets and capture market share.
In particular, the nutrition and diagnostics business should maintain momentum and boost the bottom line due to an improvement in operating margins.
Abbott Labs currently carries a Zacks Rank #3 (Hold). As of now, Nuvasive ( NUVA ) looks attractive with a Zacks Rank #1 (Strong Buy). Exactech ( EXAC ) also looks well placed with a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
EXACTECH INC (EXAC): Free Stock Analysis Report
NUVASIVE INC (NUVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We remind investors that in Jan 2013, Abbott Labs separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) recently announced that the company is initiating a voluntary recall of its FreeStyle InsuLinx Blood Glucose Meters in the US. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that in Jan 2013, Abbott Labs separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). Abbott Labs decided to recall the its FreeStyle InsuLinx Blood Glucose Meters as it found that the device displayed and stored wrong test results in patients with extremely high blood glucose levels. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that in Jan 2013, Abbott Labs separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). Abbott Labs decided to recall the its FreeStyle InsuLinx Blood Glucose Meters as it found that the device displayed and stored wrong test results in patients with extremely high blood glucose levels. | We remind investors that in Jan 2013, Abbott Labs separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier in 2011, the company obtained CE mark and Health Canada approval for ts FreeStyle InsuLinx Blood Glucose Meters. |
27620.0 | 2013-04-18 00:00:00 UTC | Abbott Launches Automated Solution - Analyst Blog | ABBV | https://www.nasdaq.com/articles/abbott-launches-automated-solution-analyst-blog-2013-04-18 | nan | nan | Abbott Laboratories ( ABT ) recently announced that the company has launched ACCELERATOR a3600 - its next-generation track system to increase efficiency in laboratories.
A laboratory automation track system, ACCELERATOR a3600 enables processing for up to 3,600 samples per hour along with handling multiple tube sizes and types simultaneously.
Moreover, this system automates routine, manual tasks which in turn should lead to reduction in error and improvement in efficiency. Further, automation helps laboratories around the world to cope with staffing shortages, budget constraints, and increased demands.
Abbott Labs developed ACCELERATOR a3600 with its Swiss partner Inpeco SA to address the growing need for faster processing in tests while handling increased volume.
We note that the diagnostics business is one of the key businesses for Abbott Labs after having separated its proprietary pharmaceutical business into a new company called AbbVie ( ABBV ) on Jan 1, 2013.
Abbott Labs continues to focus on the development of next-generation instruments and other advanced technologies along with expansion in emerging markets in its diagnostics business. In particular, improvement in operating margins is a key area of emphasis in this segment.
A few days ago, Abbott Labs announced that the company obtained CE Marking (Conformite Europeenne) for its ARCHITECT Galectin-3 assay test. The CE mark is mandatory confirmation for products placed in the European markets. Abbott developed this test in collaboration with BG Medicine, Inc. ( BGMD ) to run on its ARCHITECT immunochemistry platform.
The test is primarily aimed to enable doctors in assessing the prognosis of patients diagnosed with chronic heart failure (HF). ARCHITECT Galectin-3 assay test is available in several European countries.
Galectin-3 can indicate heart failure by chalking out the pathophysiology of HF. Subsequently, the doctors can identify the susceptible patients for heart failure who are at high risk.
We believe that Abbott Labs is extremely diversified with a presence in the nutrition, diagnostics, generic pharmaceuticals and medical devices markets. In particular, the nutrition and diagnostics business should maintain momentum and boost the bottom line due to an improvement in operating margins.
Abbott Labs currently carries a Zacks Rank #3 (Hold). Nuvasive ( NUVA ) currently looks attractive with a Zacks Rank #1 (Strong Buy)
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
BG MEDICINE INC (BGMD): Free Stock Analysis Report
NUVASIVE INC (NUVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We note that the diagnostics business is one of the key businesses for Abbott Labs after having separated its proprietary pharmaceutical business into a new company called AbbVie ( ABBV ) on Jan 1, 2013. Nuvasive ( NUVA ) currently looks attractive with a Zacks Rank #1 (Strong Buy) ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BG MEDICINE INC (BGMD): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. A laboratory automation track system, ACCELERATOR a3600 enables processing for up to 3,600 samples per hour along with handling multiple tube sizes and types simultaneously. | Nuvasive ( NUVA ) currently looks attractive with a Zacks Rank #1 (Strong Buy) ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BG MEDICINE INC (BGMD): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. We note that the diagnostics business is one of the key businesses for Abbott Labs after having separated its proprietary pharmaceutical business into a new company called AbbVie ( ABBV ) on Jan 1, 2013. Abbott Laboratories ( ABT ) recently announced that the company has launched ACCELERATOR a3600 - its next-generation track system to increase efficiency in laboratories. | We note that the diagnostics business is one of the key businesses for Abbott Labs after having separated its proprietary pharmaceutical business into a new company called AbbVie ( ABBV ) on Jan 1, 2013. Nuvasive ( NUVA ) currently looks attractive with a Zacks Rank #1 (Strong Buy) ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BG MEDICINE INC (BGMD): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) recently announced that the company has launched ACCELERATOR a3600 - its next-generation track system to increase efficiency in laboratories. | We note that the diagnostics business is one of the key businesses for Abbott Labs after having separated its proprietary pharmaceutical business into a new company called AbbVie ( ABBV ) on Jan 1, 2013. Nuvasive ( NUVA ) currently looks attractive with a Zacks Rank #1 (Strong Buy) ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BG MEDICINE INC (BGMD): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) recently announced that the company has launched ACCELERATOR a3600 - its next-generation track system to increase efficiency in laboratories. |
27621.0 | 2013-04-17 00:00:00 UTC | Abbott Reports In-Line 1Q Earnings - Analyst Blog | ABBV | https://www.nasdaq.com/articles/abbott-reports-in-line-1q-earnings-analyst-blog-2013-04-17 | nan | nan | Abbott Laboratories ( ABT ) reported first quarter 2013 earnings of 42 cents per share, in line with the Zacks Consensus Estimate and 5.0% above the year-ago earnings. Including one-time items, first quarter earnings decreased 56.4% to 34 cents per share.
Abbott Labs generated revenues of $5.4 billion in the first quarter of 2013, up 1.8% year over year and in line with the Zacks Consensus Estimate. The year over year growth was primarily driven by the Nutrition and Diagnostics segments.
However, unfavorable movement in foreign exchange rates negatively impacted revenues by 1.7%.
We note that the reported quarter is the first full quarter for Abbott Labs after having separated its proprietary pharmaceutical business into a new company called AbbVie ( ABBV ) on Jan 1, 2013.
Quarter in Detail
Abbott Labs now operates through four segments, namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics, and Nutritionals.
EPD sales declined 1.9% year over year to $1.2 billion including a negative impact of 1.9% due to currency fluctuation. This division primarily focuses on key emerging markets where sales grew 4.4%. However, sales in other markets which include developed markets, such as Western Europe and Japan, among others declined 7.0% primarily due to carry-over effects of austerity measures undertaken in Europe in 2012 and pricing actions in Japan.
Abbott Labs expects key emerging markets sales to grow in double-digits in 2013 - performance is expected to improve from the second quarter as the company strengthens its position in these markets. Meanwhile, performance in other countries should also improve from the second half of the year with the lessening of the impact of austerity measures and pricing actions.
The Medical Devices business generated sales of $1.3 billion, down 4.6% mainly due to a decline in the vascular business. The vascular business was down 7.7% due to an expected decline of certain royalty and supply arrangement revenues (including Promus) along with the negative impact from pricing. Diabetes Care sales declined 0.5% while Medical Optics sales declined 0.6%.
The Nutrition business grew 8.7% year over year to $1.7 billion fueled by solid growth in emerging markets which account for 45% of the total sales in this division. Nutrition sales in the US increased 2.1% to $718 million. Outside the US, sales grew 14.2% to $981 million. Pediatric Nutrition sales grew 13.2% while Adult Nutrition sales grew 3.1%.
Diagnostics business sales increased 4.4% year over year to $1.0 billion. Key areas of focus in this division include the Core Laboratory Diagnostics, Molecular Diagnostics, and Point of Care Diagnostics businesses. Core Laboratory sales increased 3.6% and Point of Care Diagnostics increased 17.3%. Worldwide sales of Molecular Diagnostics increased 0.7%.
2013 Outlook Reiterated
Abbott Labs continues to expect earnings per share in the range of $1.98 to $2.04 in 2013. The Zacks Consensus Estimate currently stands at $2.01 per share.
For the second quarter of 2013, Abbott Labs estimates earnings per share in the range of 43 cents to 45 cents. The Zacks Consensus Estimate of 45 cents per share is within the company's guidance.
We believe that Abbott Labs is extremely diversified with a presence in the nutrition, diagnostics, generic pharmaceuticals and medical devices markets. In particular, the Nutrition business should maintain momentum and boost the bottom line due to an improvement in operating margins.
Abbott Labs currently carries a Zacks Rank #3 (Hold). As of now, Nuvasive ( NUVA ) looks attractive with a Zacks Rank #1 (Strong Buy). Exactech ( EXAC ) also looks well placed with a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
EXACTECH INC (EXAC): Free Stock Analysis Report
NUVASIVE INC (NUVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We note that the reported quarter is the first full quarter for Abbott Labs after having separated its proprietary pharmaceutical business into a new company called AbbVie ( ABBV ) on Jan 1, 2013. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Detail Abbott Labs now operates through four segments, namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics, and Nutritionals. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. We note that the reported quarter is the first full quarter for Abbott Labs after having separated its proprietary pharmaceutical business into a new company called AbbVie ( ABBV ) on Jan 1, 2013. Abbott Laboratories ( ABT ) reported first quarter 2013 earnings of 42 cents per share, in line with the Zacks Consensus Estimate and 5.0% above the year-ago earnings. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. We note that the reported quarter is the first full quarter for Abbott Labs after having separated its proprietary pharmaceutical business into a new company called AbbVie ( ABBV ) on Jan 1, 2013. Abbott Labs generated revenues of $5.4 billion in the first quarter of 2013, up 1.8% year over year and in line with the Zacks Consensus Estimate. | We note that the reported quarter is the first full quarter for Abbott Labs after having separated its proprietary pharmaceutical business into a new company called AbbVie ( ABBV ) on Jan 1, 2013. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) reported first quarter 2013 earnings of 42 cents per share, in line with the Zacks Consensus Estimate and 5.0% above the year-ago earnings. |
27622.0 | 2013-04-11 00:00:00 UTC | Abbott's Heart FailureTest in Europe - Analyst Blog | ABBV | https://www.nasdaq.com/articles/abbotts-heart-failuretest-in-europe-analyst-blog-2013-04-11 | nan | nan | Abbott Labs ( ABT ) recently announced that the company obtained CE Marking (Conformite Europeenne) for its ARCHITECT Galectin-3 assay test.
We note that CE mark is mandatory confirmation for products placed in the European markets. Abbott developed this test in collabration with BG Medicine, Inc. ( BGMD ) to run on the ARCHITECT immunochemistry platform of Abbott..
The test is primarily aimed to enable doctors in assessing the prognosis of patients diagnosed with chronic heart failure (HF). ARCHITECT Galectin-3 assay test is available in several European countries.
Galectin-3 can indicate heart failure by chalking out the pathophysiology of heart failure. Subsequently, the doctors can identify susceptible patients for heart failure who are at high risk.
Abbott continues to focus on the development of next-generation instruments and other advanced technologies along with expansion in emerging markets in its diagnostics business.
Abbott looks to improve operating margins in this segment. In 2012, the company took steps to streamline various commercial operations in order to reduce costs and thereby improve efficiencies.
Meanwhile, Abbott is working on boosting its vascular products portfolio and expects to launch several products in the next five years.
The company intends to work on increasing international MitraClip sales and developing ABSORB, its bioresorbable vascular scaffold (BVS) device.
Abbott is also focusing on strengthening its drug eluting product portfolio, powered by the launch of Xience Xpedition drug-eluting stent in Europe in Aug 2012 and in the US in Jan 2013. Abbott expects to launch Xpedition in Japan in mid-2013 and market products in the Xience family.
We believe that Abbott is extremely diversified with businesses in nutrition, diagnostics, generic pharmaceuticals and medical devices after spinning off its pharmaceuticals business into a separate company, Abbvie Inc. ( ABBV ).
Abbott currently carries a Zacks Rank #3 (Hold). Right now, Nuvasive, Inc . ( NUVA ) looks better placed in the medical devices sector with a Zacks Rank #1 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
BG MEDICINE INC (BGMD): Free Stock Analysis Report
NUVASIVE INC (NUVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We believe that Abbott is extremely diversified with businesses in nutrition, diagnostics, generic pharmaceuticals and medical devices after spinning off its pharmaceuticals business into a separate company, Abbvie Inc. ( ABBV ). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BG MEDICINE INC (BGMD): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) recently announced that the company obtained CE Marking (Conformite Europeenne) for its ARCHITECT Galectin-3 assay test. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BG MEDICINE INC (BGMD): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. We believe that Abbott is extremely diversified with businesses in nutrition, diagnostics, generic pharmaceuticals and medical devices after spinning off its pharmaceuticals business into a separate company, Abbvie Inc. ( ABBV ). Meanwhile, Abbott is working on boosting its vascular products portfolio and expects to launch several products in the next five years. | We believe that Abbott is extremely diversified with businesses in nutrition, diagnostics, generic pharmaceuticals and medical devices after spinning off its pharmaceuticals business into a separate company, Abbvie Inc. ( ABBV ). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BG MEDICINE INC (BGMD): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott developed this test in collabration with BG Medicine, Inc. ( BGMD ) to run on the ARCHITECT immunochemistry platform of Abbott.. | We believe that Abbott is extremely diversified with businesses in nutrition, diagnostics, generic pharmaceuticals and medical devices after spinning off its pharmaceuticals business into a separate company, Abbvie Inc. ( ABBV ). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BG MEDICINE INC (BGMD): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Abbott is working on boosting its vascular products portfolio and expects to launch several products in the next five years. |
27623.0 | 2013-04-10 00:00:00 UTC | Roche Teams Up with Isis - Analyst Blog | ABBV | https://www.nasdaq.com/articles/roche-teams-up-with-isis-analyst-blog-2013-04-10 | nan | nan | Roche ( RHHBY ) recently announced an alliance with Isis Pharmaceuticals, Inc ( ISIS ) to develop therapies for Huntington's disease (HD).
This alliance will combine Isis' antisense oligonucleotide (ASO) technology with Roche's scientific expertise to develop neurodegenerative therapeutics for treating HD.
Isis develops antisense drug discovery programs targeting cardiovascular, severe and rare neurologic and metabolic diseases and cancer.
In addition, Roche will combine its proprietary brain shuttle technology with Isis ASO technology to enable systemic administration of antisense drugs for treating asymptomatic patients.
As per the agreement, Roche will make an upfront payment of $30 million to Isis. The total payment comprising license fee and pre- and post-licensing milestone payments is expected to touch $362 million including potential commercial milestone payments up to $80 million.
Additionally, Isis is eligible to receive royalties on sales of the drugs whereas Roche has the option to license the drugs from Isis through the completion of the first phase I trial. Before Roche exercises this option, Isis will be responsible for discovering and developing of an antisense drug targeting huntingtin (HTT) protein in collaboration with Roche.
Once Roche exercises its option, it will be responsible for the global development, regulatory and commercialization activities for all drugs resulting from the alliance. As per Roche, currently there is no effective cure for HD.
We are positive on the deal with Isis as the market for HD represents a huge unmet medical need.
The deal comes close on the heels of the Japanese approval of the subcutaneous injectable version of Roche's rheumatoid arthritis (RA) drug Actemra (tocilizumab). The subcutaneous version of the drug has been approved for treating RA patients who have not responded adequately to one or more existing medications for the disease.
Actemra primarily faces competition from AbbVie Inc.'s ( ABBV ) Humira in the RA space.
Roche, a large cap pharma company, carries a Zacks Rank #4 (Sell). Favorably placed large cap pharma stocks include Novartis ( NVS ) with a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ISIS PHARMACEUT (ISIS): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Actemra primarily faces competition from AbbVie Inc.'s ( ABBV ) Humira in the RA space. ABBVIE INC (ABBV): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. This alliance will combine Isis' antisense oligonucleotide (ASO) technology with Roche's scientific expertise to develop neurodegenerative therapeutics for treating HD. | ABBVIE INC (ABBV): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. Actemra primarily faces competition from AbbVie Inc.'s ( ABBV ) Humira in the RA space. This alliance will combine Isis' antisense oligonucleotide (ASO) technology with Roche's scientific expertise to develop neurodegenerative therapeutics for treating HD. | ABBVIE INC (ABBV): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. Actemra primarily faces competition from AbbVie Inc.'s ( ABBV ) Humira in the RA space. Additionally, Isis is eligible to receive royalties on sales of the drugs whereas Roche has the option to license the drugs from Isis through the completion of the first phase I trial. | Actemra primarily faces competition from AbbVie Inc.'s ( ABBV ) Humira in the RA space. ABBVIE INC (ABBV): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. Roche ( RHHBY ) recently announced an alliance with Isis Pharmaceuticals, Inc ( ISIS ) to develop therapies for Huntington's disease (HD). |
27624.0 | 2013-04-01 00:00:00 UTC | AbbVie Offers Nice Dividend Yield, Stock At New High | ABBV | https://www.nasdaq.com/articles/abbvie-offers-nice-dividend-yield-stock-new-high-2013-04-01 | nan | nan | DrugmakerAbbVie ( ABBV ) offers a nice dividend yield as the stock marches higher.
AbbVie, which was spun off fromAbbott Laboratories ( ABT ) earlier this year, is at its highest level since going public Jan. 2. It's climbed 17% since its IPO.
Meanwhile, the company on Feb. 15 declared a quarterly cash dividend of 40 cents a share, or $1.60 a year. That brings the annual dividend yield to 3.9% at the current share price. The dividend is payable May 15 to shareholders of record on April 15.
AbbVie was named to the S&P 500 Dividend Aristocrats Index of companies that have boosted their dividend for at least 25 straight years after the index changed its treatment of spin-off companies.
Bank of America on March 11 reaffirmed its buy rating on AbbVie shares and raised its price target by $2 to $42, which is 2% above Monday's close of 41.12.
AbbVie, formerly the pharmaceuticals unit of Abbott Labs, relies heavily on Humira, a treatment for rheumatoid arthritis, psoriasis and Crohn's disease that accounts for almost half of the company's revenue. Sales of testosterone-boosting treatment AndroGel have also picked up. AbbVie is currently working on a hepatitis C regimen that analysts expect will debut in 2015.
The company expects to earn between $3.03 and $3.13 a share in 2013, which is in line with Wall Street's expectations.
AbbVie's A- Accumulation/Distribution Rating points to strong institutional demand for the shares.
AbbVie is in the 40-member Medical-Ethical Drugs industry group, which hosts a number of current and former market leaders, including IBD 50 stock Valeant Pharmaceuticals ( VRX ) andQuestcor Pharmaceuticals ( QCOR ).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie, which was spun off fromAbbott Laboratories ( ABT ) earlier this year, is at its highest level since going public Jan. 2. Bank of America on March 11 reaffirmed its buy rating on AbbVie shares and raised its price target by $2 to $42, which is 2% above Monday's close of 41.12. AbbVie, formerly the pharmaceuticals unit of Abbott Labs, relies heavily on Humira, a treatment for rheumatoid arthritis, psoriasis and Crohn's disease that accounts for almost half of the company's revenue. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. DrugmakerAbbVie ( ABBV ) offers a nice dividend yield as the stock marches higher. AbbVie, which was spun off fromAbbott Laboratories ( ABT ) earlier this year, is at its highest level since going public Jan. 2. | AbbVie was named to the S&P 500 Dividend Aristocrats Index of companies that have boosted their dividend for at least 25 straight years after the index changed its treatment of spin-off companies. AbbVie, formerly the pharmaceuticals unit of Abbott Labs, relies heavily on Humira, a treatment for rheumatoid arthritis, psoriasis and Crohn's disease that accounts for almost half of the company's revenue. AbbVie is in the 40-member Medical-Ethical Drugs industry group, which hosts a number of current and former market leaders, including IBD 50 stock Valeant Pharmaceuticals ( VRX ) andQuestcor Pharmaceuticals ( QCOR ). | AbbVie, which was spun off fromAbbott Laboratories ( ABT ) earlier this year, is at its highest level since going public Jan. 2. Bank of America on March 11 reaffirmed its buy rating on AbbVie shares and raised its price target by $2 to $42, which is 2% above Monday's close of 41.12. DrugmakerAbbVie ( ABBV ) offers a nice dividend yield as the stock marches higher. |
27625.0 | 2013-03-27 00:00:00 UTC | Positive Data on Biogen's Plegridy - Analyst Blog | ABBV | https://www.nasdaq.com/articles/positive-data-on-biogens-plegridy-analyst-blog-2013-03-27 | nan | nan | Biogen Idec ( BIIB ) recently presented full first-year phase III results on its multiple sclerosis candidate, Plegridy (peginterferon beta-1a). Results from the ADVANCE study, which were initially reported in Jan 2013, showed that Plegridy met the primary endpoint as well as secondary endpoints.
Detailed Results
Plegridy was compared to placebo in the study that was conducted to evaluate the safety and efficacy of the candidate in patients suffering from relapsing-remitting multiple sclerosis (RRMS).
Plegridy (dosed once in two weeks) met the primary endpoint of annualized relapse rate (ARR) at one year. ARR reduction was 36% compared to placebo.
Secondary endpoints included reduction of the risk of 12-week confirmed disability progression as measured by the Expanded Disability Status Scale (by 38%), reduction in the proportion of patients who relapsed (by 39%) and reduction in the number of new or newly enlarging T2-hyperintense lesions on brain MRI scans (by 67%) compared to placebo. The number of gadolinium-enhancing (Gd+) lesions was reduced by 86% in the Plegridy arm.
These results were presented at the annual meeting of the American Academy of Neurology. While a once-in-four weeks dosing regimen of Plegridy was also evaluated in the study, the once- every-two weeks dosing arm was more effective.
Meanwhile, with these positive results in hand, the company should be able to go ahead with its plans of filing for US and EU approval this year.
Our Take
We are pleased with Biogen's progress with its multiple sclerosis pipeline. A less frequent dosing schedule and a favorable safety and efficacy profile should work in Plegridy's favor once it is launched.
Biogen is the market leader in therapies for the treatment of multiple sclerosis. We believe the company will continue to retain a leading position in the multiple sclerosis market. Biogen has an important regulatory event coming up with an FDA decision on its oral multiple sclerosis candidate, Tecfidera, expected in the coming days. We believe Tecfidera could become a leader in the oral multiple sclerosis market once launched. Biogen has another multiple sclerosis candidate, daclizumab, in development with AbbVie ( ABBV ).
Biogen currently carries a Zacks Rank #2 (Buy). Other stocks that currently look more attractive include companies like Athersys, Inc. ( ATHX ), and Cytokinetics, Inc. ( CYTK ). Both are Zacks Rank #1 (Strong Buy) stocks.
ABBVIE INC (ABBV): Free Stock Analysis Report
ATHERSYS INC (ATHX): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
CYTOKINETCS INC (CYTK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Biogen has another multiple sclerosis candidate, daclizumab, in development with AbbVie ( ABBV ). ABBVIE INC (ABBV): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen Idec ( BIIB ) recently presented full first-year phase III results on its multiple sclerosis candidate, Plegridy (peginterferon beta-1a). | ABBVIE INC (ABBV): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen has another multiple sclerosis candidate, daclizumab, in development with AbbVie ( ABBV ). Plegridy (dosed once in two weeks) met the primary endpoint of annualized relapse rate (ARR) at one year. | ABBVIE INC (ABBV): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen has another multiple sclerosis candidate, daclizumab, in development with AbbVie ( ABBV ). Biogen Idec ( BIIB ) recently presented full first-year phase III results on its multiple sclerosis candidate, Plegridy (peginterferon beta-1a). | Biogen has another multiple sclerosis candidate, daclizumab, in development with AbbVie ( ABBV ). ABBVIE INC (ABBV): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Detailed Results Plegridy was compared to placebo in the study that was conducted to evaluate the safety and efficacy of the candidate in patients suffering from relapsing-remitting multiple sclerosis (RRMS). |
27626.0 | 2013-03-27 00:00:00 UTC | Japanese Approval for Bayer's drug - Analyst Blog | ABBV | https://www.nasdaq.com/articles/japanese-approval-for-bayers-drug-analyst-blog-2013-03-27 | nan | nan | Bayer 's ( BAYRY ) HealthCare segment recently received encouraging news as the Ministry of Health, Labour and Welfare (MHLW) in Japan approved Stivarga (regorafenib). Stivarga is approved in Japan for the treatment of patients suffering from unresectable, advanced/recurrent colorectal cancer (CRC).
Bayer stated in its press release that CRC is the third most common cause of cancer death in Japan. More than 40,000 people die in Japan every year due to CRC.
The Japanese approval of Stivarga was based on results from the phase III CORRECT study. Results from the study showed improvement in overall survival and progression-free survival in comparison to placebo, in patients suffering from metastatic CRC (mCRC) and whose disease had progressed after approved standard therapies.
Stivarga is already approved in the US for treating patients suffering from mCRC, whose disease had progressed even after treatment with standard drugs prescribed for the disease. Stivarga is also approved for metastatic gastrointestinal stromal tumors (GIST) indication in the US. Bayer is also seeking EU approval of Stivarga for the treatment of mCRC.
Bayer, meanwhile, received a huge setback earlier this month when the company and its partner Johnson & Johnson ( JNJ ) received a second complete response letter (CRL) from the US Food and Drug Administration (FDA) for their supplemental New Drug Application (sNDA) for Xarelto (2.5 mg twice daily) for the reduction of the risk of secondary cardiovascular events in patients suffering from ACS.
The second CRL for Xarelto is a big disappointment for the company. Bayer, a large cap pharma company, currently carries a Zacks Rank #4 (Sell). Meanwhile, other large cap pharma stocks such as Novo Nordisk ( NVO ) and AbbVie Inc. ( ABBV ) are better positioned carrying a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, other large cap pharma stocks such as Novo Nordisk ( NVO ) and AbbVie Inc. ( ABBV ) are better positioned carrying a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. Bayer 's ( BAYRY ) HealthCare segment recently received encouraging news as the Ministry of Health, Labour and Welfare (MHLW) in Japan approved Stivarga (regorafenib). | ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, other large cap pharma stocks such as Novo Nordisk ( NVO ) and AbbVie Inc. ( ABBV ) are better positioned carrying a Zacks Rank #2 (Buy). Results from the study showed improvement in overall survival and progression-free survival in comparison to placebo, in patients suffering from metastatic CRC (mCRC) and whose disease had progressed after approved standard therapies. | ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, other large cap pharma stocks such as Novo Nordisk ( NVO ) and AbbVie Inc. ( ABBV ) are better positioned carrying a Zacks Rank #2 (Buy). Results from the study showed improvement in overall survival and progression-free survival in comparison to placebo, in patients suffering from metastatic CRC (mCRC) and whose disease had progressed after approved standard therapies. | Meanwhile, other large cap pharma stocks such as Novo Nordisk ( NVO ) and AbbVie Inc. ( ABBV ) are better positioned carrying a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. Stivarga is approved in Japan for the treatment of patients suffering from unresectable, advanced/recurrent colorectal cancer (CRC). |
27627.0 | 2013-03-27 00:00:00 UTC | Good News for Roche - Analyst Blog | ABBV | https://www.nasdaq.com/articles/good-news-for-roche-analyst-blog-2013-03-27 | nan | nan | Chugai Pharmaceutical Company, Limited - a subsidiary of Roche ( RHHBY ) - announced that the subcutaneous injectable version of its rheumatoid arthritis (RA) drug Actemra (tocilizumab) has been approved by the Japanese health authorities. The subcutaneous version of the drug has been approved for treating RA patients who have not responded adequately to one or more existing medications for the disease.
We note that a phase III study, conducted in Japan, demonstrated that the subcutaneous version of Actemra was as effective as its intravenous formulation. Moreover, the safety profiles of both versions were comparable. The subcutaneous version of the RA drug is currently under review in the US and the EU.
We remind investors that the intravenous version of Actemra is available in Japan since Jun 2005. Subsequently, the drug was cleared for additional RA indications (including prevention of structural damage of joints), polyarticular-course juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis (sJIA).
We note that the intravenous version of the drug is available in the EU (brand name: RoActemra) since 2009 for treating adult RA patients who have either responded insufficiently to, or were intolerant to, previous medication with one or more disease-modifying antirheumatic drugs (DMARDs) or tumor necrosis factor (TNF) inhibitors.
Actemra was approved by the US Food and Drug Administration (FDA) in Jan 2010 for treating adults suffering from moderately to severely active RA who have responded inadequately to one or more TNF inhibitors. The indication was expanded in Oct 2012.
The intravenous version is currently approved in more than 100 countries including the US, EU, India, Brazil, Switzerland and Australia. The RA market is highly competitive. Actemra primarily faces competition from UCB 's ( UCBJF ) Cimzia and AbbVie Inc. 's ( ABBV ) Humira in the RA space.
Roche, a large cap pharma company, carries a Zacks Rank #4 (Sell), reflecting short-term pressure on the stock. Novo Nordisk ( NVO ) appears to be favorably placed in the large cap pharma space, carrying a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ROCHE HLDG LTD (RHHBY): Get Free Report
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Actemra primarily faces competition from UCB 's ( UCBJF ) Cimzia and AbbVie Inc. 's ( ABBV ) Humira in the RA space. ABBVIE INC (ABBV): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Chugai Pharmaceutical Company, Limited - a subsidiary of Roche ( RHHBY ) - announced that the subcutaneous injectable version of its rheumatoid arthritis (RA) drug Actemra (tocilizumab) has been approved by the Japanese health authorities. | ABBVIE INC (ABBV): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Actemra primarily faces competition from UCB 's ( UCBJF ) Cimzia and AbbVie Inc. 's ( ABBV ) Humira in the RA space. Roche, a large cap pharma company, carries a Zacks Rank #4 (Sell), reflecting short-term pressure on the stock. | ABBVIE INC (ABBV): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Actemra primarily faces competition from UCB 's ( UCBJF ) Cimzia and AbbVie Inc. 's ( ABBV ) Humira in the RA space. Chugai Pharmaceutical Company, Limited - a subsidiary of Roche ( RHHBY ) - announced that the subcutaneous injectable version of its rheumatoid arthritis (RA) drug Actemra (tocilizumab) has been approved by the Japanese health authorities. | Actemra primarily faces competition from UCB 's ( UCBJF ) Cimzia and AbbVie Inc. 's ( ABBV ) Humira in the RA space. ABBVIE INC (ABBV): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. The subcutaneous version of the drug has been approved for treating RA patients who have not responded adequately to one or more existing medications for the disease. |
27628.0 | 2013-03-25 00:00:00 UTC | Positive Data on Novartis' Gilenya - Analyst Blog | ABBV | https://www.nasdaq.com/articles/positive-data-on-novartis-gilenya-analyst-blog-2013-03-25 | nan | nan | Novartis ( NVS ) recently presented new data on Gilenya (fingolimod), which demonstrated that the drug can considerably reduce the rate of brain volume loss.
Gilenya is the first approved once-daily oral therapy for the treatment of relapsing forms of multiple sclerosis (MS). The data also showed that Gilenya reduced annualized relapse rates across patients in different age groups.
Results from three large pivotal phase III studies (TRANSFORMS, FREEDOMS and FREEDOMS II) revealed that Gilenya can significantly lessen the rate of brain volume loss versus a comparator.
Additionally, new extension data from FREEDOMS II reinforces the safety profile of Gilenya in patients who were treated up to four years.
Earlier, in Oct 2012, Novartis presented results from the FREEDOMS (n=1272) and FREEDOMS II (n=1083) studies. These studies revealed that early treatment with Gilenya has a significant positive effect on relapses and magnetic resonance imaging MRI outcomes, including loss of brain volume, in MS patients.
The difference between the drug and placebo was significant by day 82 in FREEDOMS study, whereas the same was observed by day 64 in the FREEDOMS II study.
We note that Gilenya is approved in the US for relapsing forms of MS. In the EU, Gilenya is approved for adult patients with highly active relapsing-remitting MS (RRMS), which is also known as rapidly evolving severe RRMS.
Novartis licensed Gilenya from Mitsubishi Tanabe Pharma Corporation. Gilenya is currently approved in over 65 countries around the world.
Gilenya recorded $349 million of sales in the fourth quarter of 2012, up 74% from the year-ago quarter. For 2012, sales touched $1.2 billion, up 147% from 2011.
Hence, we are encouraged by the new data presented on Gilenya, which should bolster growth for Novartis.
Right now, Novartis carries a Zacks Rank #3 (Hold). Pharma stocks, which currently look more attractive include Novo Nordisk ( NVO ), Furiex Pharmaceuticals Inc. ( FURX ), and Abbvie ( ABBV ) all with a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
FURIEX PHARMACT (FURX): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Pharma stocks, which currently look more attractive include Novo Nordisk ( NVO ), Furiex Pharmaceuticals Inc. ( FURX ), and Abbvie ( ABBV ) all with a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report FURIEX PHARMACT (FURX): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis ( NVS ) recently presented new data on Gilenya (fingolimod), which demonstrated that the drug can considerably reduce the rate of brain volume loss. | ABBVIE INC (ABBV): Free Stock Analysis Report FURIEX PHARMACT (FURX): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Pharma stocks, which currently look more attractive include Novo Nordisk ( NVO ), Furiex Pharmaceuticals Inc. ( FURX ), and Abbvie ( ABBV ) all with a Zacks Rank #2 (Buy). Results from three large pivotal phase III studies (TRANSFORMS, FREEDOMS and FREEDOMS II) revealed that Gilenya can significantly lessen the rate of brain volume loss versus a comparator. | ABBVIE INC (ABBV): Free Stock Analysis Report FURIEX PHARMACT (FURX): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Pharma stocks, which currently look more attractive include Novo Nordisk ( NVO ), Furiex Pharmaceuticals Inc. ( FURX ), and Abbvie ( ABBV ) all with a Zacks Rank #2 (Buy). Results from three large pivotal phase III studies (TRANSFORMS, FREEDOMS and FREEDOMS II) revealed that Gilenya can significantly lessen the rate of brain volume loss versus a comparator. | Pharma stocks, which currently look more attractive include Novo Nordisk ( NVO ), Furiex Pharmaceuticals Inc. ( FURX ), and Abbvie ( ABBV ) all with a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report FURIEX PHARMACT (FURX): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis ( NVS ) recently presented new data on Gilenya (fingolimod), which demonstrated that the drug can considerably reduce the rate of brain volume loss. |
27629.0 | 2013-03-25 00:00:00 UTC | Lilly, Boehringer Ingelheim Start Diabetes Study - Analyst Blog | ABBV | https://www.nasdaq.com/articles/lilly-boehringer-ingelheim-start-diabetes-study-analyst-blog-2013-03-25 | nan | nan | Eli Lilly and Company ( LLY ) and Boehringer Ingelheim Pharmaceuticals, Inc. recently announced that they have commenced a phase IIIb study with Tradjenta (linagliptin) in type II diabetes patients with prevalent albuminuria who are currently receiving standard treatment for diabetic nephropathy.
The 24-week, multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group study, MARINA (efficacy, safety & Modification of Albuminuria in type 2 diabetes subjects with Renal disease with LINAgliptin), will evaluate the glycemic efficacy and safety of once-daily Tradjenta (5 mg). The study is slated to complete in 2014.
Tradjenta is currently approved for use in type II diabetes patients along with diet and exercise.
We are pleased with Eli Lilly's efforts to strengthen its diabetes franchise. Earlier this year, Eli Lilly and Boehringer Ingelheim had announced positive top-line results on empagliflozin from four phase III trials. Empagliflozin (10 and 25 mg taken once daily), a sodium glucose co-transporter-2 (SGLT-2) inhibitor, was found to be more effective in lowering blood sugar levels compared to placebo. Eli Lilly and Boehringer Ingelheim recently submitted a new drug application for empagliflozin in the US.
Eli Lilly currently carries a Zacks Rank #3 (Hold). The biggest near-term challenge for Eli Lilly will be to replace the revenues that will be lost to generic competition now that Zyprexa has lost US and EU exclusivity. The generic threat will continue to pose challenges for Eli Lilly with Cymbalta slated to lose patent protection in late 2013 and Evista in 2014.
On the flip side, the Animal Health business and the diabetes franchise should provide some downside support. We are also pleased to see Eli Lilly pursuing small acquisitions and in-licensing deals to boost its pipeline.
Currently, large-cap companies like Novo Nordisk ( NVO ) and AbbVie ( ABBV ) carry a Zacks Rank #2 (Buy). Meanwhile, UCB ( UCBJF ) carries a Zacks Rank #1 (Strong Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Currently, large-cap companies like Novo Nordisk ( NVO ) and AbbVie ( ABBV ) carry a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Earlier this year, Eli Lilly and Boehringer Ingelheim had announced positive top-line results on empagliflozin from four phase III trials. | Currently, large-cap companies like Novo Nordisk ( NVO ) and AbbVie ( ABBV ) carry a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Eli Lilly and Company ( LLY ) and Boehringer Ingelheim Pharmaceuticals, Inc. recently announced that they have commenced a phase IIIb study with Tradjenta (linagliptin) in type II diabetes patients with prevalent albuminuria who are currently receiving standard treatment for diabetic nephropathy. | ABBVIE INC (ABBV): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Currently, large-cap companies like Novo Nordisk ( NVO ) and AbbVie ( ABBV ) carry a Zacks Rank #2 (Buy). Eli Lilly and Company ( LLY ) and Boehringer Ingelheim Pharmaceuticals, Inc. recently announced that they have commenced a phase IIIb study with Tradjenta (linagliptin) in type II diabetes patients with prevalent albuminuria who are currently receiving standard treatment for diabetic nephropathy. | Currently, large-cap companies like Novo Nordisk ( NVO ) and AbbVie ( ABBV ) carry a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Eli Lilly and Company ( LLY ) and Boehringer Ingelheim Pharmaceuticals, Inc. recently announced that they have commenced a phase IIIb study with Tradjenta (linagliptin) in type II diabetes patients with prevalent albuminuria who are currently receiving standard treatment for diabetic nephropathy. |
27630.0 | 2013-03-25 00:00:00 UTC | CHMP Positive on Bayer's Xarelto - Analyst Blog | ABBV | https://www.nasdaq.com/articles/chmp-positive-on-bayers-xarelto-analyst-blog-2013-03-25 | nan | nan | Bayer 's ( BAYRY ) HealthCare segment recently received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP) for Xarelto (rivaroxaban) in combination with standard antiplatelet therapy.
Bayer is looking to get Xarelto's label expanded for the prevention of atherothrombotic events (myocardial infarction, cardiovascular death or stroke) after an acute coronary syndrome (ACS) in adults having elevated cardiac biomarkers.
A final decision from the European Commission on the approval of the new indication of Xarelto is expected soon. We note that though the European Commission is not bound to follow the CHMP's decision, it generally does so.
Xarelto was studied in the phase III ATLAS ACS 2-TIMI 51 study. Results from the study showed that Xarelto along with standard antiplatelet therapy significantly reduced cardiovascular death, myocardial infarction or stroke in patients after an ACS in comparison to those who received standard antiplatelet therapy alone.
Xarelto is marketed by Johnson & Johnson ( JNJ ) in the US and by Bayer outside the US.
We note that Xarelto is already approved for several indications in the US including stroke prevention in nonvalvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE) and reducing the risk of recurrent DVT and PE. The drug performed impressively last year. In 2012, Xarelto sales increased 265.9% year over year to €322 million (approximately $414.1 million).
Earlier this month, Bayer and Johnson & Johnson received a huge setback with the US Food and Drug Administration (FDA) issuing a second complete response letter (CRL) for the supplemental New Drug Application (sNDA) for Xarelto (2.5 mg twice daily) for the reduction of the risk of secondary cardiovascular events in patients suffering from ACS.
A second CRL from the US regulatory body is a huge disappointment for the company. Bayer, a large cap pharma company, currently carries a Zacks Rank #4 (Sell). Meanwhile other large cap pharma stocks such as Novo Nordisk ( NVO ) and AbbVie Inc. ( ABBV ) are better positioned carrying a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile other large cap pharma stocks such as Novo Nordisk ( NVO ) and AbbVie Inc. ( ABBV ) are better positioned carrying a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. Bayer 's ( BAYRY ) HealthCare segment recently received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP) for Xarelto (rivaroxaban) in combination with standard antiplatelet therapy. | ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile other large cap pharma stocks such as Novo Nordisk ( NVO ) and AbbVie Inc. ( ABBV ) are better positioned carrying a Zacks Rank #2 (Buy). Results from the study showed that Xarelto along with standard antiplatelet therapy significantly reduced cardiovascular death, myocardial infarction or stroke in patients after an ACS in comparison to those who received standard antiplatelet therapy alone. | ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile other large cap pharma stocks such as Novo Nordisk ( NVO ) and AbbVie Inc. ( ABBV ) are better positioned carrying a Zacks Rank #2 (Buy). Results from the study showed that Xarelto along with standard antiplatelet therapy significantly reduced cardiovascular death, myocardial infarction or stroke in patients after an ACS in comparison to those who received standard antiplatelet therapy alone. | Meanwhile other large cap pharma stocks such as Novo Nordisk ( NVO ) and AbbVie Inc. ( ABBV ) are better positioned carrying a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. A final decision from the European Commission on the approval of the new indication of Xarelto is expected soon. |
27631.0 | 2013-03-18 00:00:00 UTC | AbbVie-Receptos Collaborate - Analyst Blog | ABBV | https://www.nasdaq.com/articles/abbvie-receptos-collaborate-analyst-blog-2013-03-18 | nan | nan | AbbVie ( ABBV ) recently entered into a collaboration with biopharma company, Receptos Inc., whereby the latter in-licensed RPC4046 from AbbVie.
The Candidate - RPC4046
RPC4045 is a humanized anti-interleukin-13 (IL-13) antibody asset. AbbVie has already conducted a phase I study with RPC4046 - results showed that RPC4046 was well tolerated in healthy people as well as in patients suffering from mild to moderate persistent asthma. Moreover, the results supported the use of RPC4046 in both single dose IV administration and multiple subcutaneous doses.
Terms of the Deal
Under the Development License and Option Agreement, Receptos will conduct a phase II proof-of-concept study with the candidate which is being developed for eosinophilic esophagitis (EoE). Once results from this study are available and following discussions with the FDA, AbbVie has the exclusive option to enter into a worldwide co-development collaboration with Receptos for RPC4046.
Once AbbVie exercises its option, both companies will share costs related to the phase III and future development of the candidate equally. While Receptos would retain co-promotion and equal profit rights in the US, AbbVie will hold sole commercial rights in ex-US territories. Receptos would be eligible to receive double-digit royalties on net sales outside the US. The companies may also choose to pursue additional indications under the collaboration.
Meanwhile, if AbbVie does not exercise its option, worldwide exclusive commercial license to all indications for RPC4046 would remain with Receptos.
AbbVie currently carries a Zacks Rank #3 (Hold). While we are positive on the company's strong late-stage pipeline, dividend yield and growth strategy, we remain concerned about AbbVie's dependence on Humira. We believe the company will continue pursuing licensing deals and collaborations to boost its pipeline.
Large-cap companies that currently look more attractive include Eli Lilly ( LLY ) and Novo Nordisk ( NVO ). Both companies carry a Zacks Rank #2 (Buy). Meanwhile, companies like QLT Inc. ( QLTI ) carry a Zacks Rank #1 (Strong Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
QLT INC (QLTI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie has already conducted a phase I study with RPC4046 - results showed that RPC4046 was well tolerated in healthy people as well as in patients suffering from mild to moderate persistent asthma. Once AbbVie exercises its option, both companies will share costs related to the phase III and future development of the candidate equally. While we are positive on the company's strong late-stage pipeline, dividend yield and growth strategy, we remain concerned about AbbVie's dependence on Humira. | Meanwhile, if AbbVie does not exercise its option, worldwide exclusive commercial license to all indications for RPC4046 would remain with Receptos. ABBVIE INC (ABBV): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report QLT INC (QLTI): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ( ABBV ) recently entered into a collaboration with biopharma company, Receptos Inc., whereby the latter in-licensed RPC4046 from AbbVie. | AbbVie ( ABBV ) recently entered into a collaboration with biopharma company, Receptos Inc., whereby the latter in-licensed RPC4046 from AbbVie. Once AbbVie exercises its option, both companies will share costs related to the phase III and future development of the candidate equally. ABBVIE INC (ABBV): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report QLT INC (QLTI): Free Stock Analysis Report To read this article on Zacks.com click here. | Once results from this study are available and following discussions with the FDA, AbbVie has the exclusive option to enter into a worldwide co-development collaboration with Receptos for RPC4046. Meanwhile, if AbbVie does not exercise its option, worldwide exclusive commercial license to all indications for RPC4046 would remain with Receptos. AbbVie ( ABBV ) recently entered into a collaboration with biopharma company, Receptos Inc., whereby the latter in-licensed RPC4046 from AbbVie. |
27632.0 | 2013-03-01 00:00:00 UTC | After Hours Most Active for Mar 1, 2013 : CERS, SIRI, ABT, SBGL, ABBV, VOD, BAC, NOK, QQQ, AMD, INTC, HOLX | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-mar-1-2013-cers-siri-abt-sbgl-abbv-vod-bac-nok-qqq-amd-intc-holx | nan | nan | The NASDAQ 100 After Hours Indicator is down -.84 to 2,746.91. The total After hours volume is currently 28,730,449 shares traded.
The following are the most active stocks for the after hours session :
Cerus Corporation ( CERS ) is -0.11 at $3.55, with 2,817,070 shares traded. As reported in the last short interest update the days to cover for CERS is 45.834328; this calculation is based on the average trading volume of the stock.
Sirius XM Radio Inc. ( SIRI ) is +0.005 at $3.14, with 2,157,260 shares traded. SIRI's current last sale is 95.15% of the target price of $3.3.
Abbott Laboratories ( ABT ) is +0.04 at $33.64, with 2,078,381 shares traded. ABT's current last sale is 89.71% of the target price of $37.5.
Sibanye Gold Limited ( SBGL ) is +0.2619 at $6.12, with 2,058,647 shares traded.
AbbVie Inc. ( ABBV ) is unchanged at $37.81, with 2,057,147 shares traded. ABBV's current last sale is 100.83% of the target price of $37.5.
Vodafone Group Plc ( VOD ) is -0.01 at $25.40, with 1,778,199 shares traded. VOD's current last sale is 78.88% of the target price of $32.2.
Bank of America Corporation ( BAC ) is -0.01 at $11.33, with 1,016,747 shares traded. BAC's current last sale is 87.15% of the target price of $13.
Nokia Corporation ( NOK ) is -0.03 at $3.56, with 744,895 shares traded. As reported in the last short interest update the days to cover for NOK is 8.366578; this calculation is based on the average trading volume of the stock.
PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.02 at $67.40, with 692,034 shares traded. This represents a 12.26% increase from its 52 Week Low.
Advanced Micro Devices, Inc. ( AMD ) is +0.01 at $2.43, with 644,665 shares traded. AMD's current last sale is 88.36% of the target price of $2.75.
Intel Corporation ( INTC ) is +0.04 at $21.06, with 524,249 shares traded. INTC's current last sale is 94.65% of the target price of $22.25.
Hologic, Inc. ( HOLX ) is unchanged at $21.61, with 366,664 shares traded. Over the last four weeks they have had 8 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2013. The consensus EPS forecast is $0.4. As reported by Zacks, the current mean recommendation for HOLX is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ( ABBV ) is unchanged at $37.81, with 2,057,147 shares traded. ABBV's current last sale is 100.83% of the target price of $37.5. The following are the most active stocks for the after hours session : Cerus Corporation ( CERS ) is -0.11 at $3.55, with 2,817,070 shares traded. | AbbVie Inc. ( ABBV ) is unchanged at $37.81, with 2,057,147 shares traded. ABBV's current last sale is 100.83% of the target price of $37.5. The total After hours volume is currently 28,730,449 shares traded. | AbbVie Inc. ( ABBV ) is unchanged at $37.81, with 2,057,147 shares traded. ABBV's current last sale is 100.83% of the target price of $37.5. The total After hours volume is currently 28,730,449 shares traded. | AbbVie Inc. ( ABBV ) is unchanged at $37.81, with 2,057,147 shares traded. ABBV's current last sale is 100.83% of the target price of $37.5. The following are the most active stocks for the after hours session : Cerus Corporation ( CERS ) is -0.11 at $3.55, with 2,817,070 shares traded. |
27633.0 | 2013-02-27 00:00:00 UTC | After Hours Most Active for Feb 27, 2013 : F, GRPN, JCI, ABT, ABBV, JCP, GTAT, QQQ, BAC, TLAB, ENDP, ACWI | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-feb-27-2013-f-grpn-jci-abt-abbv-jcp-gtat-qqq-bac-tlab-endp-acwi | nan | nan | The NASDAQ 100 After Hours Indicator is down -1.06 to 2,740.2. The total After hours volume is currently 31,871,127 shares traded.
The following are the most active stocks for the after hours session :
Ford Motor Company ( F ) is +0.0301 at $12.79, with 13,290,050 shares traded. F's current last sale is 85.27% of the target price of $15.
Groupon, Inc. ( GRPN ) is -1.34 at $4.64, with 10,031,806 shares traded. RTT News Reports: Groupon Q4 Loss Widens, Shares Plunge
Johnson Controls, Inc. ( JCI ) is +0.0012 at $31.41, with 4,570,953 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2013. The consensus EPS forecast is $0.89. JCI's current last sale is 95.19% of the target price of $33.
Abbott Laboratories ( ABT ) is +0.1201 at $34.38, with 2,093,690 shares traded. ABT's current last sale is 91.68% of the target price of $37.5.
AbbVie Inc. ( ABBV ) is unchanged at $36.73, with 2,082,586 shares traded. ABBV's current last sale is 97.95% of the target price of $37.5.
J.C. Penney Company, Inc. Holding Company ( JCP ) is -1.25 at $19.91, with 1,319,299 shares traded. RTT News Reports: Vornado Chairman Roth Named CEO As Fascitelli Resigns
GT Advanced Technologies, Inc. ( GTAT ) is unchanged at $3.07, with 1,083,932 shares traded. RTT News Reports: GT Advanced Technologies Provides Q4 Outlook - Quick Facts
PowerShares QQQ Trust, Series 1 ( QQQ ) is +0.01 at $67.24, with 1,054,976 shares traded. This represents a 11.99% increase from its 52 Week Low.
Bank of America Corporation ( BAC ) is -0.01 at $11.29, with 1,021,463 shares traded. BAC's current last sale is 86.85% of the target price of $13.
Tellabs, Inc. ( TLAB ) is +0.01 at $2.04, with 735,744 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2013. The consensus EPS forecast is $0.01. TLAB's current last sale is 90.67% of the target price of $2.25.
Endo Health Solutions Inc. ( ENDP ) is -0.4187 at $30.38, with 606,100 shares traded.ENDP is scheduled to provide an earnings report on 2/28/2013, for the fiscal quarter ending Dec2012. The consensus earnings per share forecast is 1.56 per share, which represents a 140 percent increase over the EPS one Year Ago
iShares MSCI ACWI Index Fund ( ACWI ) is -0.0588 at $49.85, with 507,710 shares traded. This represents a 21.41% increase from its 52 Week Low.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ( ABBV ) is unchanged at $36.73, with 2,082,586 shares traded. ABBV's current last sale is 97.95% of the target price of $37.5. The following are the most active stocks for the after hours session : Ford Motor Company ( F ) is +0.0301 at $12.79, with 13,290,050 shares traded. | Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2013. AbbVie Inc. ( ABBV ) is unchanged at $36.73, with 2,082,586 shares traded. ABBV's current last sale is 97.95% of the target price of $37.5. | AbbVie Inc. ( ABBV ) is unchanged at $36.73, with 2,082,586 shares traded. ABBV's current last sale is 97.95% of the target price of $37.5. RTT News Reports: Groupon Q4 Loss Widens, Shares Plunge Johnson Controls, Inc. ( JCI ) is +0.0012 at $31.41, with 4,570,953 shares traded. | AbbVie Inc. ( ABBV ) is unchanged at $36.73, with 2,082,586 shares traded. ABBV's current last sale is 97.95% of the target price of $37.5. The NASDAQ 100 After Hours Indicator is down -1.06 to 2,740.2. |
27634.0 | 2013-02-20 00:00:00 UTC | Patent Challenge from Perrigo - Analyst Blog | ABBV | https://www.nasdaq.com/articles/patent-challenge-from-perrigo-analyst-blog-2013-02-20 | nan | nan | Recently, Perrigo Company ( PRGO ) announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market its generic version of AbbVie Inc. 's ( ABBV ) Androgel 1.62%. Perrigo believes that it is the first-to-file, entitling it to 180 days exclusivity of generic Androgel 1.62%.
We note that AndroGel 1.62% (testosterone gel 1.62%) is marketed for treating males (above 18 years of age) with low or no testosterone in their body. The annual sales of this product were approximately $680 million, according to data released by Wolters Kluwer Health.
AbbVie came into existence earlier this year following its separation from Abbott Laboratories ( ABT ). AbbVie provided its guidance for 2013. The company expects to earn $3.03-$3.13 per share in 2013 on total revenues of more than $18 billion. Currency movement is expected to negatively impact revenues by about 1%.
We remind investors that Perrigo reported lower-than-expected revenues, but higher-than-expected earnings in its second quarter 2013 (ended Dec 29, 2012).
Apart from announcing its financial results, Perrigo inked a deal to buy animal health company Velcera, Inc. for $160 million in cash. The deal is expected to close in calendar year 2013. Perrigo intends to strengthen its position in the OTC retail pet healthcare market through the impending acquisition.
Perrigo, which develops, manufactures and distributes OTC and generic prescription pharmaceuticals among others, carries a Zacks Rank #2 (Buy) in the short-run. Meanwhile, biopharma stock, Actelion Ltd. ( ALIOF ) has a Zacks Rank #1 (Strong Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ACTELION LTD (ALIOF): Get Free Report
PERRIGO COMPANY (PRGO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Recently, Perrigo Company ( PRGO ) announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market its generic version of AbbVie Inc. 's ( ABBV ) Androgel 1.62%. AbbVie came into existence earlier this year following its separation from Abbott Laboratories ( ABT ). AbbVie provided its guidance for 2013. | Recently, Perrigo Company ( PRGO ) announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market its generic version of AbbVie Inc. 's ( ABBV ) Androgel 1.62%. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report PERRIGO COMPANY (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie came into existence earlier this year following its separation from Abbott Laboratories ( ABT ). | Recently, Perrigo Company ( PRGO ) announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market its generic version of AbbVie Inc. 's ( ABBV ) Androgel 1.62%. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report PERRIGO COMPANY (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie came into existence earlier this year following its separation from Abbott Laboratories ( ABT ). | Recently, Perrigo Company ( PRGO ) announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market its generic version of AbbVie Inc. 's ( ABBV ) Androgel 1.62%. AbbVie came into existence earlier this year following its separation from Abbott Laboratories ( ABT ). AbbVie provided its guidance for 2013. |
27635.0 | 2013-02-11 00:00:00 UTC | Weekly 52 Week Highs: ABBV, ABT, YUM, AET | ABBV | https://www.nasdaq.com/articles/weekly-52-week-highs-abbv-abt-yum-aet-2013-02-11 | nan | nan | According to GuruFocus Insider Data , these are the largest insider buys during the past week: AbbVie Inc. ( ABBV ), Abbot Laboratories ( ABT ), Yum! Brands Inc. ( YUM ), and Aetna Inc. ( AET ).
The overall trend of insiders is illustrated in the chart below:
AbbVie Inc. ( ABBV ): Director Frederick H. Waddell Bought 2,000 Shares
Director of AbbVie Inc., Frederick H. Waddell, bought 2,000 shares on 2/04/2013 at an average price of $36.22. AbbVie Inc. has a market cap of $57.28 billion; its shares were traded at around $36.22 with and P/S ratio of 3.1756. The dividend yield of AbbVie Inc. stocks is 1.1%.
On Jan. 30, AbbVie confirmed it delivered strong sales growth with its marketed pharmaceutical products in 2012. The proprietary pharmaceutical segment of Abbott, representing the majority of AbbVie's revenue, grew more than 8 percent globally on an operational basis, excluding a nearly 3 percent negative impact from foreign exchange.
Abbott Laboratories ( ABT ): Director William A. Osborn Bought 15,000 Shares
Director of Abbott Laboratories, William A. Osborn, bought 15,000 shares during the past week at an average price of $34.42. Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott Laboratories has a market cap of $54.39 billion; its shares were traded at around $34.42 with a P/E ratio of 8.3682 and P/S ratio of 1.386. The dividend yield of Abbott Laboratories stocks is 4.85%. Abbott Laboratories had an annual average earnings growth of 8.9% over the past 10 years. GuruFocus rated Abbott Laboratories the business predictability rank of 3-star .
On Jan. 23, Abbott announced financial results for the fourth quarter ended Dec. 31, 2012. Fourth-quarter diluted earnings per share, excluding specified items, were $1.51. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.66, including specified items. Full-year diluted earnings per share, excluding specified items, were $5.07, exceeding Abbott's initial guidance range. Diluted earnings per share under GAAP were $3.72, including specified items.
Last week, Director William A. Osborn bought 10,000 shares of ABT stock. Senior Vice President Stephen R. Fussell sold 9,690 shares this month. Executive Vice President Laura J. Schumacher and Senior Vice President A. David Forrest sold shares in December, and Chairman and CEO Miles D. White sold shares in November.
Yum! Brands Inc. ( YUM ): Director Robert D. Walter Bought 35,000 Shares
Director of Yum! Brands Inc., Robert D. Walter, bought 35,000 shares on 2/06/2013 at an average price of $65.37. Yum! Brands Inc. was incorporated under the laws of the state of North Carolina in 1997. Yum! Brands Inc. has a market cap of $29.5 billion; its shares were traded at around $65.37 with a P/E ratio of 19.2308 and P/S ratio of 2.2857. The dividend yield of Yum! Brands Inc. stocks is 1.9%. Yum Brands Inc. had an annual average earnings growth of 10.3% over the past 10 years.
On Feb. 4, Yum! Brands Inc. reported results for the fourth quarter ended Dec. 29, 2012 including EPS of $0.83, excluding Special Items. Reported EPS was $0.72 for the quarter and $3.38 for the year.
Last week, Director Robert D. Walter bought 35,000 shares of YUM stock. Senior Vice President and Chief Public Affairs Jonathan David Blum sold 3,242 shares this month. Senior Vice President and Chief Public Affairs Jonathan David Blum sold 3,244 shares in January. Director Massimo Ferragamo, Chief People Officer Hollan Anne Byerlein, Chair and CEO China Division Jingshyh S. Su and Senior Vice President Finance and CFO Richard Carucci sold shares in December.
Aetna Inc. ( AET ): Executive Vice President, Local/Regional Bus Karen Rohan Bought 4,035 Shares
Executive Vice President, Local/Regional Bus of Aetna Inc., Karen Rohan, bought 4,035 shares on 02/06/2013 at an average price of $50.56. Aetna Inc. was incorporated in Pennsylvania in 1982 under the name of United States Health Care Systems Inc. Aetna Inc. has a market cap of $16.93 billion; its shares were traded at around $50.56 with a P/E ratio of 9.6712 and P/S ratio of 0.5052. The dividend yield of Aetna Inc. stocks is 1.43%. Aetna Inc. had an annual average earnings growth of 22.7% over the past 10 years. GuruFocus rated Aetna Inc. the business predictability rank of 2-star.
On Jan. 31, Aetna announced fourth-quarter 2012 operating earnings of $317.0 million, or $.94 per share. Full-year 2012 operating earnings were $1.77 billion, or $5.13 per share. Net income for the fourth quarter of 2012 was $190.1 million, or $.56 per share, and includes $.44 per share of charges for other items, primarily a litigation-related settlement, offset by $.06 per share of net realized capital gains. Full-year net income was $1.66 billion, or $4.81 per share.
Last week, Executive Vice President, Local/Regional Business Karen Rohan bought 4,035 shares of AET stock. Director Molly Joel Coye, Director Edward J. Ludwig, Senior Vice President and General Counsel William James Casazza, Vice President, Controller and Chief Accounting Officer Rajan Parmeswar, and Chairman, CEO and President Mark T. Bertolini sold shares in December.
For the complete list of stocks that were bought by their company executives, go to: Insider Buys.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | According to GuruFocus Insider Data , these are the largest insider buys during the past week: AbbVie Inc. ( ABBV ), Abbot Laboratories ( ABT ), Yum! The overall trend of insiders is illustrated in the chart below: AbbVie Inc. ( ABBV ): Director Frederick H. Waddell Bought 2,000 Shares Director of AbbVie Inc., Frederick H. Waddell, bought 2,000 shares on 2/04/2013 at an average price of $36.22. AbbVie Inc. has a market cap of $57.28 billion; its shares were traded at around $36.22 with and P/S ratio of 3.1756. | The overall trend of insiders is illustrated in the chart below: AbbVie Inc. ( ABBV ): Director Frederick H. Waddell Bought 2,000 Shares Director of AbbVie Inc., Frederick H. Waddell, bought 2,000 shares on 2/04/2013 at an average price of $36.22. According to GuruFocus Insider Data , these are the largest insider buys during the past week: AbbVie Inc. ( ABBV ), Abbot Laboratories ( ABT ), Yum! AbbVie Inc. has a market cap of $57.28 billion; its shares were traded at around $36.22 with and P/S ratio of 3.1756. | The overall trend of insiders is illustrated in the chart below: AbbVie Inc. ( ABBV ): Director Frederick H. Waddell Bought 2,000 Shares Director of AbbVie Inc., Frederick H. Waddell, bought 2,000 shares on 2/04/2013 at an average price of $36.22. According to GuruFocus Insider Data , these are the largest insider buys during the past week: AbbVie Inc. ( ABBV ), Abbot Laboratories ( ABT ), Yum! AbbVie Inc. has a market cap of $57.28 billion; its shares were traded at around $36.22 with and P/S ratio of 3.1756. | According to GuruFocus Insider Data , these are the largest insider buys during the past week: AbbVie Inc. ( ABBV ), Abbot Laboratories ( ABT ), Yum! The overall trend of insiders is illustrated in the chart below: AbbVie Inc. ( ABBV ): Director Frederick H. Waddell Bought 2,000 Shares Director of AbbVie Inc., Frederick H. Waddell, bought 2,000 shares on 2/04/2013 at an average price of $36.22. AbbVie Inc. has a market cap of $57.28 billion; its shares were traded at around $36.22 with and P/S ratio of 3.1756. |
27636.0 | 2013-02-06 00:00:00 UTC | The Market's Highest-Yielding Pharma Stocks | ABBV | https://www.nasdaq.com/articles/markets-highest-yielding-pharma-stocks-2013-02-06 | nan | nan | Big pharmaceuticalstocks have fallen out of favor, especially among investors seeking high-growthinvestments . Not only are these firms releasing fewer new blockbuster drugs, but the sector as a whole is seeing the headwinds from efforts to limit health care spending worldwide.
Still, the pharma sector has some phenomenalinvestment opportunities fordividend investors. Many of the industry giants -- Johnson & Johnson (NYSE: JNJ ), Bristol Myers Squibb ( BMY ) and Merck ( MRK ) , for example -- are paying 3-4% dividend yields, with someoffering yields as high as 9%.
Of course,yield alone doesn't make a good investment. It's also important to consider the company's financial strength, and history ofearnings and dividend growth.
Here is a look at the five top-yielding pharmaceutical companies and my top picks for investors seeking reliable dividend income.
1. PDL BioPharma
Yield: 9%
PDL BioPharma (Nasdaq: PDLI) owns a patented process for creating difficult-to-produce humanized antibodies, and licenses this technology to biotech firms in exchange for royalties. Drug companies are using this technology to develop new treatments for cancer, autoimmune and infectious diseases.
Since 2004, PDL'srevenue from royalties has grown 20% a year. PDL improvedearnings per share ( EPS ) 23% to .08 during the first nine months of 2012 compared with the year-ago period, and the consensusanalyst estimate for annualEPS growth is 14% for the next five years. PDL has paid an annual dividend of 60 cents a share since 2011.
Payout is conservative at 43% and the dividend yield is generous at almost 9%.
2. Psychemedics
Yield: 5%
Psychemedics (Nasdaq: PMD) is the world's largest provider of hair tests that detect drug abuse. The company's clients are corporations and government agencies, including more than 10% ofFortune 500 companies, the largest police forces in the United States and nine Federal Reserve regional banks.
Last quarter, Psychemedics launched new tests for detecting cocaine, opiates, PCP, methamphetamine and marijuana from head and body hair. It also expanded its lab capacity to include production on Saturdays. Investments in new technology caused EPS to fall 11% to 51 cents in the first nine months of 2012 compared with a year earlier, but bode well for future growth.Analysts predict 20% EPS gains in 2013.
Psychemedics is debt-free and generates industry-leading 22% operating margins. The company has paid 65 dividends 65quarters in a row and hiked payments 25% last year to an annual rate of 60 cents. Payout is rich at 93%, but is likely sustainable, given the company's good growth prospects and zero debt.
3. GlaxoSmithKline
Yield: 5%
GlaxoSmithKline ( GSK ) is one of the world's largest pharmaceutical companies and a top holding ofWarren Buffett . The company facespatent expirations on several key products, including blockbuster asthma drug Advair, but has beeninvesting in its pipeline, which should support long-term growth prospects.
New drugs poised to launch include a weekly treatment for diabetes and a daily bronchodilator for chronic obstructive pulmonary disease. Last year's billionacquisition of Human Genome Sciences also adds new drug candidates for heart disease and diabetes to the pipeline.
In the past decade, Glaxo's EPS growth has averaged 12% a year, but analysts predict a 20% EPS decline this year due to continuing weakness in Europe and growth slowing to 6% in each of the next five years.
Glaxo has a consistent record for dividend growth, which includes a 6% increase last year. Payout is high at 78% andshares yield about 5%. Debt is high at billion and 250% ofequity , but Glaxo has .4 billion ofcash and healthycash flow exceeding .4 billion a year to service its debt.
4. PetMed Express
Yield: 5%
PetMed (Nasdaq: PETS) distributes prescription and nonprescription medicines to pet owners, mainly through online channels. This is a pure play on the billion spent on pet care every year in the United States.
The company's top-line growth has slowed because of competition from other online vendors such as Amazon (Nasdaq: AMZN) . But PetMed hopes to re-energize sales by expanding product offerings and advertising, and shifting sales to higher-margin items.
Cost-reduction efforts are beginning to pay off, too. EPS improved 3% to 63 cents for the nine months ended Dec. 31, 2012 from the year-ago period. Analysts expect PetMed to deliver 5% growth in each of the next five years.
The company has no debt and generates .5 million of annualized cash flow, which is more than enough to cover million in dividend payments. PetMed has raised its dividend 50% in three years and shares yield almost 5%. Shareholders were recently rewarded with a special one-time dividend this past December.
5. Abbvie
Yield: 4%
Abbvie ( ABBV ) was formed through last year's spin-off of Abbott's pharmaceutical business into a newpublic company . Abbvie owns the world's top-selling drug, Humira, which is used to treat arthritis. The drug is expected to have generated billion in sales in 2012, which accounts for roughly half of Abbvie's sales.
A big concern for Abbvie investors is the loss of patent protection on Humira in 2016, but the company is replenishing its pipeline through internal drug development and licensing. For example, Abbvie is considered second only to Gilead Sciences (Nasdaq: GILD) in the strength of its hepatitis C drug franchise. Beginning in 2015, the company expects to launch four major new drugs in rapid succession, each of which is expected to produce at least billion in peak sales.
Although Abbvie hasn't reported financial results as a stand-alone business yet, year-over-year income generated by Abbott's pharmaceutical business rose 13% in the first nine months of 2012 to .6 billion. Analysts target 15% annual earnings growth for Abbvie during the next five years.
Abbvie has .2 billion of cash and annual cash flow of billion, which provides two-fold coverage of the dividend. The company targets 50% payout and is committed to dividend growth. At present, Abbvie pays a .60 annual dividend yielding about 4%.
Risks to Consider: Abbvie and Glaxo rely on new drugs for future growth, but drug development is inherently risky. Companies may spend hundreds of millions of dollars on research and still fail to win FDA approval for a new drug. Glaxo investors should also be aware ofcurrency risk since dividend payments are made in British pounds. However, unlike other foreign countries, the U.K. doesn't withholdtaxes on dividends paid to U.S. residents.
Action to Take --> My top pick overall is Abbvie. This company has a greatbalance sheet and cash flow, a strong commitment to growing its dividend and superior growth prospects. Glaxo and Psychemedics are a bit riskier due to their high payout. PDL has a poor record for growing its dividend and PetMed faces increasing challenges from competitors, though thestock is a great play on the ever-increasing pet-care industry in the United States.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2016 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A big concern for Abbvie investors is the loss of patent protection on Humira in 2016, but the company is replenishing its pipeline through internal drug development and licensing. Abbvie Yield: 4% Abbvie ( ABBV ) was formed through last year's spin-off of Abbott's pharmaceutical business into a newpublic company . Abbvie owns the world's top-selling drug, Humira, which is used to treat arthritis. | Abbvie Yield: 4% Abbvie ( ABBV ) was formed through last year's spin-off of Abbott's pharmaceutical business into a newpublic company . Abbvie owns the world's top-selling drug, Humira, which is used to treat arthritis. The drug is expected to have generated billion in sales in 2012, which accounts for roughly half of Abbvie's sales. | Abbvie Yield: 4% Abbvie ( ABBV ) was formed through last year's spin-off of Abbott's pharmaceutical business into a newpublic company . Abbvie owns the world's top-selling drug, Humira, which is used to treat arthritis. The drug is expected to have generated billion in sales in 2012, which accounts for roughly half of Abbvie's sales. | At present, Abbvie pays a .60 annual dividend yielding about 4%. Abbvie Yield: 4% Abbvie ( ABBV ) was formed through last year's spin-off of Abbott's pharmaceutical business into a newpublic company . Abbvie owns the world's top-selling drug, Humira, which is used to treat arthritis. |
27637.0 | 2013-02-04 00:00:00 UTC | AbbVie Provides 2013 Outlook - Analyst Blog | ABBV | https://www.nasdaq.com/articles/abbvie-provides-2013-outlook-analyst-blog-2013-02-04 | nan | nan | AbbVie ( ABBV ) recently confirmed its sales figures for 2012 and provided guidance for 2013 as an independent company. AbbVie came into existence earlier this year following its separation from Abbott Laboratories ( ABT ).
AbbVie said that excluding the negative impact of currency fluctuation (3%), pharmaceutical segment revenues grew more than 8% in the fourth quarter of 2012 despite the genericization of TriCor. Results were driven by Humira, AndroGel and Synthroid.
The company also provided first-time guidance for 2013. AbbVie expects to earn $3.03 - $3.13 per share in 2013 on total revenues of more than $18 billion. Currency movement is expected to negatively impact revenues by about 1%. Humira, which posted sales of $9.3 billion in 2012, up 16.7%, is expected to deliver low double-digit growth in 2013.
AbbVie expects to spend 14.5% of sales on R&D. SG&A spend is expected to be about 26% of sales.
First quarter 2013 earnings are expected in the range of 64 - 66 cents. Sales are slated to grow in low single digits despite the negative impact of generic competition for the lipid franchise.
We believe AbbVie is poised for strong growth. Humira should continue driving sales thanks to factors like additional indications, increasing penetration, geographic expansion, and share gains. New indications could boost peak sales potential for Humira by another $1.5 billion.
The pipeline also represents significant potential and AbbVie is targeting 15 regulatory approvals between 2013 and 2017. The company's late-stage pipeline includes 11 compounds or indications in phase III development targeting therapeutic areas like hepatitis C, immunology, multiple sclerosis, endometriosis and Parkinson's disease.
2013 and 2014 represent a transition period for the company which is facing generic competition for its lipid franchise - TriCor, TriLipix and Niaspan. The company expects 2013 sales from this franchise to decline by roughly $1.2 billion to less than $1 billion.
AbbVie currently carries a Zacks Rank #3 (Hold). While we are positive on the company's strong late-stage pipeline, dividend yield and growth strategy, we remain concerned about AbbVie's dependence on Humira. We believe the company will continue pursuing in-licensing deals and collaborations to boost its pipeline.
Large-cap companies that currently look more attractive include Sanofi ( SNY ) and Novo Nordisk ( NVO ). Both companies carry a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie said that excluding the negative impact of currency fluctuation (3%), pharmaceutical segment revenues grew more than 8% in the fourth quarter of 2012 despite the genericization of TriCor. While we are positive on the company's strong late-stage pipeline, dividend yield and growth strategy, we remain concerned about AbbVie's dependence on Humira. AbbVie ( ABBV ) recently confirmed its sales figures for 2012 and provided guidance for 2013 as an independent company. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ( ABBV ) recently confirmed its sales figures for 2012 and provided guidance for 2013 as an independent company. AbbVie came into existence earlier this year following its separation from Abbott Laboratories ( ABT ). | While we are positive on the company's strong late-stage pipeline, dividend yield and growth strategy, we remain concerned about AbbVie's dependence on Humira. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ( ABBV ) recently confirmed its sales figures for 2012 and provided guidance for 2013 as an independent company. | AbbVie expects to earn $3.03 - $3.13 per share in 2013 on total revenues of more than $18 billion. AbbVie ( ABBV ) recently confirmed its sales figures for 2012 and provided guidance for 2013 as an independent company. AbbVie came into existence earlier this year following its separation from Abbott Laboratories ( ABT ). |
27638.0 | 2013-02-01 00:00:00 UTC | Abbott Spin-Off AbbVie Pays Juicy Dividend | ABBV | https://www.nasdaq.com/articles/abbott-spin-abbvie-pays-juicy-dividend-2013-02-01 | nan | nan | New issues are not typically known for paying juicy dividends, butAbbVie ( ABBV ) is an exception.
The former pharmaceuticals arm ofAbbott Laboratories ( ABT ) declared its inaugural dividend last month. AbbVie will pay 40 cents per share on Feb. 15 to shareholders as of Jan. 15.
On an annualized basis, AbbVie pays $1.60 a share, which works out to a yield of 4.4% vs. about 2.5% for the S&P 500. AbbVie has the third highest yield among the 15 dividend-paying stocks in IBD's Medical-Ethical Drugs industry group.
The company was recently added to the S&P 500 Dividend Aristocrats index, which tracks the performance of big-cap stocks that have paid increasing dividends for at least 25 years. Although AbbVie has just declared its first-ever dividend, it was added to the Dividend Aristocrats due to the S&P's treatment of spin-offs.
"We have a solid financial foundation including strong profitability and robust cash flow," said CEO Richard Gonzalez in a conference call on Jan. 30. "We have a commitment to return cash to shareholders including a strong and growing dividend."
CFO William J. Chase noted that growth in the company's dividend is expected to pick up when its pipeline of new drugs comes to market.
North Chicago, Ill.-based AbbVie spun off from Abbott Labs at the start of the year. While the parent company focuses on diagnostic systems, nutritional supplements and medical devices, AbbVie develops drugs for maladies such as hepatitis C, cancer and renal disease.
The firm's bread and butter product is Humira, which is used to treat rheumatoid arthritis, psoriasis and Crohn's disease. Sales of Humira hit nearly $9.3 billion in 2012, or about half of AbbVie's annual revenue. The company sees low double-digit percentage growth in Humira sales in 2013.
The company expects to earn between $3.03 and $3.13 a share in 2013, which is in line with Wall Street's expectations.
AbbVie doesn't have a long trading history and has yet to form its first base. The stock climbed as much as 10% from its $34.92 Jan. 2 opening price. But it has pulled back in recent sessions.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | While the parent company focuses on diagnostic systems, nutritional supplements and medical devices, AbbVie develops drugs for maladies such as hepatitis C, cancer and renal disease. New issues are not typically known for paying juicy dividends, butAbbVie ( ABBV ) is an exception. AbbVie will pay 40 cents per share on Feb. 15 to shareholders as of Jan. 15. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New issues are not typically known for paying juicy dividends, butAbbVie ( ABBV ) is an exception. AbbVie will pay 40 cents per share on Feb. 15 to shareholders as of Jan. 15. | Although AbbVie has just declared its first-ever dividend, it was added to the Dividend Aristocrats due to the S&P's treatment of spin-offs. While the parent company focuses on diagnostic systems, nutritional supplements and medical devices, AbbVie develops drugs for maladies such as hepatitis C, cancer and renal disease. New issues are not typically known for paying juicy dividends, butAbbVie ( ABBV ) is an exception. | AbbVie will pay 40 cents per share on Feb. 15 to shareholders as of Jan. 15. On an annualized basis, AbbVie pays $1.60 a share, which works out to a yield of 4.4% vs. about 2.5% for the S&P 500. New issues are not typically known for paying juicy dividends, butAbbVie ( ABBV ) is an exception. |
27639.0 | 2013-01-31 00:00:00 UTC | Repros Delays ZA-301 Study Results - Analyst Blog | ABBV | https://www.nasdaq.com/articles/repros-delays-za-301-study-results-analyst-blog-2013-01-31 | nan | nan | Repros Therapeutics Inc. ( RPRX ) recently announced that results from the first pivotal study (ZA-301) of Androxal will be declared in the third quarter of 2013 instead of the second quarter. The candidate is being evaluated for the treatment of secondary hypogonadism.
In this study, the patient population of one of the sites which had enrolled 40 subjects was found to be different from the other 16 sites where baseline sperm count was concerned. Thus, Repros considered it wise to remove this site from the study and replace the subjects with those enrolled at other sites.
The Androxal phase III program includes two identical pivotal phase III studies, ZA-301 and ZA-302. Enrollment for ZA-302 is expected to be completed by the first quarter of 2013. The shortfall of subjects in ZA-301 would be made up by moving enrolled subjects from the ZA-302 study.
The company still expects to file a New Drug Application (NDA) for Androxal by mid-2014.
Meanwhile, earlier this year, the company announced that it has completed the enrollment process for the one-year study, DEXA (ZA-303), evaluating the effects of Androxal on bone mineral density.
Our Take
The delay in the company's plans for reporting ZA-301 results is disappointing. We note that the market for the treatment of secondary hypogonadism is already crowded given the presence of drugs like AbbVie Inc. 's ( ABBV ) Androgel, Auxilium Pharmaceuticals Inc. 's ( AUXL ) Testim and Eli Lilly and Company 's ( LLY ) Axiron.
While Repros carries a Zacks Rank #3 (Hold), Eli Lily carries a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
AUXILIUM PHARMA (AUXL): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
REPROS THERAPEU (RPRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We note that the market for the treatment of secondary hypogonadism is already crowded given the presence of drugs like AbbVie Inc. 's ( ABBV ) Androgel, Auxilium Pharmaceuticals Inc. 's ( AUXL ) Testim and Eli Lilly and Company 's ( LLY ) Axiron. ABBVIE INC (ABBV): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. The company still expects to file a New Drug Application (NDA) for Androxal by mid-2014. | We note that the market for the treatment of secondary hypogonadism is already crowded given the presence of drugs like AbbVie Inc. 's ( ABBV ) Androgel, Auxilium Pharmaceuticals Inc. 's ( AUXL ) Testim and Eli Lilly and Company 's ( LLY ) Axiron. ABBVIE INC (ABBV): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. While Repros carries a Zacks Rank #3 (Hold), Eli Lily carries a Zacks Rank #2 (Buy). | ABBVIE INC (ABBV): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. We note that the market for the treatment of secondary hypogonadism is already crowded given the presence of drugs like AbbVie Inc. 's ( ABBV ) Androgel, Auxilium Pharmaceuticals Inc. 's ( AUXL ) Testim and Eli Lilly and Company 's ( LLY ) Axiron. Thus, Repros considered it wise to remove this site from the study and replace the subjects with those enrolled at other sites. | We note that the market for the treatment of secondary hypogonadism is already crowded given the presence of drugs like AbbVie Inc. 's ( ABBV ) Androgel, Auxilium Pharmaceuticals Inc. 's ( AUXL ) Testim and Eli Lilly and Company 's ( LLY ) Axiron. ABBVIE INC (ABBV): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. Repros Therapeutics Inc. ( RPRX ) recently announced that results from the first pivotal study (ZA-301) of Androxal will be declared in the third quarter of 2013 instead of the second quarter. |
27640.0 | 2013-01-25 00:00:00 UTC | Biogen Advances with MS Candidate - Analyst Blog | ABBV | https://www.nasdaq.com/articles/biogen-advances-with-ms-candidate-analyst-blog-2013-01-25 | nan | nan | Biogen Idec ( BIIB ) recently announced positive top-line data on its phase III multiple sclerosis candidate, peginterferon beta-1a. Results from the ADVANCE study showed that peginterferon beta-1a met the primary endpoint as well as secondary endpoints.
Detailed Results
Two doses (once in two weeks and once in four weeks) of peginterferon beta-1a were compared to placebo in the study that was conducted to evaluate the safety and efficacy of the candidate in patients suffering from relapsing-remitting multiple sclerosis (RRMS).
Both dosing regimens met the primary endpoint of annualized relapse rate (ARR) at one year. While ARR reduction was 35.6% in the two-week regimen, the four-week regimen saw a 27.5% reduction in ARR.
Secondary endpoints included reduction of the risk of 12-week confirmed disability progression as measured by the Expanded Disability Status Scale (38% for both dosing arms), reduction in the proportion of patients who relapsed (39% the two-week dosing arm and 26% in the four-week dosing arm) and reduction in the number of new or newly enlarging T2-hyperintense lesions on brain MRI scans (67% in the two-week dosing arm and 28% in the four-week dosing arm). Biogen said that safety and tolerability profiles were favorable in both arms.
Biogen intends to present data from this study at the upcoming annual meeting of the American Academy of Neurology (AAN) in March. Meanwhile, with these positive results in hand, the company should be able to go ahead with its plans of filing for US and EU approval this year.
Our Take
We are pleased with Biogen's progress with its multiple sclerosis (MS) pipeline. A less frequent dosing schedule (not more than 26 doses in a year) and a favorable safety and efficacy profile should work in peginterferon beta-1a's favor once it is launched.
Biogen is the market leader in therapies for the treatment of multiple sclerosis. We believe the company will continue to retain a leading position in the multiple sclerosis market. Biogen has an important regulatory event coming up with an FDA decision on its oral multiple sclerosis candidate, BG-12, expected in late March. We believe BG-12 could become a leader in the oral multiple sclerosis market once launched. Biogen has another multiple scelrosis candidate, daclizumab, in development with AbbVie ( ABBV ).
Biogen currently carries a Zacks #3 Rank (Hold). Biopharma stocks that currently look attractive include companies like Alkermes ( ALKS ) and Medivation ( MDVN ) - both companies are Zacks Rank #1 (Strong Buy) stocks.
ABBVIE INC (ABBV): Free Stock Analysis Report
ALKERMES INC (ALKS): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
MEDIVATION INC (MDVN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Biogen has another multiple scelrosis candidate, daclizumab, in development with AbbVie ( ABBV ). ABBVIE INC (ABBV): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen Idec ( BIIB ) recently announced positive top-line data on its phase III multiple sclerosis candidate, peginterferon beta-1a. | ABBVIE INC (ABBV): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen has another multiple scelrosis candidate, daclizumab, in development with AbbVie ( ABBV ). Both dosing regimens met the primary endpoint of annualized relapse rate (ARR) at one year. | ABBVIE INC (ABBV): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen has another multiple scelrosis candidate, daclizumab, in development with AbbVie ( ABBV ). Detailed Results Two doses (once in two weeks and once in four weeks) of peginterferon beta-1a were compared to placebo in the study that was conducted to evaluate the safety and efficacy of the candidate in patients suffering from relapsing-remitting multiple sclerosis (RRMS). | Biogen has another multiple scelrosis candidate, daclizumab, in development with AbbVie ( ABBV ). ABBVIE INC (ABBV): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report To read this article on Zacks.com click here. A less frequent dosing schedule (not more than 26 doses in a year) and a favorable safety and efficacy profile should work in peginterferon beta-1a's favor once it is launched. |
27641.0 | 2013-01-23 00:00:00 UTC | Abbott Beats on EPS, Guides In-Line - Analyst Blog | ABBV | https://www.nasdaq.com/articles/abbott-beats-eps-guides-line-analyst-blog-2013-01-23 | nan | nan | Abbott Labs ( ABT ) reported fourth quarter 2012 earnings of $1.51 per share, a penny ahead of the Zacks Consensus Estimate and 4.1% above the year-ago earnings. Including one-time items, fourth quarter earnings decreased 35.3% to 66 cents per share.
Fourth quarter revenues increased 4.4% to $10.8 billion, narrowly beating the Zacks Consensus Estimate of $10.6 billion. Full year earnings came in at $5.07 per share, a penny above the Zacks Consensus Estimate and 8.8% above the year-ago earnings.
Full-year earnings were within the guidance range of $5.06 to $5.08 per share. Revenues increased 2.6% to $39.9 billion in 2012, edging past the Zacks Consensus Estimate of $39.6 billion.
Pharma Business Spun Off
We note that Abbott recently separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). The decision to spin off the business was taken back in Oct 2011 when Abbott decided to separate its business into two publicly traded companies - one in diversified medical products and the other in research-based pharmaceuticals.
The research-based pharmaceutical company, AbbVie, includes proprietary pharmaceuticals and biologics including products like Humira, Lupron, Synagis, Kaletra, Creon and Synthroid. The new company started trading from the beginning of 2013.
Quarter in Detail
Fourth quarter results are for the combined company. Almost all the business categories performed well during the quarter. Proprietary Pharmaceutical sales were $5.1 billion, up 7.4%. Humira was a major contributor with sales coming in at $2.7 billion, up 23.1%. Humira recorded sales growth in both the US (31.1%) and international markets (15.2%) during the quarter.
Abbott Labs is looking to get Humira approved for additional indications, which would help drive growth further. Lupron, Androgel, Creon and Synthroid also contributed to Proprietary Pharmaceutical sales growth.
The Nutritionals business grew 10.2% to $1.7 billion. Nutrition sales in the US increased 9.4% to $743 million. Outside the US, Nutrition sales continued to experience double-digit growth with sales increasing 10.8% to $972 million. Strong performance in emerging markets helped drive international nutrition sales.
Other areas that witnessed growth include the Core Laboratory Diagnostics, Molecular Diagnostics, Diabetes Care and Point of Care Diagnostics businesses. Established Pharmaceuticals sales, however, declined 2.4% to $1.3 billion.
In-Line Outlook for 2013
Along with releasing fourth quarter results, Abbott Labs provided guidance for 2013. The company expects 2012 earnings in the range of $1.98 to $2.04 per share. Guidance was in line with the Zacks Consensus Estimate, currently standing at $2.00 per share. The guidance excludes the newly formed AbbVie, which started functioning as an independent company from the beginning of 2013.
Abbott carries a Zacks Rank #5 (Strong Sell) in the short run. However, not all large-cap pharma stocks are performing as poorly as Abbott. Large-cap pharma companies that currently look more attractive include Bayer ( BAYRY ) and Sanofi ( SNY ). Both companies carry a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The guidance excludes the newly formed AbbVie, which started functioning as an independent company from the beginning of 2013. Pharma Business Spun Off We note that Abbott recently separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). The research-based pharmaceutical company, AbbVie, includes proprietary pharmaceuticals and biologics including products like Humira, Lupron, Synagis, Kaletra, Creon and Synthroid. | The research-based pharmaceutical company, AbbVie, includes proprietary pharmaceuticals and biologics including products like Humira, Lupron, Synagis, Kaletra, Creon and Synthroid. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Pharma Business Spun Off We note that Abbott recently separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Pharma Business Spun Off We note that Abbott recently separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). The research-based pharmaceutical company, AbbVie, includes proprietary pharmaceuticals and biologics including products like Humira, Lupron, Synagis, Kaletra, Creon and Synthroid. | Pharma Business Spun Off We note that Abbott recently separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). The research-based pharmaceutical company, AbbVie, includes proprietary pharmaceuticals and biologics including products like Humira, Lupron, Synagis, Kaletra, Creon and Synthroid. The guidance excludes the newly formed AbbVie, which started functioning as an independent company from the beginning of 2013. |
27642.0 | 2013-01-09 00:00:00 UTC | AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for January 11, 2013 | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-ex-dividend-date-scheduled-january-11-2013-2013-01-09 | nan | nan | AbbVie Inc. ( ABBV ) has announced an ex-dividend date of January 11, 2013 and a cash dividend payment of $0.4 per share scheduled for February 15, 2013. Shareholders who purchased ABBV stock prior to the ex-dividend date are eligible for the cash dividend payment.
The previous trading day's last sale of ABBV was $33.71, representing a -9.06% decrease from the 52 week high of $37.07 and a 3.69% increase over the 52 week low of $32.51.
For more information on the declaration, record and payment dates, visit the ABBV Dividend History page.
Interested in gaining exposure to ABBV through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABBV as a top-10 holding:
Select Sector SPDR Fund - Health Care ( XLV )
iShares Dow Jones U.S. Health Care Index Fund ( IYH )
Pax MSCI North America ESG Index ETF (based on the MSCI North ( NASI )
Schwab US Dividend Equity ETF ( SCHD )
QuantShares U.S. Market Neutral Anti Beta Fund ETF ( BTAL ).
The top-performing ETF of this group is NASI with an increase of 12.92% over the last 100 days. XLV has the highest percent weighting of ABBV at 3.51%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ( ABBV ) has announced an ex-dividend date of January 11, 2013 and a cash dividend payment of $0.4 per share scheduled for February 15, 2013. Shareholders who purchased ABBV stock prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABBV Dividend History page. | The following ETF(s) have ABBV as a top-10 holding: Select Sector SPDR Fund - Health Care ( XLV ) iShares Dow Jones U.S. Health Care Index Fund ( IYH ) Pax MSCI North America ESG Index ETF (based on the MSCI North ( NASI ) Schwab US Dividend Equity ETF ( SCHD ) QuantShares U.S. Market Neutral Anti Beta Fund ETF ( BTAL ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie Inc. ( ABBV ) has announced an ex-dividend date of January 11, 2013 and a cash dividend payment of $0.4 per share scheduled for February 15, 2013. | AbbVie Inc. ( ABBV ) has announced an ex-dividend date of January 11, 2013 and a cash dividend payment of $0.4 per share scheduled for February 15, 2013. The following ETF(s) have ABBV as a top-10 holding: Select Sector SPDR Fund - Health Care ( XLV ) iShares Dow Jones U.S. Health Care Index Fund ( IYH ) Pax MSCI North America ESG Index ETF (based on the MSCI North ( NASI ) Schwab US Dividend Equity ETF ( SCHD ) QuantShares U.S. Market Neutral Anti Beta Fund ETF ( BTAL ). Shareholders who purchased ABBV stock prior to the ex-dividend date are eligible for the cash dividend payment. | AbbVie Inc. ( ABBV ) has announced an ex-dividend date of January 11, 2013 and a cash dividend payment of $0.4 per share scheduled for February 15, 2013. The following ETF(s) have ABBV as a top-10 holding: Select Sector SPDR Fund - Health Care ( XLV ) iShares Dow Jones U.S. Health Care Index Fund ( IYH ) Pax MSCI North America ESG Index ETF (based on the MSCI North ( NASI ) Schwab US Dividend Equity ETF ( SCHD ) QuantShares U.S. Market Neutral Anti Beta Fund ETF ( BTAL ). Shareholders who purchased ABBV stock prior to the ex-dividend date are eligible for the cash dividend payment. |
27643.0 | 2013-01-08 00:00:00 UTC | This Stock Could be Perfect for the "Dividend Decade" | ABBV | https://www.nasdaq.com/articles/stock-could-be-perfect-dividend-decade-2013-01-08 | nan | nan | If you're a regular StreetAuthority reader, then you may have heard of the "Dividend Decade." If you haven't, then it's a prediction that in the next 10 years, the broadermarket will be absolutely flat . Instead, dividends will account for all of the market's total return.
This means companies that steadily raise dividends will outperform the overall market in the next decade. And one of my favoritestocks that could benefit from this trend just went through a major change, making it an even sweeter deal.
Health care giant Abbott Laboratories ( ABT ) celebrated the New Year by splitting itself in two. The legacy pharmaceutical business, which was renamed Abbvie ( ABBV ) ,will focus on breakthrough drug therapies. The company's diagnostic tests, medical devices, nutritional products and branded generic pharmaceutical operations were combined into a second business that retains the Abbott name. Abbott structured the breakup as a tax-free distribution to shareholders, with investors receiving one Abbvie share for every Abbott share they held.
Abbott made a brilliant move by spinning off its pharmaceutical business. Humira, its top-selling drug, accounts for more than half this segment's business, and itspatent expires in 2017. Spinning off this segment frees the rest of the company from its risks. StreetAuthority Co-Founder Paul Tracy has even identified it as one of the Top 10 Stocks for 2013 .
Abbvie will pay a rich $1.60 annualdividend , which at the current $35 share price, provides a hefty 4.6%yield . Equally important, Abbvie is already showing many of the characteristics of a high-quality dividendstock . Abbvie generates plenty ofearnings andcash flow , has a cash-richbalance sheet and a hugely valuableasset in its blockbuster drug Humira.
The top-selling drug is used to treat rheumatoid arthritis, psoriasis, Crohn's disease and other common auto-immune disorders. Sales of the drug have doubled in the past four years. Humira is expected to earn $10 billion inrevenue this year and accounts for roughly half of Abbvie's total sales.
There is risk associated with Abbvie's loss ofpatent protection on Humira three years from now, but analysts don't anticipate sales will decline for several reasons. First, Humira belongs to a class of drugs (biologics) that is extremely difficult to manufacture. This will likely limit competition from generics. Second, because of Humira's proven track record and dominant share in themarket for rheumatoid arthritis drugs, physicians will probably continue to utilize Humira as a first-line treatment even after generic versions are launched. Third, overall sales of auto-immune drugs are projected to grow 6% a year to reach about $48 billion by 2015. Humira has already been approved as a treatment for nine different illnesses and Abbvie has four more indications in late-stage clinical trials that should help drive future sales growth. For these reasons, analysts say Humira sales will likely continue to rise and peak at more than $12 billion by 2017.
Abbvie also owns other category winners. These include a leading testosterone replacement therapy drug, a hormonal therapy for thyroid disease and two of the top-selling antiviral medicines for HIV.
Of course, when all is said and done, any pharmaceutical company is only as good as its drug discovery pipeline. But AbbVie has made impressive progress in recent years through internal drug development, and licensing and collaboration deals. The company is considered second only to Gilead Sciences (Nasdaq: GILD) in the strength of its hepatitis C drug franchise. Both companies are developing new oral treatments for hepatitis C, a deadly disorder that infects 180 million individuals worldwide.
Beginning in 2015, Abbvie expects to begin launching four major new drugs in rapid succession, each of which is estimated to be worth $4 to $6 billion in peak sales. In all, the company has a total of 20 new drugs in mid- to late-stage development.
In addition to a flourishing new-drug pipeline, Abbvie has a global footprint that few new-drug companies can match. The company has commercial operations worldwide and sales in more than 150 countries. Abbvie plans toleverage this global presence in the next several years and is targeting nearly $1 billion in new sales from developing markets.
Thestock split happened in early January, so Abbvie won't be reporting sales and earnings as a stand-alone company until the first quarter is completed. However, the past performance of Abbott's proprietary pharmaceuticals business provides a framework for what Abbvie investors can expect. During the first nine months of 2012, sales of proprietary pharmaceuticals improved 7% to $12.9 billion, fueled by a 29% jump in Androgel sales and a 19% increase in Humira sales.Operating income for this business rose 13% to $5.6 billion andprofit margins were generous even by pharmaceutical industry standards at 43%. Analysts predict Abbvie will likely generate sales of $18 billion next year and 2013 earnings per share estimates range from $3.03 to $3.17.
This stock has $7.2 billion ofcash and an investment-gradecredit rating . The company is also a cash machine that generates roughly $6 billion of cash flow a year, which will more than twice covers the $2.5 billion annual dividend payment. Management targets 50% payout of cash earnings for the dividend on an ongoing basis and is strongly committed to dividend growth.
Old Abbott had a stellar track record, increasing dividends 40 years in a row, including a 6% dividend increase just prior to the breakup to an annualized rate of $2.16 a share. Abbott divided the dividend amount between the two companies when they split. As stated before, Abbvie plans to pay a $1.60 annual dividend currently yielding 4.6%, while Abbott will pay a 56-cent annual dividend that yields 0.9%.
Risks to Consider: Many new drugs never reach the market and there is noguarantee that Abbvie's pipeline will deliver future revenue and profits. However, this risk is mitigated by the fact that half of Abbvie's pipeline products are in late-stage development when risks are smaller. Also, in connection with the breakup, Abbvie raised $14.7 billion of debt, which was used to make an $8.5 billion cash payment to Abbott. However, with cash flow from operations close to $6 billion annually and no major debtmaturities before 2015, Abbvie shouldn't have any problem servicing its debt.
Action to Take --> By purchasing Abbvieshares now, investors can collect a 4.6% dividend while they wait for new drugs to launch beginning in 2015, which should fuel earnings growth as well as share price gains.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2016 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Thestock split happened in early January, so Abbvie won't be reporting sales and earnings as a stand-alone company until the first quarter is completed. Action to Take --> By purchasing Abbvieshares now, investors can collect a 4.6% dividend while they wait for new drugs to launch beginning in 2015, which should fuel earnings growth as well as share price gains. The legacy pharmaceutical business, which was renamed Abbvie ( ABBV ) ,will focus on breakthrough drug therapies. | Humira is expected to earn $10 billion inrevenue this year and accounts for roughly half of Abbvie's total sales. Analysts predict Abbvie will likely generate sales of $18 billion next year and 2013 earnings per share estimates range from $3.03 to $3.17. As stated before, Abbvie plans to pay a $1.60 annual dividend currently yielding 4.6%, while Abbott will pay a 56-cent annual dividend that yields 0.9%. | Humira is expected to earn $10 billion inrevenue this year and accounts for roughly half of Abbvie's total sales. The legacy pharmaceutical business, which was renamed Abbvie ( ABBV ) ,will focus on breakthrough drug therapies. Abbott structured the breakup as a tax-free distribution to shareholders, with investors receiving one Abbvie share for every Abbott share they held. | Humira is expected to earn $10 billion inrevenue this year and accounts for roughly half of Abbvie's total sales. Abbvie plans toleverage this global presence in the next several years and is targeting nearly $1 billion in new sales from developing markets. Analysts predict Abbvie will likely generate sales of $18 billion next year and 2013 earnings per share estimates range from $3.03 to $3.17. |
27644.0 | 2013-01-03 00:00:00 UTC | Three Actionable Trading Ideas Right Now | ABBV | https://www.nasdaq.com/articles/three-actionable-trading-ideas-right-now-2013-01-03 | nan | nan | On the first trading day of the New Year the U.S. stock market exploded higher in the wake of a last-minute Congressional deal to avert the fiscal cliff. Investor exuberance sent the Dow Jones Industrial Average rocketing more than 300 points higher to over 13,400.
The Nasdaq did even better, starting 2013 with a tidy three percent gain. In terms of stock market history, Wednesday's trading session was nearly unprecedented for the opening day of a New Year.
Investor enthusiasm is riding high and market participants are hoping that the huge rally is a sign of things to come in 2013. Historically, when the stock market moves higher over the course of the first five trading days of January, there is an 86 percent chance that stocks will close the year with a gain.
This phenomenon is referred to as the "January effect," and the market rises nearly 14 percent on average when it is triggered. With the uptrend that began in March 2009 still firmly intact it may be time for individual investors to put more capital to work. Below, Benzinga offers readers three actionable ideas that could bring near-term profits this month.
Herbalife (NYSE: HLF ) - In recent weeks, multilevel marketing company Herbalife has been one of the most volatile and talked about stocks on the New York Stock Exchange. The company sells nutritional and weight-management products through third-party distributors who are compensated on both sales and recruiting of other distributors.
Over the last month, the stock has fallen around 30 percent on massive volume after billionaire hedge fund manager Bill Ackman revealed that his firm is short more than $1 billion of the stock. The Pershing Square Capital Management founder disclosed his massive bearish bet against the company on December 20th at the Ira Sohn investment conference during a three hour presentation which included 342 PowerPoint slides .
Ackman's essential thesis for the trade is that Herbalife, despite consistent and prolific sales and profit growth, is a pyramid scheme which will eventually come under intense regulatory scrutiny or collapse. The hedge fund manager said that Herbalife is his highest conviction short ever and that his price target for the stock is $0.
While Ackman has clearly done his homework on the trade, not everyone is convinced. A number of Wall Street analysts immediately came to the defense of the company and were critical of the hedge fund manager's research and conclusions. In fact, D.A. Davidson analyst Timothy Ramey said that the stock was a "Best Idea" for 2013 on Wednesday. He has a "Buy" rating on the shares and a $72 price target.
Herbalife CEO Michael Johnson also provided an aggressive response to the accusations leveled against his company and said that Ackman was engaged in "blatant market manipulation." He said that "This appears to be another attempt to illegally manipulate the market by a group of short sellers." The company also released a statement calling the presentation "a malicious attack on Herbalife's business model based largely on outdated, distorted and inaccurate information."
In recent days, the stock has bounced back strongly from its worst levels. Shares bottomed out on December 24 at around $25 and have subsequently jumped almost 29 percent from that level to $32.20. Looking ahead, there is a very specific catalyst that could provide more near-term upside in the name.
Herbalife has scheduled an analyst and investor meeting for January 10, 2013 in New York. At this meeting, Herbalife will provide comprehensive responses to questions about its business model and address Ackman's accusations in detail. It will also update investors on its business and growth prospects. In addition, Herbalife has retained Moelis & Company as a strategic advisor to defend itself against the attacks against the company.
Although this is a risky situation, being long HLF into this analyst meeting could pay off handsomely in a short period of time. Along with this catalyst, Herbalife also has $950 million remaining on its existing $1 billion share repurchase authorization and there is a good chance that it will deploy this money in an effort to fight back against Bill Ackman and other short-sellers. At current levels, Herbalife has a market cap of just under $3.5 billion so the company could buy back a huge chunk of stock in light of the steep sell-off.
Facebook (NASDAQ: FB ) - Don't look now, but Facebook has convincingly broken its lengthy downtrend and is now moving aggressively higher. The stock opened the New Year with a better than 5 percent gain and is now trading at $28. Although shares are still down around 26 percent from their $38 initial public offering price, the stock has surged roughly the same amount over the last three months and is sitting at its best levels since late July.
There are a number of near-term catalysts that could continue to propel Facebook in the month of January. The most important of these catalysts is the end of the lock-up periods in the stock. The final large lock-up expired on December 14 when 156 million Facebook shares began freely trading.
When the company went public in May, a massive number of shares held by employees and early investors were prohibited from trading for a period of time. This is commonplace in the IPO process, but it seems to have been a particularly burdensome headwind for Facebook's stock price. These lock-ups were staggered over time and were a source of large-scale selling when they expired.
This dynamic seems to have been driven in part by momentum. In the weeks and months after Facebook came public, the IPO tanked badly. The reasons for this included a very rich initial valuation combined with a large offering of shares, among other things. As the stock plunged, concerned investors became much more apt to dump large numbers of Facebook shares as they were subsequently "unlocked."
When PayPal co-founder and early Facebook investor Peter Thiel sold a huge chunk of his stock in August the sell-off in the social networking giant accelerated and prices hit new lows. The lock-up headwind has now been removed from the stock and Facebook is regaining its luster in time for the New Year.
Analysts are also turning decidedly bullish on the stock and that could lead to more significant gains in January. On Wednesday, analysts at JP Morgan (NYSE: JPM ) reiterated their "overweight" rating on the shares and bumped their price target by $6 to $35.
In a client note, JP Morgan analyst Doug Anmuth wrote, "We are incrementally positive on Facebook shares into 2013 as we believe it remains very early in the trajectory of Facebook's mobile advertising, and recent marketer feedback on mobile and News Feed ads has been positive."
The investment bank also raised its revenue estimates for the company's Mobile News Feed to $2.37 billion in 2013 and $4.0 billion in 2014 versus its previous projections of $2.0 billion and $3.3 billion, respectively.
Similar sentiments were reflected by Morgan Stanley (NYSE: MS ) analysts on Wednesday. They also lifted their earnings and revenue estimates for the company and raised their price target on the stock to $32 from $31. Morgan Stanley has an "overweight" rating on the shares and is bullish on the company's mobile prospects.
In a client note, they wrote "Facebook is making strong progress in mobile monetization, and has introduced new revenue-generating products such as a real-time bidding exchange and gifts."
The firm lifted its long-term revenue and earnings estimates by 2%-4% and is modeling EPS of $0.52/$0.85/$1.15 for fiscal 2012 through fiscal 2014. In light of the multiple catalysts that have converged around the New Year for Facebook shares, this could be a name that investors can ride to profits during the first part of 2013.
AbbVie (NYSE: ABBV ) - On Wednesday, Abbott Labs (NYSE: ABT ) completed a planned spinoff of its pharmaceutical division into a separate publicly-traded company known as AbbVie ( ABBV ). The stock climbed 2.8 percent on the day and closed at $35.12.
The goal of the spinoff, which was announced in 2011, was to unlock shareholder value for Abbott investors by creating two independent companies with distinct business lines. Prior to the completion of the deal, Abbott was one of the largest healthcare companies in the world and the two companies will remain among the most dominant in their respective sectors with market capitalizations above $50 billion.
The spinoff entity, AbbvVie, includes in its portfolio the anti-inflammation drug Humira, the painkiller Vicodin, and cholesterol drug Niaspan. Abbott Labs' products include cardiac stents, nutrition items and diagnostic tests along with well-known brands such as Ensure and Pedialyte.
Abbott's chairman and CEO Miles White called the event "the most transformative action" in the company's 125-history. AbbVie CEO Richard Gonzalez said that with his company's existing assets and focus on innovation "we intend to create significant value for our shareholders."
Investors should keep an eye on both of these stocks as similar transactions have resulted in big gains in recent years. Two of the most prominent have been Expedia's (NASDAQ: EXPE ) spinoff of TripAdvisor (NASDAQ: TRIP ) and Conoco's (NYSE: COP ) spinoff of Phillips 66 (NYSE: PSX ).
Since the two companies split in December 2011, Expedia shares have soared more than 110 percent while TripAdvisor is up over 70 percent. Similarly, Phillips 66 is up almost 69 percent since being spun-off by ConocoPhillips in May 2012. Conoco shares have gained around 5 percent during the same time period.
Although these type of gains for Abbot Labs and AbbVie may not be likely, in large part because of the sheer size of both companies, both stocks could benefit significantly in the coming year.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Gain access to more investing ideas, tools & education. Get Started on Marketfy, the first ever curated & verified Marketplace for everything trading.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV ) - On Wednesday, Abbott Labs (NYSE: ABT ) completed a planned spinoff of its pharmaceutical division into a separate publicly-traded company known as AbbVie ( ABBV ). The spinoff entity, AbbvVie, includes in its portfolio the anti-inflammation drug Humira, the painkiller Vicodin, and cholesterol drug Niaspan. AbbVie CEO Richard Gonzalez said that with his company's existing assets and focus on innovation "we intend to create significant value for our shareholders." | AbbVie (NYSE: ABBV ) - On Wednesday, Abbott Labs (NYSE: ABT ) completed a planned spinoff of its pharmaceutical division into a separate publicly-traded company known as AbbVie ( ABBV ). The spinoff entity, AbbvVie, includes in its portfolio the anti-inflammation drug Humira, the painkiller Vicodin, and cholesterol drug Niaspan. AbbVie CEO Richard Gonzalez said that with his company's existing assets and focus on innovation "we intend to create significant value for our shareholders." | AbbVie (NYSE: ABBV ) - On Wednesday, Abbott Labs (NYSE: ABT ) completed a planned spinoff of its pharmaceutical division into a separate publicly-traded company known as AbbVie ( ABBV ). The spinoff entity, AbbvVie, includes in its portfolio the anti-inflammation drug Humira, the painkiller Vicodin, and cholesterol drug Niaspan. AbbVie CEO Richard Gonzalez said that with his company's existing assets and focus on innovation "we intend to create significant value for our shareholders." | AbbVie (NYSE: ABBV ) - On Wednesday, Abbott Labs (NYSE: ABT ) completed a planned spinoff of its pharmaceutical division into a separate publicly-traded company known as AbbVie ( ABBV ). The spinoff entity, AbbvVie, includes in its portfolio the anti-inflammation drug Humira, the painkiller Vicodin, and cholesterol drug Niaspan. AbbVie CEO Richard Gonzalez said that with his company's existing assets and focus on innovation "we intend to create significant value for our shareholders." |
27645.0 | 2013-01-03 00:00:00 UTC | Abbott Spins Off Pharma Business - Analyst Blog | ABBV | https://www.nasdaq.com/articles/abbott-spins-off-pharma-business-analyst-blog-2013-01-03 | nan | nan | AbbottLaboratories ( ABT ) recently announced that the company has separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ).
The decision to spin off the business was taken back in October 2011 when Abbott decided to separate its business into two publicly traded companies - one in diversified medical products and the other in research-based pharmaceuticals.
The research-based pharmaceutical company, AbbVie, includes proprietary pharmaceuticals and biologics including products like Humira, Lupron, Synagis, Kaletra, Creon and Synthroid. The business generated sales of approximately $17.4 billion in 2011 while sales are expected to exceed $18 billion in 2012.
The diversified medical products company, with estimated sales of about $23 billion, includes Abbott's branded generic pharmaceutical, devices, diagnostic and nutritional businesses.
The existing shareholders of the parent company generally get new shares in the subsidiary when the company spins off one of its business into a separate company. The subsidiary becomes a separate legal entity with its own management team and board of directors.
On Nov. 28, 2012, Abbott declared a special dividend distribution of all outstanding shares of AbbVie common stock. The shareholders of Abbott received one share of AbbVie common stock on Jan. 1, 2013 for every one share of Abbott common shares held as of close of business on Dec. 12, 2012.
The company is looking to ensure growth through this split. We are positive on the split which should allow the two separate entities to perform in a more focused manner.
As expected, the news was well received by investors with Abbott's shares increasing 2.27% in regular trading to close at $32.05.
We currently have a Neutral recommendation on Abbott, which carries a Zacks #3 Rank (Hold). Right now, Allergan, Inc. ( AGN ) looks attractive with a Zacks #2 Rank (Buy).
(ABBV): ETF Research Reports
ABBOTT LABS (ABT): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Nov. 28, 2012, Abbott declared a special dividend distribution of all outstanding shares of AbbVie common stock. AbbottLaboratories ( ABT ) recently announced that the company has separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). The research-based pharmaceutical company, AbbVie, includes proprietary pharmaceuticals and biologics including products like Humira, Lupron, Synagis, Kaletra, Creon and Synthroid. | The research-based pharmaceutical company, AbbVie, includes proprietary pharmaceuticals and biologics including products like Humira, Lupron, Synagis, Kaletra, Creon and Synthroid. (ABBV): ETF Research Reports ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottLaboratories ( ABT ) recently announced that the company has separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). | The shareholders of Abbott received one share of AbbVie common stock on Jan. 1, 2013 for every one share of Abbott common shares held as of close of business on Dec. 12, 2012. AbbottLaboratories ( ABT ) recently announced that the company has separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). The research-based pharmaceutical company, AbbVie, includes proprietary pharmaceuticals and biologics including products like Humira, Lupron, Synagis, Kaletra, Creon and Synthroid. | The shareholders of Abbott received one share of AbbVie common stock on Jan. 1, 2013 for every one share of Abbott common shares held as of close of business on Dec. 12, 2012. AbbottLaboratories ( ABT ) recently announced that the company has separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ). The research-based pharmaceutical company, AbbVie, includes proprietary pharmaceuticals and biologics including products like Humira, Lupron, Synagis, Kaletra, Creon and Synthroid. |
27646.0 | 2023-12-14 00:00:00 UTC | Ameris Bancorp (ABCB) Price Target Increased by 8.38% to 50.57 | ABCB | https://www.nasdaq.com/articles/ameris-bancorp-abcb-price-target-increased-by-8.38-to-50.57 | nan | nan | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 50.57 / share. This is an increase of 8.38% from the prior estimate of 46.66 dated November 26, 2023.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 40.40 to a high of 63.00 / share. The average price target represents a decrease of 3.04% from the latest reported closing price of 52.16 / share.
Ameris Bancorp Declares $0.15 Dividend
On September 19, 2023 the company declared a regular quarterly dividend of $0.15 per share ($0.60 annualized). Shareholders of record as of September 30, 2023 received the payment on October 9, 2023. Previously, the company paid $0.15 per share.
At the current share price of $52.16 / share, the stock's dividend yield is 1.15%.
Looking back five years and taking a sample every week, the average dividend yield has been 1.49%, the lowest has been 0.96%, and the highest has been 3.17%. The standard deviation of yields is 0.47 (n=236).
The current dividend yield is 0.72 standard deviations below the historical average.
Additionally, the company's dividend payout ratio is 0.14. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company has not increased its dividend in the last three years.
What is the Fund Sentiment?
There are 609 funds or institutions reporting positions in Ameris Bancorp. This is an increase of 13 owner(s) or 2.18% in the last quarter. Average portfolio weight of all funds dedicated to ABCB is 0.22%, an increase of 14.84%. Total shares owned by institutions decreased in the last three months by 0.70% to 74,427K shares.
The put/call ratio of ABCB is 0.01, indicating a bullish outlook.
What are Other Shareholders Doing?
IJR - iShares Core S&P Small-Cap ETF holds 4,389K shares representing 6.38% ownership of the company. In it's prior filing, the firm reported owning 4,548K shares, representing a decrease of 3.63%. The firm increased its portfolio allocation in ABCB by 12.35% over the last quarter.
Wellington Management Group Llp holds 4,032K shares representing 5.86% ownership of the company. In it's prior filing, the firm reported owning 4,461K shares, representing a decrease of 10.64%. The firm increased its portfolio allocation in ABCB by 7.30% over the last quarter.
American Century Companies holds 2,547K shares representing 3.70% ownership of the company. In it's prior filing, the firm reported owning 2,456K shares, representing an increase of 3.56%. The firm increased its portfolio allocation in ABCB by 20.65% over the last quarter.
Independent Advisor Alliance holds 2,313K shares representing 3.36% ownership of the company. In it's prior filing, the firm reported owning 2,302K shares, representing an increase of 0.46%. The firm increased its portfolio allocation in ABCB by 14.12% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,083K shares representing 3.03% ownership of the company. In it's prior filing, the firm reported owning 2,080K shares, representing an increase of 0.14%. The firm increased its portfolio allocation in ABCB by 16.64% over the last quarter.
Ameris Bancorp Background Information
(This description is provided by the company.)
Ameris Bancorp is a bank holding company headquartered in Atlanta, Georgia. The Company's banking subsidiary, Ameris Bank, had 164 locations in Georgia, Florida, South Carolina and Alabama at the end of the most recent quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 50.57 / share. Average portfolio weight of all funds dedicated to ABCB is 0.22%, an increase of 14.84%. The put/call ratio of ABCB is 0.01, indicating a bullish outlook. | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 50.57 / share. Average portfolio weight of all funds dedicated to ABCB is 0.22%, an increase of 14.84%. The put/call ratio of ABCB is 0.01, indicating a bullish outlook. | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 50.57 / share. Average portfolio weight of all funds dedicated to ABCB is 0.22%, an increase of 14.84%. The put/call ratio of ABCB is 0.01, indicating a bullish outlook. | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 50.57 / share. Average portfolio weight of all funds dedicated to ABCB is 0.22%, an increase of 14.84%. The put/call ratio of ABCB is 0.01, indicating a bullish outlook. |
27647.0 | 2023-12-07 00:00:00 UTC | Implied Volatility Surging for Ameris Bancorp (ABCB) Stock Options | ABCB | https://www.nasdaq.com/articles/implied-volatility-surging-for-ameris-bancorp-abcb-stock-options-0 | nan | nan | Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. That is because the Apr 19, 2024 $22.50 Put had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Ameris Bancorp shares, but what is the fundamental picture for the company? Currently, Ameris Bancorp is a Zacks Rank #3 (Hold) in the Banks - Southeast industry that ranks in the Top 25% of our Zacks Industry Rank. Over the last 60 days, two analysts have increased their earnings estimates for the current quarter, while one has dropped the estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.11 per share to $1.14 in that period.
Given the way analysts feel about Ameris Bancorp right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Looking to Trade Options?
Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk.
Click to see the trades now >>
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. | Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. | Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. | Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. |
27648.0 | 2023-11-29 00:00:00 UTC | Validea's Top Financial Stocks Based On Warren Buffett - 11/29/2023 | ABCB | https://www.nasdaq.com/articles/valideas-top-financial-stocks-based-on-warren-buffett-11-29-2023 | nan | nan | The following are the top rated Financial stocks according to Validea's Patient Investor model based on the published strategy of Warren Buffett. This strategy seeks out firms with long-term, predictable profitability and low debt that trade at reasonable valuations.
AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. The rating according to our strategy based on Warren Buffett is 65% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ameris Bancorp is a financial holding company, which through its subsidiary, Ameris Bank (the Bank) provides a range of banking services to its retail and commercial customers in 164 locations in Georgia, Alabama, Florida, North Carolina and South Carolina. It has five segments. The Banking Division provides full service financial services, including commercial loans, consumer loans and deposit accounts. The Retail Mortgage Division is engaged in origination, sales and servicing of one-to-four family residential mortgage loans. The Warehouse Lending Division is engaged in the origination and servicing of warehouse lines to other businesses, which are secured by underlying one-to-four family residential mortgage loans and residential mortgage servicing rights. The SBA Division is engaged in the origination, sales and servicing of small business administration loans. The Premium Finance Division is engaged in the origination and servicing of commercial insurance premium finance loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS PREDICTABILITY: PASS
RETURN ON EQUITY: FAIL
RETURN ON ASSETS: FAIL
FREE CASH FLOW: PASS
USE OF RETAINED EARNINGS: PASS
SHARE REPURCHASE: PASS
INITIAL RATE OF RETURN: PASS
EXPECTED RETURN: PASS
Detailed Analysis of AMERIS BANCORP
ABCB Guru Analysis
ABCB Fundamental Analysis
Warren Buffett Portfolio
Top Warren Buffett Stocks
About Warren Buffett: Warren Buffett is considered by many to be the greatest investor of all time. As the chairman of Berkshire Hathaway, Buffett has consistently outperformed the S&P 500 for decades, and in the process has become one of the world's richest men. (Forbes puts his net worth at $37 billion.) Despite his fortune, Buffett is known for living a modest lifestyle, by billionaire standards. His primary residence remains the gray stucco Nebraska home he purchased for $31,500 nearly 50 years ago, according to Forbes, and his folksy Midwestern manner and penchant for simple pleasures -- a cherry Coke, a good burger, and a good book are all near the top of the list -- have been well-documented.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis Warren Buffett Portfolio Top Warren Buffett Stocks About Warren Buffett: Warren Buffett is considered by many to be the greatest investor of all time. The following are the top rated Financial stocks according to Validea's Patient Investor model based on the published strategy of Warren Buffett. | Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis Warren Buffett Portfolio Top Warren Buffett Stocks About Warren Buffett: Warren Buffett is considered by many to be the greatest investor of all time. AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. The Retail Mortgage Division is engaged in origination, sales and servicing of one-to-four family residential mortgage loans. | Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis Warren Buffett Portfolio Top Warren Buffett Stocks About Warren Buffett: Warren Buffett is considered by many to be the greatest investor of all time. AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. The following are the top rated Financial stocks according to Validea's Patient Investor model based on the published strategy of Warren Buffett. | AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis Warren Buffett Portfolio Top Warren Buffett Stocks About Warren Buffett: Warren Buffett is considered by many to be the greatest investor of all time. The following are the top rated Financial stocks according to Validea's Patient Investor model based on the published strategy of Warren Buffett. |
27649.0 | 2023-11-16 00:00:00 UTC | July 2024 Options Now Available For Ameris Bancorp (ABCB) | ABCB | https://www.nasdaq.com/articles/july-2024-options-now-available-for-ameris-bancorp-abcb | nan | nan | Investors in Ameris Bancorp (Symbol: ABCB) saw new options become available today, for the July 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 246 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABCB options chain for the new July 2024 contracts and identified one put and one call contract of particular interest.
The put contract at the $25.00 strike price has a current bid of 30 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $25.00, but will also collect the premium, putting the cost basis of the shares at $24.70 (before broker commissions). To an investor already interested in purchasing shares of ABCB, that could represent an attractive alternative to paying $42.58/share today.
Because the $25.00 strike represents an approximate 41% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 1.20% return on the cash commitment, or 1.78% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Ameris Bancorp, and highlighting in green where the $25.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $45.00 strike price has a current bid of $1.50. If an investor was to purchase shares of ABCB stock at the current price level of $42.58/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $45.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 9.21% if the stock gets called away at the July 2024 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABCB shares really soar, which is why looking at the trailing twelve month trading history for Ameris Bancorp, as well as studying the business fundamentals becomes important. Below is a chart showing ABCB's trailing twelve month trading history, with the $45.00 strike highlighted in red:
Considering the fact that the $45.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 3.52% boost of extra return to the investor, or 5.23% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $42.58) to be 39%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
Also see:
Alphabetical List of All Hedge Funds
Funds Holding CTIC
Top Ten Hedge Funds Holding PDEC
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABCB shares really soar, which is why looking at the trailing twelve month trading history for Ameris Bancorp, as well as studying the business fundamentals becomes important. Below is a chart showing ABCB's trailing twelve month trading history, with the $45.00 strike highlighted in red: Considering the fact that the $45.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Ameris Bancorp (Symbol: ABCB) saw new options become available today, for the July 2024 expiration. | Below is a chart showing ABCB's trailing twelve month trading history, with the $45.00 strike highlighted in red: Considering the fact that the $45.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Ameris Bancorp (Symbol: ABCB) saw new options become available today, for the July 2024 expiration. | Below is a chart showing ABCB's trailing twelve month trading history, with the $45.00 strike highlighted in red: Considering the fact that the $45.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Ameris Bancorp (Symbol: ABCB) saw new options become available today, for the July 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABCB options chain for the new July 2024 contracts and identified one put and one call contract of particular interest. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABCB options chain for the new July 2024 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABCB's trailing twelve month trading history, with the $45.00 strike highlighted in red: Considering the fact that the $45.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Ameris Bancorp (Symbol: ABCB) saw new options become available today, for the July 2024 expiration. |
27650.0 | 2023-11-02 00:00:00 UTC | ABCB Crosses Above Key Moving Average Level | ABCB | https://www.nasdaq.com/articles/abcb-crosses-above-key-moving-average-level-1 | nan | nan | In trading on Thursday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $38.66, changing hands as high as $40.02 per share. Ameris Bancorp shares are currently trading up about 4.6% on the day. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average:
Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $39.98.
Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average »
Also see:
Funds Holding SCHE
SHO Options Chain
ETFs Holding CMRX
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $38.66, changing hands as high as $40.02 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $39.98. Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: Funds Holding SCHE SHO Options Chain ETFs Holding CMRX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $38.66, changing hands as high as $40.02 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $39.98. Ameris Bancorp shares are currently trading up about 4.6% on the day. | In trading on Thursday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $38.66, changing hands as high as $40.02 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $39.98. Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: Funds Holding SCHE SHO Options Chain ETFs Holding CMRX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $38.66, changing hands as high as $40.02 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $39.98. Ameris Bancorp shares are currently trading up about 4.6% on the day. |
27651.0 | 2023-10-31 00:00:00 UTC | Validea John Neff Strategy Daily Upgrade Report - 10/31/2023 | ABCB | https://www.nasdaq.com/articles/validea-john-neff-strategy-daily-upgrade-report-10-31-2023 | nan | nan | The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
SCIENCE APPLICATIONS INTERNATIONAL CORP (SAIC) is a mid-cap value stock in the Computer Services industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Science Applications International Corporation is a provider of technical, engineering and enterprise information technology (IT) services primarily to the United States Government. The Company provides its services for large, complex government projects and offers a range of services with a targeted emphasis on differentiated technology services. The Company is organized as a matrix consisting of two customer-facing operating sectors supported by an enterprise solutions and operations organization. Its offerings include engineering, technology integration, information technology (IT) modernization, maintenance of ground and maritime systems, training and simulation, operation and program support services and end-to-end services spanning the design, development, integration, deployment, management and operations, sustainment and security of its customers entire IT infrastructure. Its customers include the United States Army, Navy and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of SCIENCE APPLICATIONS INTERNATIONAL CORP
SAIC Guru Analysis
SAIC Fundamental Analysis
BLACK STONE MINERALS LP (BSM) is a mid-cap value stock in the Oil & Gas Operations industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Black Stone Minerals, L.P. is an owner and manager of oil and natural gas mineral interests in the United States. The Company's principal business is maximizing the value of its existing mineral and royalty assets through active management and expanding its asset base through acquisitions of additional mineral and royalty interests. The Company owns mineral interests in approximately 16.8 million gross acres. It also owns nonparticipating royalty interests (NPRIs) in 1.8 million gross acres and overriding royalty interests (ORRIs) in 1.6 million gross acres. The Company's mineral and royalty interests are located in 41 states in the continental United States, including all of the onshore producing basins. Many of these interests are in active resource plays, including the Haynesville/Bossier shales in East Texas/Western Louisiana, the Wolfcamp/Spraberry/Bone Springs in the Permian Basin, the Bakken/Three Forks in the Williston Basin, and the Eagle Ford shale in South Texas.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of BLACK STONE MINERALS LP
BSM Guru Analysis
BSM Fundamental Analysis
AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ameris Bancorp is a financial holding company, which through its subsidiary, Ameris Bank (the Bank) provides a range of banking services to its retail and commercial customers in 164 locations in Georgia, Alabama, Florida, North Carolina and South Carolina. It has five segments. The Banking Division provides full service financial services, including commercial loans, consumer loans and deposit accounts. The Retail Mortgage Division is engaged in origination, sales and servicing of one-to-four family residential mortgage loans. The Warehouse Lending Division is engaged in the origination and servicing of warehouse lines to other businesses, which are secured by underlying one-to-four family residential mortgage loans and residential mortgage servicing rights. The SBA Division is engaged in the origination, sales and servicing of small business administration loans. The Premium Finance Division is engaged in the origination and servicing of commercial insurance premium finance loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of AMERIS BANCORP
ABCB Guru Analysis
ABCB Fundamental Analysis
ARCH CAPITAL GROUP LTD. (ACGL) is a large-cap value stock in the Insurance (Prop. & Casualty) industry. The rating according to our strategy based on John Neff changed from 62% to 100% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Arch Capital Group Ltd. is a Bermuda-based company, which provides insurance, reinsurance and mortgage insurance through its subsidiaries. The insurance segment consists of the Company's insurance underwriting units, which offer specialty product lines, including construction and national accounts; excess and surplus casualty; professional lines; programs; property, energy, marine and aviation; travel, accident and health; warranty and lenders solutions, and others (consisting of alternative markets, excess workers' compensation and surety business). The reinsurance segment consists of its reinsurance underwriting units, which offer specialty product lines, including casualty; marine and aviation; other specialty; property catastrophe; property excluding property catastrophe, and other (consisting of life reinsurance and other). The mortgage segment includes its United States primary mortgage insurance business, investment and services related to United States credit-risk transfer.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of ARCH CAPITAL GROUP LTD.
ACGL Guru Analysis
ACGL Fundamental Analysis
John Neff Portfolio
About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. He was mild-mannered and low-key, and the same might be said of the Windsor Fund that he managed for more than three decades. In fact, Neff himself described the fund as "relatively prosaic, dull, [and] conservative." There was nothing dull about his results, however. From 1964 to 1995, Neff guided Windsor to a 13.7 percent average annual return, easily outpacing the S&P 500's 10.6 percent return during that time. That 3.1 percentage point difference is huge over time -- a $10,000 investment in Windsor (with dividends reinvested) at the start of Neff's tenure would have ended up as more than $564,000 by the time he retired, more than twice what the same investment in the S&P would have yielded (about $233,000). Considering the length of his tenure, that track record may be the best ever for a manager of such a large fund.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of BLACK STONE MINERALS LP BSM Guru Analysis BSM Fundamental Analysis AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis ARCH CAPITAL GROUP LTD. (ACGL) is a large-cap value stock in the Insurance (Prop. Company Description: Science Applications International Corporation is a provider of technical, engineering and enterprise information technology (IT) services primarily to the United States Government. | Detailed Analysis of BLACK STONE MINERALS LP BSM Guru Analysis BSM Fundamental Analysis AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis ARCH CAPITAL GROUP LTD. (ACGL) is a large-cap value stock in the Insurance (Prop. Detailed Analysis of SCIENCE APPLICATIONS INTERNATIONAL CORP SAIC Guru Analysis SAIC Fundamental Analysis BLACK STONE MINERALS LP (BSM) is a mid-cap value stock in the Oil & Gas Operations industry. | A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. Detailed Analysis of BLACK STONE MINERALS LP BSM Guru Analysis BSM Fundamental Analysis AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis ARCH CAPITAL GROUP LTD. (ACGL) is a large-cap value stock in the Insurance (Prop. | Detailed Analysis of BLACK STONE MINERALS LP BSM Guru Analysis BSM Fundamental Analysis AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis ARCH CAPITAL GROUP LTD. (ACGL) is a large-cap value stock in the Insurance (Prop. Company Description: Science Applications International Corporation is a provider of technical, engineering and enterprise information technology (IT) services primarily to the United States Government. |
27652.0 | 2023-10-26 00:00:00 UTC | Ameris Bancorp (ABCB) Reports Q3 Earnings: What Key Metrics Have to Say | ABCB | https://www.nasdaq.com/articles/ameris-bancorp-abcb-reports-q3-earnings%3A-what-key-metrics-have-to-say | nan | nan | Ameris Bancorp (ABCB) reported $270.93 million in revenue for the quarter ended September 2023, representing a year-over-year decline of 2.7%. EPS of $1.16 for the same period compares to $1.32 a year ago.
The reported revenue represents a surprise of -1.35% over the Zacks Consensus Estimate of $274.65 million. With the consensus EPS estimate being $1.13, the EPS surprise was +2.65%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Ameris Bancorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Efficiency ratio: 52.2% versus the four-analyst average estimate of 53.9%.
Net Interest Margin: 3.5% versus 3.5% estimated by four analysts on average.
Net charge-offs to average loans: 0.2% versus 0.2% estimated by three analysts on average.
Average Balances-Interest earning assets: $23.56 billion compared to the $23.69 billion average estimate based on two analysts.
Net Interest Income(FTE): $208.70 million versus the four-analyst average estimate of $209.16 million.
Total Non-Interest Income: $63.18 million versus $67.68 million estimated by four analysts on average.
Net Interest Income: $207.75 million versus $208.25 million estimated by two analysts on average.
View all Key Company Metrics for Ameris Bancorp here>>>
Shares of Ameris Bancorp have returned -5.5% over the past month versus the Zacks S&P 500 composite's -3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ameris Bancorp (ABCB) reported $270.93 million in revenue for the quarter ended September 2023, representing a year-over-year decline of 2.7%. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. | Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Ameris Bancorp (ABCB) reported $270.93 million in revenue for the quarter ended September 2023, representing a year-over-year decline of 2.7%. Net Interest Income(FTE): $208.70 million versus the four-analyst average estimate of $209.16 million. | Ameris Bancorp (ABCB) reported $270.93 million in revenue for the quarter ended September 2023, representing a year-over-year decline of 2.7%. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Here is how Ameris Bancorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Efficiency ratio: 52.2% versus the four-analyst average estimate of 53.9%. | Ameris Bancorp (ABCB) reported $270.93 million in revenue for the quarter ended September 2023, representing a year-over-year decline of 2.7%. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Here is how Ameris Bancorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Efficiency ratio: 52.2% versus the four-analyst average estimate of 53.9%. |
27653.0 | 2023-10-24 00:00:00 UTC | City Holding (CHCO) Tops Q3 Earnings and Revenue Estimates | ABCB | https://www.nasdaq.com/articles/city-holding-chco-tops-q3-earnings-and-revenue-estimates | nan | nan | City Holding (CHCO) came out with quarterly earnings of $1.98 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $1.83 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 3.66%. A quarter ago, it was expected that this bank holding company for City National Bank of West Virginia would post earnings of $1.90 per share when it actually produced earnings of $2.16, delivering a surprise of 13.68%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
City Holding, which belongs to the Zacks Banks - Southeast industry, posted revenues of $73.27 million for the quarter ended September 2023, surpassing the Zacks Consensus Estimate by 0.91%. This compares to year-ago revenues of $67.35 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
City Holding shares have lost about 4.8% since the beginning of the year versus the S&P 500's gain of 9.8%.
What's Next for City Holding?
While City Holding has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for City Holding: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.82 on $71.1 million in revenues for the coming quarter and $7.58 on $288.83 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Southeast is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Ameris Bancorp (ABCB), has yet to report results for the quarter ended September 2023. The results are expected to be released on October 26.
This bank is expected to post quarterly earnings of $1.13 per share in its upcoming report, which represents a year-over-year change of -14.4%. The consensus EPS estimate for the quarter has been revised 1.3% lower over the last 30 days to the current level.
Ameris Bancorp's revenues are expected to be $274.65 million, down 1.3% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
City Holding Company (CHCO) : Free Stock Analysis Report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Another stock from the same industry, Ameris Bancorp (ABCB), has yet to report results for the quarter ended September 2023. Click to get this free report City Holding Company (CHCO) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. | Click to get this free report City Holding Company (CHCO) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock from the same industry, Ameris Bancorp (ABCB), has yet to report results for the quarter ended September 2023. City Holding, which belongs to the Zacks Banks - Southeast industry, posted revenues of $73.27 million for the quarter ended September 2023, surpassing the Zacks Consensus Estimate by 0.91%. | Another stock from the same industry, Ameris Bancorp (ABCB), has yet to report results for the quarter ended September 2023. Click to get this free report City Holding Company (CHCO) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. City Holding (CHCO) came out with quarterly earnings of $1.98 per share, beating the Zacks Consensus Estimate of $1.91 per share. | Another stock from the same industry, Ameris Bancorp (ABCB), has yet to report results for the quarter ended September 2023. Click to get this free report City Holding Company (CHCO) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. |
27654.0 | 2023-10-19 00:00:00 UTC | Financial Sector Update for 10/19/2023: ABCB, BX, WABC, CUEN | ABCB | https://www.nasdaq.com/articles/financial-sector-update-for-10-19-2023%3A-abcb-bx-wabc-cuen | nan | nan | Financial stocks fell in late Thursday afternoon trading with the NYSE Financial Index down 1% and the Financial Select Sector SPDR Fund (XLF) shedding 1.2%
The Philadelphia Housing Index dropped 1.4%, and the Real Estate Select Sector SPDR Fund (XLRE) slumped 2.1%.
Bitcoin (BTC-USD) increased 1.4% to $28,705, and the yield for 10-year US Treasuries rose 7.1 basis points to 4.973%.
In economic news, Federal Reserve Chair Jerome Powell said Thursday the Federal Open Market Committee might have to increase its benchmark rate further if there's more evidence of "persistently above-trend" economic growth, or that tightness in the labor market is no longer easing.
Data from the US Labor Department showed initial jobless claims fell sequentially to 198,000 in the week ended Oct. 14 from an upwardly revised 211,000, compared with expectations for 210,000 in a survey of analysts compiled by Bloomberg.
In company news, Ameris Bancorp (ABCB) subsidiary Ameris Bank and the US Department of Justice said they reached a settlement to resolve the alleged violations of fair lending laws by the bank in Jacksonville, Florida, from 2016 to 2021. Ameris Bancorp shares fell 1.1%.
Blackstone (BX) posted Q3 earnings that missed Wall Street's estimates, while assets under management grew. Its shares tumbled 7.4%.
Westamerica Bancorporation (WABC) shares were fractionally higher after it reported Q3 earnings Thursday of $1.56 per diluted share, up from $1.29 a year earlier. Three analysts polled by Capital IQ expected $1.44.
Cuentas (CUEN) will acquire a majority stake in World Health Energy, the latter said Thursday. Cuentas shares were shedding 4.7%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, Ameris Bancorp (ABCB) subsidiary Ameris Bank and the US Department of Justice said they reached a settlement to resolve the alleged violations of fair lending laws by the bank in Jacksonville, Florida, from 2016 to 2021. In economic news, Federal Reserve Chair Jerome Powell said Thursday the Federal Open Market Committee might have to increase its benchmark rate further if there's more evidence of "persistently above-trend" economic growth, or that tightness in the labor market is no longer easing. Data from the US Labor Department showed initial jobless claims fell sequentially to 198,000 in the week ended Oct. 14 from an upwardly revised 211,000, compared with expectations for 210,000 in a survey of analysts compiled by Bloomberg. | In company news, Ameris Bancorp (ABCB) subsidiary Ameris Bank and the US Department of Justice said they reached a settlement to resolve the alleged violations of fair lending laws by the bank in Jacksonville, Florida, from 2016 to 2021. Financial stocks fell in late Thursday afternoon trading with the NYSE Financial Index down 1% and the Financial Select Sector SPDR Fund (XLF) shedding 1.2% The Philadelphia Housing Index dropped 1.4%, and the Real Estate Select Sector SPDR Fund (XLRE) slumped 2.1%. Ameris Bancorp shares fell 1.1%. | In company news, Ameris Bancorp (ABCB) subsidiary Ameris Bank and the US Department of Justice said they reached a settlement to resolve the alleged violations of fair lending laws by the bank in Jacksonville, Florida, from 2016 to 2021. Financial stocks fell in late Thursday afternoon trading with the NYSE Financial Index down 1% and the Financial Select Sector SPDR Fund (XLF) shedding 1.2% The Philadelphia Housing Index dropped 1.4%, and the Real Estate Select Sector SPDR Fund (XLRE) slumped 2.1%. In economic news, Federal Reserve Chair Jerome Powell said Thursday the Federal Open Market Committee might have to increase its benchmark rate further if there's more evidence of "persistently above-trend" economic growth, or that tightness in the labor market is no longer easing. | In company news, Ameris Bancorp (ABCB) subsidiary Ameris Bank and the US Department of Justice said they reached a settlement to resolve the alleged violations of fair lending laws by the bank in Jacksonville, Florida, from 2016 to 2021. Financial stocks fell in late Thursday afternoon trading with the NYSE Financial Index down 1% and the Financial Select Sector SPDR Fund (XLF) shedding 1.2% The Philadelphia Housing Index dropped 1.4%, and the Real Estate Select Sector SPDR Fund (XLRE) slumped 2.1%. Ameris Bancorp shares fell 1.1%. |
27655.0 | 2023-10-19 00:00:00 UTC | Ameris Bancorp (ABCB) Expected to Beat Earnings Estimates: Should You Buy? | ABCB | https://www.nasdaq.com/articles/ameris-bancorp-abcb-expected-to-beat-earnings-estimates%3A-should-you-buy-1 | nan | nan | Ameris Bancorp (ABCB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The earnings report, which is expected to be released on October 26, 2023, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This bank is expected to post quarterly earnings of $1.13 per share in its upcoming report, which represents a year-over-year change of -14.4%.
Revenues are expected to be $274.65 million, down 1.3% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1.33% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Ameris Bancorp?
For Ameris Bancorp, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +2.66%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that Ameris Bancorp will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Ameris Bancorp would post earnings of $1.12 per share when it actually produced earnings of $0.91, delivering a surprise of -18.75%.
The company has not been able to beat consensus EPS estimates in any of the last four quarters.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Ameris Bancorp appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected Results
Another stock from the Zacks Banks - Southeast industry, Live Oak Bancshares (LOB), is soon expected to post earnings of $0.49 per share for the quarter ended September 2023. This estimate indicates a year-over-year change of -49%. Revenues for the quarter are expected to be $115.52 million, down 18.4% from the year-ago quarter.
The consensus EPS estimate for Live Oak Bancshares has been revised 0.4% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -6.12%.
This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that Live Oak Bancshares will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ameris Bancorp (ABCB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2023. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report To read this article on Zacks.com click here. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. | Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report To read this article on Zacks.com click here. Ameris Bancorp (ABCB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2023. An Industry Player's Expected Results Another stock from the Zacks Banks - Southeast industry, Live Oak Bancshares (LOB), is soon expected to post earnings of $0.49 per share for the quarter ended September 2023. | Ameris Bancorp (ABCB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2023. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. | Ameris Bancorp (ABCB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2023. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report To read this article on Zacks.com click here. The company has not been able to beat consensus EPS estimates in any of the last four quarters. |
27656.0 | 2023-10-11 00:00:00 UTC | DA Davidson Upgrades Ameris Bancorp (ABCB) | ABCB | https://www.nasdaq.com/articles/da-davidson-upgrades-ameris-bancorp-abcb | nan | nan | Fintel reports that on October 10, 2023, DA Davidson upgraded their outlook for Ameris Bancorp (NASDAQ:ABCB) from Neutral to Buy .
Analyst Price Forecast Suggests 23.01% Upside
As of October 5, 2023, the average one-year price target for Ameris Bancorp is 48.11. The forecasts range from a low of 43.43 to a high of $54.60. The average price target represents an increase of 23.01% from its latest reported closing price of 39.11.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ameris Bancorp is 1,180MM, an increase of 24.43%. The projected annual non-GAAP EPS is 5.49.
Ameris Bancorp Declares $0.15 Dividend
On September 19, 2023 the company declared a regular quarterly dividend of $0.15 per share ($0.60 annualized). Shareholders of record as of September 30, 2023 received the payment on October 9, 2023. Previously, the company paid $0.15 per share.
At the current share price of $39.11 / share, the stock's dividend yield is 1.53%.
Looking back five years and taking a sample every week, the average dividend yield has been 1.47%, the lowest has been 0.90%, and the highest has been 3.17%. The standard deviation of yields is 0.48 (n=236).
The current dividend yield is 0.14 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.14. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company has not increased its dividend in the last three years.
What is the Fund Sentiment?
There are 597 funds or institutions reporting positions in Ameris Bancorp. This is a decrease of 53 owner(s) or 8.15% in the last quarter. Average portfolio weight of all funds dedicated to ABCB is 0.20%, a decrease of 9.61%. Total shares owned by institutions increased in the last three months by 0.21% to 75,162K shares.
The put/call ratio of ABCB is 0.07, indicating a bullish outlook.
What are Other Shareholders Doing?
IJR - iShares Core S&P Small-Cap ETF holds 4,548K shares representing 6.60% ownership of the company. In it's prior filing, the firm reported owning 4,752K shares, representing a decrease of 4.47%. The firm decreased its portfolio allocation in ABCB by 13.31% over the last quarter.
Wellington Management Group Llp holds 4,461K shares representing 6.47% ownership of the company. In it's prior filing, the firm reported owning 4,860K shares, representing a decrease of 8.95%. The firm increased its portfolio allocation in ABCB by 481.80% over the last quarter.
North Reef Capital Management holds 2,458K shares representing 3.57% ownership of the company. In it's prior filing, the firm reported owning 1,785K shares, representing an increase of 27.39%. The firm decreased its portfolio allocation in ABCB by 11.63% over the last quarter.
American Century Companies holds 2,456K shares representing 3.56% ownership of the company. In it's prior filing, the firm reported owning 2,282K shares, representing an increase of 7.10%. The firm decreased its portfolio allocation in ABCB by 3.66% over the last quarter.
Independent Advisor Alliance holds 2,302K shares representing 3.34% ownership of the company. In it's prior filing, the firm reported owning 1,929K shares, representing an increase of 16.21%. The firm decreased its portfolio allocation in ABCB by 1.52% over the last quarter.
Ameris Bancorp Background Information
(This description is provided by the company.)
Ameris Bancorp is a bank holding company headquartered in Atlanta, Georgia. The Company's banking subsidiary, Ameris Bank, had 164 locations in Georgia, Florida, South Carolina and Alabama at the end of the most recent quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on October 10, 2023, DA Davidson upgraded their outlook for Ameris Bancorp (NASDAQ:ABCB) from Neutral to Buy . Average portfolio weight of all funds dedicated to ABCB is 0.20%, a decrease of 9.61%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. | Fintel reports that on October 10, 2023, DA Davidson upgraded their outlook for Ameris Bancorp (NASDAQ:ABCB) from Neutral to Buy . Average portfolio weight of all funds dedicated to ABCB is 0.20%, a decrease of 9.61%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. | Fintel reports that on October 10, 2023, DA Davidson upgraded their outlook for Ameris Bancorp (NASDAQ:ABCB) from Neutral to Buy . Average portfolio weight of all funds dedicated to ABCB is 0.20%, a decrease of 9.61%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. | Fintel reports that on October 10, 2023, DA Davidson upgraded their outlook for Ameris Bancorp (NASDAQ:ABCB) from Neutral to Buy . Average portfolio weight of all funds dedicated to ABCB is 0.20%, a decrease of 9.61%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. |
27657.0 | 2023-10-10 00:00:00 UTC | Financial Sector Update for 10/10/2023: MSCI, TFC, ABCB | ABCB | https://www.nasdaq.com/articles/financial-sector-update-for-10-10-2023%3A-msci-tfc-abcb | nan | nan | Financial stocks advanced in late Tuesday afternoon trading with the NYSE Financial Index adding 0.9% and the Financial Select Sector SPDR Fund (XLF) ahead 0.8%.
The Philadelphia Housing Index climbed 1.4%, and the Real Estate Select Sector SPDR Fund (XLRE) gained 0.5%.
Bitcoin (BTC-USD) fell 0.8% to $27,373, and the yield for 10-year US Treasuries tumbled 14 basis points to 4.66%.
In economic news, wholesale inventories fell 0.1% in August, unrevised from the advance reading as expected in a survey compiled by Bloomberg and following a 0.3% decrease in July.
In company news, MSCI (MSCI) said Tuesday it has signed an agreement to acquire Trove Research, a specialist data and advisory firm, to offer expanded climate solutions. MSCI shares rose 1.5%.
Truist Financial (TFC) is in talks to sell its insurance brokerage division to Stone Point for about $10 billion, Semafor reported. Truist shares jumped 6.1%.
Ameris Bancorp (ABCB) shares climbed 2.2% after DA Davidson upgraded the company to buy from neutral with a target price of $44.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ameris Bancorp (ABCB) shares climbed 2.2% after DA Davidson upgraded the company to buy from neutral with a target price of $44. In economic news, wholesale inventories fell 0.1% in August, unrevised from the advance reading as expected in a survey compiled by Bloomberg and following a 0.3% decrease in July. Truist Financial (TFC) is in talks to sell its insurance brokerage division to Stone Point for about $10 billion, Semafor reported. | Ameris Bancorp (ABCB) shares climbed 2.2% after DA Davidson upgraded the company to buy from neutral with a target price of $44. Financial stocks advanced in late Tuesday afternoon trading with the NYSE Financial Index adding 0.9% and the Financial Select Sector SPDR Fund (XLF) ahead 0.8%. The Philadelphia Housing Index climbed 1.4%, and the Real Estate Select Sector SPDR Fund (XLRE) gained 0.5%. | Ameris Bancorp (ABCB) shares climbed 2.2% after DA Davidson upgraded the company to buy from neutral with a target price of $44. Financial stocks advanced in late Tuesday afternoon trading with the NYSE Financial Index adding 0.9% and the Financial Select Sector SPDR Fund (XLF) ahead 0.8%. In company news, MSCI (MSCI) said Tuesday it has signed an agreement to acquire Trove Research, a specialist data and advisory firm, to offer expanded climate solutions. | Ameris Bancorp (ABCB) shares climbed 2.2% after DA Davidson upgraded the company to buy from neutral with a target price of $44. Financial stocks advanced in late Tuesday afternoon trading with the NYSE Financial Index adding 0.9% and the Financial Select Sector SPDR Fund (XLF) ahead 0.8%. Bitcoin (BTC-USD) fell 0.8% to $27,373, and the yield for 10-year US Treasuries tumbled 14 basis points to 4.66%. |
27658.0 | 2023-10-10 00:00:00 UTC | Financial Sector Update for 10/10/2023: TFC, ABCB, JPM | ABCB | https://www.nasdaq.com/articles/financial-sector-update-for-10-10-2023%3A-tfc-abcb-jpm | nan | nan | Financial stocks advanced in Tuesday afternoon trading with the NYSE Financial Index rising 1.2% and the Financial Select Sector SPDR Fund (XLF) ahead 0.9%.
The Philadelphia Housing Index climbed 1.7%, and the Real Estate Select Sector SPDR Fund (XLRE) gained 0.8%.
Bitcoin (BTC-USD) fell 0.8% to $27,377, and the yield for 10-year US Treasuries tumbled 16 basis points to 4.64%.
In economic news, wholesale inventories fell 0.1% in August, unrevised from the advance reading as expected in a survey compiled by Bloomberg and following a 0.3% decrease in July.
In company news, Truist Financial (TFC) is in talks to sell its insurance brokerage division to Stone Point for about $10 billion, Semafor reported. Truist shares jumped 6.6%.
Ameris Bancorp (ABCB) shares climbed 2.6% after DA Davidson upgraded the company to buy from neutral with a target price of $44.
JPMorgan (JPM) rose 0.9% after the company expanded its Fusion data technology to the cloud-native delivery of custody, fund accounting and middle office data to institutional investors.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ameris Bancorp (ABCB) shares climbed 2.6% after DA Davidson upgraded the company to buy from neutral with a target price of $44. In economic news, wholesale inventories fell 0.1% in August, unrevised from the advance reading as expected in a survey compiled by Bloomberg and following a 0.3% decrease in July. In company news, Truist Financial (TFC) is in talks to sell its insurance brokerage division to Stone Point for about $10 billion, Semafor reported. | Ameris Bancorp (ABCB) shares climbed 2.6% after DA Davidson upgraded the company to buy from neutral with a target price of $44. Financial stocks advanced in Tuesday afternoon trading with the NYSE Financial Index rising 1.2% and the Financial Select Sector SPDR Fund (XLF) ahead 0.9%. The Philadelphia Housing Index climbed 1.7%, and the Real Estate Select Sector SPDR Fund (XLRE) gained 0.8%. | Ameris Bancorp (ABCB) shares climbed 2.6% after DA Davidson upgraded the company to buy from neutral with a target price of $44. Financial stocks advanced in Tuesday afternoon trading with the NYSE Financial Index rising 1.2% and the Financial Select Sector SPDR Fund (XLF) ahead 0.9%. In company news, Truist Financial (TFC) is in talks to sell its insurance brokerage division to Stone Point for about $10 billion, Semafor reported. | Ameris Bancorp (ABCB) shares climbed 2.6% after DA Davidson upgraded the company to buy from neutral with a target price of $44. Financial stocks advanced in Tuesday afternoon trading with the NYSE Financial Index rising 1.2% and the Financial Select Sector SPDR Fund (XLF) ahead 0.9%. Bitcoin (BTC-USD) fell 0.8% to $27,377, and the yield for 10-year US Treasuries tumbled 16 basis points to 4.64%. |
27659.0 | 2023-10-10 00:00:00 UTC | Ameris Bancorp Breaks Above 200-Day Moving Average - Bullish for ABCB | ABCB | https://www.nasdaq.com/articles/ameris-bancorp-breaks-above-200-day-moving-average-bullish-for-abcb | nan | nan | In trading on Tuesday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $39.53, changing hands as high as $40.99 per share. Ameris Bancorp shares are currently trading up about 3.5% on the day. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average:
Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $39.51.
Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average »
Also see:
Institutional Holders of CVRR
FCTY Historical Stock Prices
SBUX Price Target
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $39.53, changing hands as high as $40.99 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $39.51. Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: Institutional Holders of CVRR FCTY Historical Stock Prices SBUX Price Target The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $39.53, changing hands as high as $40.99 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $39.51. Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: Institutional Holders of CVRR FCTY Historical Stock Prices SBUX Price Target The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $39.53, changing hands as high as $40.99 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $39.51. Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: Institutional Holders of CVRR FCTY Historical Stock Prices SBUX Price Target The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $39.53, changing hands as high as $40.99 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $39.51. Ameris Bancorp shares are currently trading up about 3.5% on the day. |
27660.0 | 2023-09-26 00:00:00 UTC | Ex-Dividend Reminder: Ameris Bancorp, Starwood Property Trust and Kennedy-Wilson Holdings | ABCB | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-ameris-bancorp-starwood-property-trust-and-kennedy-wilson-holdings | nan | nan | Looking at the universe of stocks we cover at Dividend Channel, on 9/28/23, Ameris Bancorp (Symbol: ABCB), Starwood Property Trust Inc. (Symbol: STWD), and Kennedy-Wilson Holdings Inc (Symbol: KW) will all trade ex-dividend for their respective upcoming dividends. Ameris Bancorp will pay its quarterly dividend of $0.15 on 10/9/23, Starwood Property Trust Inc. will pay its quarterly dividend of $0.48 on 10/16/23, and Kennedy-Wilson Holdings Inc will pay its quarterly dividend of $0.24 on 10/5/23. As a percentage of ABCB's recent stock price of $37.74, this dividend works out to approximately 0.40%, so look for shares of Ameris Bancorp to trade 0.40% lower — all else being equal — when ABCB shares open for trading on 9/28/23. Similarly, investors should look for STWD to open 2.43% lower in price and for KW to open 1.60% lower, all else being equal.
Below are dividend history charts for ABCB, STWD, and KW, showing historical dividends prior to the most recent ones declared.
Ameris Bancorp (Symbol: ABCB):
Starwood Property Trust Inc. (Symbol: STWD):
Kennedy-Wilson Holdings Inc (Symbol: KW):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 1.59% for Ameris Bancorp, 9.73% for Starwood Property Trust Inc., and 6.42% for Kennedy-Wilson Holdings Inc.
In Tuesday trading, Ameris Bancorp shares are currently off about 0.3%, Starwood Property Trust Inc. shares are down about 0.6%, and Kennedy-Wilson Holdings Inc shares are off about 1.4% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
Also see:
High Beta Stocks
EXXI Historical Stock Prices
ECCC Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As a percentage of ABCB's recent stock price of $37.74, this dividend works out to approximately 0.40%, so look for shares of Ameris Bancorp to trade 0.40% lower — all else being equal — when ABCB shares open for trading on 9/28/23. Looking at the universe of stocks we cover at Dividend Channel, on 9/28/23, Ameris Bancorp (Symbol: ABCB), Starwood Property Trust Inc. (Symbol: STWD), and Kennedy-Wilson Holdings Inc (Symbol: KW) will all trade ex-dividend for their respective upcoming dividends. Below are dividend history charts for ABCB, STWD, and KW, showing historical dividends prior to the most recent ones declared. | Looking at the universe of stocks we cover at Dividend Channel, on 9/28/23, Ameris Bancorp (Symbol: ABCB), Starwood Property Trust Inc. (Symbol: STWD), and Kennedy-Wilson Holdings Inc (Symbol: KW) will all trade ex-dividend for their respective upcoming dividends. Ameris Bancorp (Symbol: ABCB): Starwood Property Trust Inc. (Symbol: STWD): Kennedy-Wilson Holdings Inc (Symbol: KW): In general, dividends are not always predictable, following the ups and downs of company profits over time. As a percentage of ABCB's recent stock price of $37.74, this dividend works out to approximately 0.40%, so look for shares of Ameris Bancorp to trade 0.40% lower — all else being equal — when ABCB shares open for trading on 9/28/23. | Looking at the universe of stocks we cover at Dividend Channel, on 9/28/23, Ameris Bancorp (Symbol: ABCB), Starwood Property Trust Inc. (Symbol: STWD), and Kennedy-Wilson Holdings Inc (Symbol: KW) will all trade ex-dividend for their respective upcoming dividends. Ameris Bancorp (Symbol: ABCB): Starwood Property Trust Inc. (Symbol: STWD): Kennedy-Wilson Holdings Inc (Symbol: KW): In general, dividends are not always predictable, following the ups and downs of company profits over time. As a percentage of ABCB's recent stock price of $37.74, this dividend works out to approximately 0.40%, so look for shares of Ameris Bancorp to trade 0.40% lower — all else being equal — when ABCB shares open for trading on 9/28/23. | Looking at the universe of stocks we cover at Dividend Channel, on 9/28/23, Ameris Bancorp (Symbol: ABCB), Starwood Property Trust Inc. (Symbol: STWD), and Kennedy-Wilson Holdings Inc (Symbol: KW) will all trade ex-dividend for their respective upcoming dividends. As a percentage of ABCB's recent stock price of $37.74, this dividend works out to approximately 0.40%, so look for shares of Ameris Bancorp to trade 0.40% lower — all else being equal — when ABCB shares open for trading on 9/28/23. Below are dividend history charts for ABCB, STWD, and KW, showing historical dividends prior to the most recent ones declared. |
27661.0 | 2023-09-18 00:00:00 UTC | 12.6% of VTWV Holdings Seeing Recent Insider Buys | ABCB | https://www.nasdaq.com/articles/12.6-of-vtwv-holdings-seeing-recent-insider-buys | nan | nan | A look at the weighted underlying holdings of the Vanguard Russell 2000 Value ETF (VTWV) shows an impressive 12.6% of holdings on a weighted basis have experienced insider buying within the past six months.
Ameris Bancorp (Symbol: ABCB), which makes up 0.21% of the Vanguard Russell 2000 Value ETF (VTWV), has seen 3 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $2,065,747 worth of ABCB, making it the #107 largest holding. The table below details the recent insider buying activity observed at ABCB:
ABCB — last trade: $39.39 — Recent Insider Buys:
PURCHASED INSIDER TITLE SHARES PRICE/SHARE VALUE
05/01/2023 James A. Lahaise Chief Strategy Officer 10,000 $33.03 $330,287
05/10/2023 Nicole S. Stokes CFO 1,000 $29.07 $29,070
05/15/2023 James A. Lahaise Chief Strategy Officer 10,000 $29.65 $296,519
05/17/2023 William D. McKendry Chief Risk Officer 1,000 $30.14 $30,140
And CVB Financial Corp (Symbol: CVBF), the #129 largest holding among components of the Vanguard Russell 2000 Value ETF (VTWV), shows 3 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $1,832,130 worth of CVBF, which represents approximately 0.19% of the ETF's total assets at last check. The recent insider buying activity observed at CVBF is detailed in the table below:
CVBF — last trade: $17.31 — Recent Insider Buys:
PURCHASED INSIDER TITLE SHARES PRICE/SHARE VALUE
07/31/2023 David F. Farnsworth EVP & CCO 1,250 $18.67 $23,338
08/08/2023 George A. Borba Jr. Director 257,704 $19.37 $4,992,258
06/30/2023 Anna Kan Director 1,900 $12.90 $24,510
10 ETFs With Stocks That Insiders Are Buying »
Also see:
Stock DMA
DMYT YTD Return
VLO Options Chain
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ameris Bancorp (Symbol: ABCB), which makes up 0.21% of the Vanguard Russell 2000 Value ETF (VTWV), has seen 3 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $2,065,747 worth of ABCB, making it the #107 largest holding. The table below details the recent insider buying activity observed at ABCB: ABCB — last trade: $39.39 — Recent Insider Buys: | The table below details the recent insider buying activity observed at ABCB: ABCB — last trade: $39.39 — Recent Insider Buys: Ameris Bancorp (Symbol: ABCB), which makes up 0.21% of the Vanguard Russell 2000 Value ETF (VTWV), has seen 3 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $2,065,747 worth of ABCB, making it the #107 largest holding. | The table below details the recent insider buying activity observed at ABCB: ABCB — last trade: $39.39 — Recent Insider Buys: Ameris Bancorp (Symbol: ABCB), which makes up 0.21% of the Vanguard Russell 2000 Value ETF (VTWV), has seen 3 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $2,065,747 worth of ABCB, making it the #107 largest holding. | Ameris Bancorp (Symbol: ABCB), which makes up 0.21% of the Vanguard Russell 2000 Value ETF (VTWV), has seen 3 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $2,065,747 worth of ABCB, making it the #107 largest holding. The table below details the recent insider buying activity observed at ABCB: ABCB — last trade: $39.39 — Recent Insider Buys: |
27662.0 | 2023-09-12 00:00:00 UTC | Commit To Buy Ameris Bancorp At $35, Earn 34.8% Annualized Using Options | ABCB | https://www.nasdaq.com/articles/commit-to-buy-ameris-bancorp-at-%2435-earn-34.8-annualized-using-options | nan | nan | Investors eyeing a purchase of Ameris Bancorp (Symbol: ABCB) shares, but tentative about paying the going market price of $39.09/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $35 strike, which has a bid at the time of this writing of 10 cents. Collecting that bid as the premium represents a 0.3% return against the $35 commitment, or a 34.8% annualized rate of return (at Stock Options Channel we call this the YieldBoost).
Selling a put does not give an investor access to ABCB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $35 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Ameris Bancorp sees its shares fall 10.1% and the contract is exercised (resulting in a cost basis of $34.90 per share before broker commissions, subtracting the 10 cents from $35), the only upside to the put seller is from collecting that premium for the 34.8% annualized rate of return.
Interestingly, that annualized 34.8% figure actually exceeds the 1.5% annualized dividend paid by Ameris Bancorp by 33.3%, based on the current share price of $39.09. And yet, if an investor was to buy the stock at the going market price in order to collect the dividend, there is greater downside because the stock would have to lose 10.1% to reach the $35 strike price.
Always important when discussing dividends is the fact that, in general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Ameris Bancorp, looking at the dividend history chart for ABCB below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 1.5% annualized dividend yield.
Below is a chart showing the trailing twelve month trading history for Ameris Bancorp, and highlighting in green where the $35 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the September put at the $35 strike for the 34.8% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Ameris Bancorp (considering the last 251 trading day closing values as well as today's price of $39.09) to be 38%. For other put options contract ideas at the various different available expirations, visit the ABCB Stock Options page of StockOptionsChannel.com.
In mid-afternoon trading on Tuesday, the put volume among S&P 500 components was 2.31M contracts, with call volume at 2.59M, for a put:call ratio of 0.89 so far for the day, which is unusually high compared to the long-term median put:call ratio of .65. In other words, there are lots more put buyers out there in options trading so far today than would normally be seen, as compared to call buyers. Find out which 15 call and put options traders are talking about today.
Top YieldBoost Puts of the S&P 500 »
Also see:
Andreas Halvorsen Stock Picks
OPBK Average Annual Return
IPAS Split History
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors eyeing a purchase of Ameris Bancorp (Symbol: ABCB) shares, but tentative about paying the going market price of $39.09/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to ABCB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. In the case of Ameris Bancorp, looking at the dividend history chart for ABCB below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 1.5% annualized dividend yield. | Selling a put does not give an investor access to ABCB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. Investors eyeing a purchase of Ameris Bancorp (Symbol: ABCB) shares, but tentative about paying the going market price of $39.09/share, might benefit from considering selling puts among the alternative strategies at their disposal. In the case of Ameris Bancorp, looking at the dividend history chart for ABCB below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 1.5% annualized dividend yield. | Investors eyeing a purchase of Ameris Bancorp (Symbol: ABCB) shares, but tentative about paying the going market price of $39.09/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to ABCB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. In the case of Ameris Bancorp, looking at the dividend history chart for ABCB below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 1.5% annualized dividend yield. | Investors eyeing a purchase of Ameris Bancorp (Symbol: ABCB) shares, but tentative about paying the going market price of $39.09/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to ABCB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. In the case of Ameris Bancorp, looking at the dividend history chart for ABCB below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 1.5% annualized dividend yield. |
27663.0 | 2023-09-01 00:00:00 UTC | ABCB Crosses Above Key Moving Average Level | ABCB | https://www.nasdaq.com/articles/abcb-crosses-above-key-moving-average-level-0 | nan | nan | In trading on Friday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $41.12, changing hands as high as $41.74 per share. Ameris Bancorp shares are currently trading up about 2.2% on the day. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average:
Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $41.70.
Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average »
Also see:
CLPR Dividend History
Funds Holding VAM
ABIL shares outstanding history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Friday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $41.12, changing hands as high as $41.74 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $41.70. Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: CLPR Dividend History Funds Holding VAM ABIL shares outstanding history The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Friday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $41.12, changing hands as high as $41.74 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $41.70. Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: CLPR Dividend History Funds Holding VAM ABIL shares outstanding history The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Friday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $41.12, changing hands as high as $41.74 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $41.70. Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: CLPR Dividend History Funds Holding VAM ABIL shares outstanding history The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Friday, shares of Ameris Bancorp (Symbol: ABCB) crossed above their 200 day moving average of $41.12, changing hands as high as $41.74 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $28.33 per share, with $54.24 as the 52 week high point — that compares with a last trade of $41.70. Ameris Bancorp shares are currently trading up about 2.2% on the day. |
27664.0 | 2023-09-01 00:00:00 UTC | Are Options Traders Betting on a Big Move in Ameris Bancorp (ABCB) Stock? | ABCB | https://www.nasdaq.com/articles/are-options-traders-betting-on-a-big-move-in-ameris-bancorp-abcb-stock-0 | nan | nan | Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 20, 2023 $17.50 Put had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Ameris Bancorp shares, but what is the fundamental picture for the company? Currently, Ameris Bancorp is a Zacks Rank #3 (Hold) in the Banks - Southeast industry that ranks in the Bottom 13% of our Zacks Industry Rank. Over the last 30 days, no analysts have increased their earnings estimates for the current quarter, while one analyst has revised the estimate downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.18 per share to $1.16 in that period.
Given the way analysts feel about Ameris Bancorp right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Looking to Trade Options?
Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk.
Click to see the trades now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. | Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. | Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. | Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. |
27665.0 | 2023-08-31 00:00:00 UTC | Ameris Bancorp (ABCB) Price Target Increased by 8.19% to 49.98 | ABCB | https://www.nasdaq.com/articles/ameris-bancorp-abcb-price-target-increased-by-8.19-to-49.98 | nan | nan | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 49.98 / share. This is an increase of 8.19% from the prior estimate of 46.20 dated August 1, 2023.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 46.46 to a high of 54.60 / share. The average price target represents an increase of 24.76% from the latest reported closing price of 40.06 / share.
Ameris Bancorp Declares $0.15 Dividend
On June 5, 2023 the company declared a regular quarterly dividend of $0.15 per share ($0.60 annualized). Shareholders of record as of June 30, 2023 received the payment on July 10, 2023. Previously, the company paid $0.15 per share.
At the current share price of $40.06 / share, the stock's dividend yield is 1.50%.
Looking back five years and taking a sample every week, the average dividend yield has been 1.45%, the lowest has been 0.82%, and the highest has been 3.17%. The standard deviation of yields is 0.49 (n=236).
The current dividend yield is 0.09 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.14. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company has not increased its dividend in the last three years.
What is the Fund Sentiment?
There are 613 funds or institutions reporting positions in Ameris Bancorp. This is a decrease of 34 owner(s) or 5.26% in the last quarter. Average portfolio weight of all funds dedicated to ABCB is 0.20%, a decrease of 15.10%. Total shares owned by institutions increased in the last three months by 0.93% to 75,614K shares.
The put/call ratio of ABCB is 0.06, indicating a bullish outlook.
What are Other Shareholders Doing?
IJR - iShares Core S&P Small-Cap ETF holds 4,548K shares representing 6.60% ownership of the company. In it's prior filing, the firm reported owning 4,752K shares, representing a decrease of 4.47%. The firm decreased its portfolio allocation in ABCB by 13.31% over the last quarter.
Wellington Management Group Llp holds 4,461K shares representing 6.47% ownership of the company. In it's prior filing, the firm reported owning 4,860K shares, representing a decrease of 8.95%. The firm decreased its portfolio allocation in ABCB by 18.09% over the last quarter.
North Reef Capital Management holds 2,458K shares representing 3.57% ownership of the company. In it's prior filing, the firm reported owning 1,785K shares, representing an increase of 27.39%. The firm decreased its portfolio allocation in ABCB by 11.63% over the last quarter.
American Century Companies holds 2,456K shares representing 3.56% ownership of the company. In it's prior filing, the firm reported owning 2,282K shares, representing an increase of 7.10%. The firm decreased its portfolio allocation in ABCB by 3.66% over the last quarter.
Independent Advisor Alliance holds 2,302K shares representing 3.34% ownership of the company. In it's prior filing, the firm reported owning 1,929K shares, representing an increase of 16.21%. The firm decreased its portfolio allocation in ABCB by 1.52% over the last quarter.
Ameris Bancorp Background Information
(This description is provided by the company.)
Ameris Bancorp is a bank holding company headquartered in Atlanta, Georgia. The Company's banking subsidiary, Ameris Bank, had 164 locations in Georgia, Florida, South Carolina and Alabama at the end of the most recent quarter.
Additional reading:
Summary of Director Compensation Ameris Bancorp Effective April 18, 2023
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 49.98 / share. Average portfolio weight of all funds dedicated to ABCB is 0.20%, a decrease of 15.10%. The put/call ratio of ABCB is 0.06, indicating a bullish outlook. | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 49.98 / share. Average portfolio weight of all funds dedicated to ABCB is 0.20%, a decrease of 15.10%. The put/call ratio of ABCB is 0.06, indicating a bullish outlook. | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 49.98 / share. Average portfolio weight of all funds dedicated to ABCB is 0.20%, a decrease of 15.10%. The put/call ratio of ABCB is 0.06, indicating a bullish outlook. | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 49.98 / share. Average portfolio weight of all funds dedicated to ABCB is 0.20%, a decrease of 15.10%. The put/call ratio of ABCB is 0.06, indicating a bullish outlook. |
27666.0 | 2023-08-21 00:00:00 UTC | Analysts Expect DON To Hit $48 | ABCB | https://www.nasdaq.com/articles/analysts-expect-don-to-hit-%2448 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the WisdomTree U.S. MidCap Dividend Fund ETF (Symbol: DON), we found that the implied analyst target price for the ETF based upon its underlying holdings is $47.92 per unit.
With DON trading at a recent price near $42.32 per unit, that means that analysts see 13.24% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of DON's underlying holdings with notable upside to their analyst target prices are Kilroy Realty Corp (Symbol: KRC), Hasbro, Inc. (Symbol: HAS), and Ameris Bancorp (Symbol: ABCB). Although KRC has traded at a recent price of $34.65/share, the average analyst target is 25.15% higher at $43.36/share. Similarly, HAS has 19.20% upside from the recent share price of $63.76 if the average analyst target price of $76.00/share is reached, and analysts on average are expecting ABCB to reach a target price of $47.83/share, which is 16.30% above the recent price of $41.13. Below is a twelve month price history chart comparing the stock performance of KRC, HAS, and ABCB:
Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
WisdomTree U.S. MidCap Dividend Fund ETF DON $42.32 $47.92 13.24%
Kilroy Realty Corp KRC $34.65 $43.36 25.15%
Hasbro, Inc. HAS $63.76 $76.00 19.20%
Ameris Bancorp ABCB $41.13 $47.83 16.30%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
Also see:
EDTX shares outstanding history
OCUL Videos
HSON Historical Stock Prices
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | WisdomTree U.S. MidCap Dividend Fund ETF DON $42.32 $47.92 13.24% Kilroy Realty Corp KRC $34.65 $43.36 25.15% Hasbro, Inc. HAS $63.76 $76.00 19.20% Ameris Bancorp ABCB $41.13 $47.83 16.30% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of DON's underlying holdings with notable upside to their analyst target prices are Kilroy Realty Corp (Symbol: KRC), Hasbro, Inc. (Symbol: HAS), and Ameris Bancorp (Symbol: ABCB). Similarly, HAS has 19.20% upside from the recent share price of $63.76 if the average analyst target price of $76.00/share is reached, and analysts on average are expecting ABCB to reach a target price of $47.83/share, which is 16.30% above the recent price of $41.13. | Three of DON's underlying holdings with notable upside to their analyst target prices are Kilroy Realty Corp (Symbol: KRC), Hasbro, Inc. (Symbol: HAS), and Ameris Bancorp (Symbol: ABCB). Similarly, HAS has 19.20% upside from the recent share price of $63.76 if the average analyst target price of $76.00/share is reached, and analysts on average are expecting ABCB to reach a target price of $47.83/share, which is 16.30% above the recent price of $41.13. WisdomTree U.S. MidCap Dividend Fund ETF DON $42.32 $47.92 13.24% Kilroy Realty Corp KRC $34.65 $43.36 25.15% Hasbro, Inc. HAS $63.76 $76.00 19.20% Ameris Bancorp ABCB $41.13 $47.83 16.30% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, HAS has 19.20% upside from the recent share price of $63.76 if the average analyst target price of $76.00/share is reached, and analysts on average are expecting ABCB to reach a target price of $47.83/share, which is 16.30% above the recent price of $41.13. Three of DON's underlying holdings with notable upside to their analyst target prices are Kilroy Realty Corp (Symbol: KRC), Hasbro, Inc. (Symbol: HAS), and Ameris Bancorp (Symbol: ABCB). Below is a twelve month price history chart comparing the stock performance of KRC, HAS, and ABCB: Below is a summary table of the current analyst target prices discussed above: | WisdomTree U.S. MidCap Dividend Fund ETF DON $42.32 $47.92 13.24% Kilroy Realty Corp KRC $34.65 $43.36 25.15% Hasbro, Inc. HAS $63.76 $76.00 19.20% Ameris Bancorp ABCB $41.13 $47.83 16.30% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of DON's underlying holdings with notable upside to their analyst target prices are Kilroy Realty Corp (Symbol: KRC), Hasbro, Inc. (Symbol: HAS), and Ameris Bancorp (Symbol: ABCB). Similarly, HAS has 19.20% upside from the recent share price of $63.76 if the average analyst target price of $76.00/share is reached, and analysts on average are expecting ABCB to reach a target price of $47.83/share, which is 16.30% above the recent price of $41.13. |
27667.0 | 2023-08-02 00:00:00 UTC | Ameris Bancorp (ABCB) Price Target Increased by 9.25% to 46.20 | ABCB | https://www.nasdaq.com/articles/ameris-bancorp-abcb-price-target-increased-by-9.25-to-46.20 | nan | nan | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 46.20 / share. This is an increase of 9.25% from the prior estimate of 42.29 dated July 5, 2023.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 37.12 to a high of 52.50 / share. The average price target represents an increase of 5.84% from the latest reported closing price of 43.65 / share.
Ameris Bancorp Declares $0.15 Dividend
On June 5, 2023 the company declared a regular quarterly dividend of $0.15 per share ($0.60 annualized). Shareholders of record as of June 30, 2023 received the payment on July 10, 2023. Previously, the company paid $0.15 per share.
At the current share price of $43.65 / share, the stock's dividend yield is 1.37%.
Looking back five years and taking a sample every week, the average dividend yield has been 1.44%, the lowest has been 0.80%, and the highest has been 3.17%. The standard deviation of yields is 0.50 (n=236).
The current dividend yield is 0.13 standard deviations below the historical average.
Additionally, the company's dividend payout ratio is 0.14. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company has not increased its dividend in the last three years.
What is the Fund Sentiment?
There are 646 funds or institutions reporting positions in Ameris Bancorp. This is a decrease of 8 owner(s) or 1.22% in the last quarter. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 18.31%. Total shares owned by institutions increased in the last three months by 0.08% to 75,692K shares.
The put/call ratio of ABCB is 0.07, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 4,860K shares representing 7.05% ownership of the company. In it's prior filing, the firm reported owning 6,102K shares, representing a decrease of 25.56%. The firm decreased its portfolio allocation in ABCB by 38.92% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 4,752K shares representing 6.89% ownership of the company. In it's prior filing, the firm reported owning 4,767K shares, representing a decrease of 0.33%. The firm decreased its portfolio allocation in ABCB by 24.85% over the last quarter.
Independent Advisor Alliance holds 2,302K shares representing 3.34% ownership of the company. In it's prior filing, the firm reported owning 1,929K shares, representing an increase of 16.21%. The firm increased its portfolio allocation in ABCB by 1.99% over the last quarter.
American Century Companies holds 2,282K shares representing 3.31% ownership of the company. In it's prior filing, the firm reported owning 2,019K shares, representing an increase of 11.53%. The firm decreased its portfolio allocation in ABCB by 15.41% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,071K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 1,996K shares, representing an increase of 3.65%. The firm decreased its portfolio allocation in ABCB by 25.63% over the last quarter.
Ameris Bancorp Background Information
(This description is provided by the company.)
Ameris Bancorp is a bank holding company headquartered in Atlanta, Georgia. The Company's banking subsidiary, Ameris Bank, had 164 locations in Georgia, Florida, South Carolina and Alabama at the end of the most recent quarter.
Additional reading:
AMERIS BANCORP ANNOUNCES FINANCIAL RESULTS FOR SECOND QUARTER 2023
Cautionary Statements This presentation contains forward-looking statements, as defined by federal securities laws, including, among other forward-looking statements, certain plans, expectations and goals. Words such as “may,” “believe,” “expect,” “a
May 2023 Investor Presentation
BYLAWS AMERIS BANCORP AS AMENDED AND RESTATED THROUGH FEBRUARY 23, 2023 ARTICLE I
SPLIT DOLLAR TERMINATION AGREEMENT
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 46.20 / share. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 18.31%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 46.20 / share. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 18.31%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 46.20 / share. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 18.31%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. | The average one-year price target for Ameris Bancorp (NASDAQ:ABCB) has been revised to 46.20 / share. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 18.31%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. |
27668.0 | 2023-08-01 00:00:00 UTC | Piper Sandler Maintains Ameris Bancorp (ABCB) Overweight Recommendation | ABCB | https://www.nasdaq.com/articles/piper-sandler-maintains-ameris-bancorp-abcb-overweight-recommendation-0 | nan | nan | Fintel reports that on July 31, 2023, Piper Sandler maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Overweight recommendation.
Analyst Price Forecast Suggests 3.12% Downside
As of July 6, 2023, the average one-year price target for Ameris Bancorp is 42.29. The forecasts range from a low of 37.12 to a high of $52.50. The average price target represents a decrease of 3.12% from its latest reported closing price of 43.65.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ameris Bancorp is 1,180MM, an increase of 27.19%. The projected annual non-GAAP EPS is 5.49.
Ameris Bancorp Declares $0.15 Dividend
On June 5, 2023 the company declared a regular quarterly dividend of $0.15 per share ($0.60 annualized). Shareholders of record as of June 30, 2023 received the payment on July 10, 2023. Previously, the company paid $0.15 per share.
At the current share price of $43.65 / share, the stock's dividend yield is 1.37%.
Looking back five years and taking a sample every week, the average dividend yield has been 1.44%, the lowest has been 0.80%, and the highest has been 3.17%. The standard deviation of yields is 0.50 (n=236).
The current dividend yield is 0.13 standard deviations below the historical average.
Additionally, the company's dividend payout ratio is 0.14. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company has not increased its dividend in the last three years.
What is the Fund Sentiment?
There are 646 funds or institutions reporting positions in Ameris Bancorp. This is a decrease of 6 owner(s) or 0.92% in the last quarter. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 9.44%. Total shares owned by institutions increased in the last three months by 0.15% to 75,689K shares.
The put/call ratio of ABCB is 0.07, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 4,860K shares representing 7.05% ownership of the company. In it's prior filing, the firm reported owning 6,102K shares, representing a decrease of 25.56%. The firm decreased its portfolio allocation in ABCB by 38.92% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 4,752K shares representing 6.89% ownership of the company. In it's prior filing, the firm reported owning 4,767K shares, representing a decrease of 0.33%. The firm decreased its portfolio allocation in ABCB by 24.85% over the last quarter.
Independent Advisor Alliance holds 2,302K shares representing 3.34% ownership of the company. In it's prior filing, the firm reported owning 1,929K shares, representing an increase of 16.21%. The firm increased its portfolio allocation in ABCB by 1.99% over the last quarter.
American Century Companies holds 2,282K shares representing 3.31% ownership of the company. In it's prior filing, the firm reported owning 2,019K shares, representing an increase of 11.53%. The firm decreased its portfolio allocation in ABCB by 15.41% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,071K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 1,996K shares, representing an increase of 3.65%. The firm decreased its portfolio allocation in ABCB by 25.63% over the last quarter.
Ameris Bancorp Background Information
(This description is provided by the company.)
Ameris Bancorp is a bank holding company headquartered in Atlanta, Georgia. The Company's banking subsidiary, Ameris Bank, had 164 locations in Georgia, Florida, South Carolina and Alabama at the end of the most recent quarter.
Additional reading:
AMERIS BANCORP ANNOUNCES FINANCIAL RESULTS FOR SECOND QUARTER 2023
Cautionary Statements This presentation contains forward-looking statements, as defined by federal securities laws, including, among other forward-looking statements, certain plans, expectations and goals. Words such as “may,” “believe,” “expect,” “a
May 2023 Investor Presentation
BYLAWS AMERIS BANCORP AS AMENDED AND RESTATED THROUGH FEBRUARY 23, 2023 ARTICLE I
SPLIT DOLLAR TERMINATION AGREEMENT
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on July 31, 2023, Piper Sandler maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Overweight recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 9.44%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. | Fintel reports that on July 31, 2023, Piper Sandler maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Overweight recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 9.44%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. | Fintel reports that on July 31, 2023, Piper Sandler maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Overweight recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 9.44%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. | Fintel reports that on July 31, 2023, Piper Sandler maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Overweight recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 9.44%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. |
27669.0 | 2023-08-01 00:00:00 UTC | Truist Securities Maintains Ameris Bancorp (ABCB) Buy Recommendation | ABCB | https://www.nasdaq.com/articles/truist-securities-maintains-ameris-bancorp-abcb-buy-recommendation-0 | nan | nan | Fintel reports that on July 31, 2023, Truist Securities maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Buy recommendation.
Analyst Price Forecast Suggests 3.12% Downside
As of July 6, 2023, the average one-year price target for Ameris Bancorp is 42.29. The forecasts range from a low of 37.12 to a high of $52.50. The average price target represents a decrease of 3.12% from its latest reported closing price of 43.65.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ameris Bancorp is 1,180MM, an increase of 27.19%. The projected annual non-GAAP EPS is 5.49.
Ameris Bancorp Declares $0.15 Dividend
On June 5, 2023 the company declared a regular quarterly dividend of $0.15 per share ($0.60 annualized). Shareholders of record as of June 30, 2023 received the payment on July 10, 2023. Previously, the company paid $0.15 per share.
At the current share price of $43.65 / share, the stock's dividend yield is 1.37%.
Looking back five years and taking a sample every week, the average dividend yield has been 1.44%, the lowest has been 0.80%, and the highest has been 3.17%. The standard deviation of yields is 0.50 (n=236).
The current dividend yield is 0.13 standard deviations below the historical average.
Additionally, the company's dividend payout ratio is 0.14. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company has not increased its dividend in the last three years.
What is the Fund Sentiment?
There are 646 funds or institutions reporting positions in Ameris Bancorp. This is a decrease of 6 owner(s) or 0.92% in the last quarter. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 9.44%. Total shares owned by institutions increased in the last three months by 0.15% to 75,689K shares.
The put/call ratio of ABCB is 0.07, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 4,860K shares representing 7.05% ownership of the company. In it's prior filing, the firm reported owning 6,102K shares, representing a decrease of 25.56%. The firm decreased its portfolio allocation in ABCB by 38.92% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 4,752K shares representing 6.89% ownership of the company. In it's prior filing, the firm reported owning 4,767K shares, representing a decrease of 0.33%. The firm decreased its portfolio allocation in ABCB by 24.85% over the last quarter.
Independent Advisor Alliance holds 2,302K shares representing 3.34% ownership of the company. In it's prior filing, the firm reported owning 1,929K shares, representing an increase of 16.21%. The firm increased its portfolio allocation in ABCB by 1.99% over the last quarter.
American Century Companies holds 2,282K shares representing 3.31% ownership of the company. In it's prior filing, the firm reported owning 2,019K shares, representing an increase of 11.53%. The firm decreased its portfolio allocation in ABCB by 15.41% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,071K shares representing 3.01% ownership of the company. In it's prior filing, the firm reported owning 1,996K shares, representing an increase of 3.65%. The firm decreased its portfolio allocation in ABCB by 25.63% over the last quarter.
Ameris Bancorp Background Information
(This description is provided by the company.)
Ameris Bancorp is a bank holding company headquartered in Atlanta, Georgia. The Company's banking subsidiary, Ameris Bank, had 164 locations in Georgia, Florida, South Carolina and Alabama at the end of the most recent quarter.
Additional reading:
AMERIS BANCORP ANNOUNCES FINANCIAL RESULTS FOR SECOND QUARTER 2023
Cautionary Statements This presentation contains forward-looking statements, as defined by federal securities laws, including, among other forward-looking statements, certain plans, expectations and goals. Words such as “may,” “believe,” “expect,” “a
May 2023 Investor Presentation
BYLAWS AMERIS BANCORP AS AMENDED AND RESTATED THROUGH FEBRUARY 23, 2023 ARTICLE I
SPLIT DOLLAR TERMINATION AGREEMENT
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on July 31, 2023, Truist Securities maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 9.44%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. | Fintel reports that on July 31, 2023, Truist Securities maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 9.44%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. | Fintel reports that on July 31, 2023, Truist Securities maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 9.44%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. | Fintel reports that on July 31, 2023, Truist Securities maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.22%, a decrease of 9.44%. The put/call ratio of ABCB is 0.07, indicating a bullish outlook. |
27670.0 | 2023-08-01 00:00:00 UTC | New Strong Sell Stocks for August 1st | ABCB | https://www.nasdaq.com/articles/new-strong-sell-stocks-for-august-1st-0 | nan | nan | Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:
Ameris Bancorp ABCB is a bank holding company for Ameris Bank. The Zacks Consensus Estimate for its current year earnings has been revised 4.3% downward over the last 60 days.
Citizens Financial Services, Inc. CZFS is a bank holding company for First Citizens Community Bank. The Zacks Consensus Estimate for its current year earnings has been revised 17.7% downward over the last 60 days.
Cracker Barrel Old Country Store, Inc. CBRL is a company which runs a restaurant and a gift store chain. The Zacks Consensus Estimate for its current year earnings has been revised 7.6% downward over the last 60 days.
View the entire Zacks Rank #5 List.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cracker Barrel Old Country Store, Inc. (CBRL) : Free Stock Analysis Report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
Citizens Financial Services Inc. (CZFS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Ameris Bancorp ABCB is a bank holding company for Ameris Bank. Click to get this free report Cracker Barrel Old Country Store, Inc. (CBRL) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report Citizens Financial Services Inc. (CZFS) : Free Stock Analysis Report To read this article on Zacks.com click here. The only question is “Will you get into the right stocks early when their growth potential is greatest?” Zacks has released a Special Report to help you do just that, and today it’s free. | Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Ameris Bancorp ABCB is a bank holding company for Ameris Bank. Click to get this free report Cracker Barrel Old Country Store, Inc. (CBRL) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report Citizens Financial Services Inc. (CZFS) : Free Stock Analysis Report To read this article on Zacks.com click here. Citizens Financial Services, Inc. CZFS is a bank holding company for First Citizens Community Bank. | Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Ameris Bancorp ABCB is a bank holding company for Ameris Bank. Click to get this free report Cracker Barrel Old Country Store, Inc. (CBRL) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report Citizens Financial Services Inc. (CZFS) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Consensus Estimate for its current year earnings has been revised 4.3% downward over the last 60 days. | Click to get this free report Cracker Barrel Old Country Store, Inc. (CBRL) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report Citizens Financial Services Inc. (CZFS) : Free Stock Analysis Report To read this article on Zacks.com click here. Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Ameris Bancorp ABCB is a bank holding company for Ameris Bank. Download FREE: How To Profit From Trillions On Spending For Infrastructure >> Want the latest recommendations from Zacks Investment Research? |
27671.0 | 2023-07-27 00:00:00 UTC | Ameris Bancorp (ABCB) Reports Q2 Earnings: What Key Metrics Have to Say | ABCB | https://www.nasdaq.com/articles/ameris-bancorp-abcb-reports-q2-earnings%3A-what-key-metrics-have-to-say | nan | nan | For the quarter ended June 2023, Ameris Bancorp (ABCB) reported revenue of $276.89 million, up 0.6% over the same period last year. EPS came in at $0.91, compared to $1.18 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $263.05 million, representing a surprise of +5.26%. The company delivered an EPS surprise of -18.75%, with the consensus EPS estimate being $1.12.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Ameris Bancorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Efficiency ratio: 53.6% compared to the 54.33% average estimate based on four analysts.
Net Interest Margin: 3.6% compared to the 3.55% average estimate based on four analysts.
Net charge-offs to average loans: 0.28% compared to the 0.21% average estimate based on three analysts.
Average Balances-Interest earning assets: $23.48 billion versus the two-analyst average estimate of $23.13 billion.
Net Interest Income(FTE): $210.49 million versus the four-analyst average estimate of $205.02 million.
Total Non-Interest Income: $67.35 million versus the four-analyst average estimate of $61.48 million.
Net Interest Income: $209.54 million versus $203.15 million estimated by two analysts on average.
View all Key Company Metrics for Ameris Bancorp here>>>
Shares of Ameris Bancorp have returned +23.2% over the past month versus the Zacks S&P 500 composite's +5.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For the quarter ended June 2023, Ameris Bancorp (ABCB) reported revenue of $276.89 million, up 0.6% over the same period last year. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. | Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. For the quarter ended June 2023, Ameris Bancorp (ABCB) reported revenue of $276.89 million, up 0.6% over the same period last year. Net Interest Income(FTE): $210.49 million versus the four-analyst average estimate of $205.02 million. | For the quarter ended June 2023, Ameris Bancorp (ABCB) reported revenue of $276.89 million, up 0.6% over the same period last year. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Here is how Ameris Bancorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Efficiency ratio: 53.6% compared to the 54.33% average estimate based on four analysts. | For the quarter ended June 2023, Ameris Bancorp (ABCB) reported revenue of $276.89 million, up 0.6% over the same period last year. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Here is how Ameris Bancorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Efficiency ratio: 53.6% compared to the 54.33% average estimate based on four analysts. |
27672.0 | 2023-07-27 00:00:00 UTC | Ameris Bancorp (ABCB) Q2 Earnings Miss Estimates | ABCB | https://www.nasdaq.com/articles/ameris-bancorp-abcb-q2-earnings-miss-estimates | nan | nan | Ameris Bancorp (ABCB) came out with quarterly earnings of $0.91 per share, missing the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.18 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -18.75%. A quarter ago, it was expected that this bank would post earnings of $1.20 per share when it actually produced earnings of $0.86, delivering a surprise of -28.33%.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.
Ameris Bancorp, which belongs to the Zacks Banks - Southeast industry, posted revenues of $276.89 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 5.26%. This compares to year-ago revenues of $275.21 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Ameris Bancorp shares have lost about 11% since the beginning of the year versus the S&P 500's gain of 18.9%.
What's Next for Ameris Bancorp?
While Ameris Bancorp has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Ameris Bancorp: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.12 on $263.55 million in revenues for the coming quarter and $4.21 on $1.06 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Southeast is currently in the bottom 7% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the broader Zacks Finance sector, Main Street Capital (MAIN), has yet to report results for the quarter ended June 2023. The results are expected to be released on August 3.
This investment firm is expected to post quarterly earnings of $0.99 per share in its upcoming report, which represents a year-over-year change of +32%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Main Street Capital's revenues are expected to be $120.03 million, up 40.9% from the year-ago quarter.
Free Report: Top EV Battery Stocks to Buy Now
Just-released report reveals 5 stocks to profit as millions of EV batteries are made. Elon Musk tweeted that lithium prices have gone to "insane levels," and they're likely to keep climbing. As a result, a handful of lithium battery stocks are set to skyrocket. Access this report to discover which battery stocks to buy and which to avoid.
Download free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
Main Street Capital Corporation (MAIN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ameris Bancorp (ABCB) came out with quarterly earnings of $0.91 per share, missing the Zacks Consensus Estimate of $1.12 per share. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report Main Street Capital Corporation (MAIN) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report Main Street Capital Corporation (MAIN) : Free Stock Analysis Report To read this article on Zacks.com click here. Ameris Bancorp (ABCB) came out with quarterly earnings of $0.91 per share, missing the Zacks Consensus Estimate of $1.12 per share. Ameris Bancorp, which belongs to the Zacks Banks - Southeast industry, posted revenues of $276.89 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 5.26%. | Ameris Bancorp (ABCB) came out with quarterly earnings of $0.91 per share, missing the Zacks Consensus Estimate of $1.12 per share. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report Main Street Capital Corporation (MAIN) : Free Stock Analysis Report To read this article on Zacks.com click here. Ameris Bancorp, which belongs to the Zacks Banks - Southeast industry, posted revenues of $276.89 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 5.26%. | Ameris Bancorp (ABCB) came out with quarterly earnings of $0.91 per share, missing the Zacks Consensus Estimate of $1.12 per share. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report Main Street Capital Corporation (MAIN) : Free Stock Analysis Report To read this article on Zacks.com click here. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. |
27673.0 | 2023-07-26 00:00:00 UTC | Validea's Top Financial Stocks Based On Warren Buffett - 7/26/2023 | ABCB | https://www.nasdaq.com/articles/valideas-top-financial-stocks-based-on-warren-buffett-7-26-2023 | nan | nan | The following are the top rated Financial stocks according to Validea's Patient Investor model based on the published strategy of Warren Buffett. This strategy seeks out firms with long-term, predictable profitability and low debt that trade at reasonable valuations.
AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. The rating according to our strategy based on Warren Buffett is 65% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ameris Bancorp is a financial holding company, which through its subsidiary, Ameris Bank (the Bank) provides a range of banking services to its retail and commercial customers in 164 locations in Georgia, Alabama, Florida, North Carolina and South Carolina. It has five segments. The Banking Division provides full service financial services, including commercial loans, consumer loans and deposit accounts. The Retail Mortgage Division is engaged in origination, sales and servicing of one-to-four family residential mortgage loans. The Warehouse Lending Division is engaged in the origination and servicing of warehouse lines to other businesses, which are secured by underlying one-to-four family residential mortgage loans and residential mortgage servicing rights. The SBA Division is engaged in the origination, sales and servicing of small business administration loans. The Premium Finance Division is engaged in the origination and servicing of commercial insurance premium finance loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS PREDICTABILITY: PASS
RETURN ON EQUITY: FAIL
RETURN ON ASSETS: FAIL
FREE CASH FLOW: PASS
USE OF RETAINED EARNINGS: PASS
SHARE REPURCHASE: PASS
INITIAL RATE OF RETURN: PASS
EXPECTED RETURN: PASS
Detailed Analysis of AMERIS BANCORP
ABCB Guru Analysis
ABCB Fundamental Analysis
Warren Buffett Portfolio
Top Warren Buffett Stocks
About Warren Buffett: Warren Buffett is considered by many to be the greatest investor of all time. As the chairman of Berkshire Hathaway, Buffett has consistently outperformed the S&P 500 for decades, and in the process has become one of the world's richest men. (Forbes puts his net worth at $37 billion.) Despite his fortune, Buffett is known for living a modest lifestyle, by billionaire standards. His primary residence remains the gray stucco Nebraska home he purchased for $31,500 nearly 50 years ago, according to Forbes, and his folksy Midwestern manner and penchant for simple pleasures -- a cherry Coke, a good burger, and a good book are all near the top of the list -- have been well-documented.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis Warren Buffett Portfolio Top Warren Buffett Stocks About Warren Buffett: Warren Buffett is considered by many to be the greatest investor of all time. The following are the top rated Financial stocks according to Validea's Patient Investor model based on the published strategy of Warren Buffett. | Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis Warren Buffett Portfolio Top Warren Buffett Stocks About Warren Buffett: Warren Buffett is considered by many to be the greatest investor of all time. AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. The Retail Mortgage Division is engaged in origination, sales and servicing of one-to-four family residential mortgage loans. | Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis Warren Buffett Portfolio Top Warren Buffett Stocks About Warren Buffett: Warren Buffett is considered by many to be the greatest investor of all time. AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. The following are the top rated Financial stocks according to Validea's Patient Investor model based on the published strategy of Warren Buffett. | AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis Warren Buffett Portfolio Top Warren Buffett Stocks About Warren Buffett: Warren Buffett is considered by many to be the greatest investor of all time. The following are the top rated Financial stocks according to Validea's Patient Investor model based on the published strategy of Warren Buffett. |
27674.0 | 2023-07-21 00:00:00 UTC | Earnings Preview: Dime Community (DCOM) Q2 Earnings Expected to Decline | ABCB | https://www.nasdaq.com/articles/earnings-preview%3A-dime-community-dcom-q2-earnings-expected-to-decline | nan | nan | Wall Street expects a year-over-year decline in earnings on lower revenues when Dime Community (DCOM) reports results for the quarter ended June 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 28. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This bank holding company is expected to post quarterly earnings of $0.59 per share in its upcoming report, which represents a year-over-year change of -41.6%.
Revenues are expected to be $87.52 million, down 17.2% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 9.62% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Dime Community?
For Dime Community, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +6.18%.
On the other hand, the stock currently carries a Zacks Rank of #5.
So, this combination makes it difficult to conclusively predict that Dime Community will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Dime Community would post earnings of $0.82 per share when it actually produced earnings of $0.95, delivering a surprise of +15.85%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Dime Community doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected Results
Ameris Bancorp (ABCB), another stock in the Zacks Banks - Southeast industry, is expected to report earnings per share of $1.12 for the quarter ended June 2023. This estimate points to a year-over-year change of -5.1%. Revenues for the quarter are expected to be $263.05 million, down 4.4% from the year-ago quarter.
The consensus EPS estimate for Ameris Bancorp has been revised 5.7% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -0.89%.
This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that Ameris Bancorp will beat the consensus EPS estimate. The company could not beat consensus EPS estimates in any of the last four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Dime Community Bancshares, Inc. (DCOM) : Free Stock Analysis Report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | An Industry Player's Expected Results Ameris Bancorp (ABCB), another stock in the Zacks Banks - Southeast industry, is expected to report earnings per share of $1.12 for the quarter ended June 2023. Click to get this free report Dime Community Bancshares, Inc. (DCOM) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. | An Industry Player's Expected Results Ameris Bancorp (ABCB), another stock in the Zacks Banks - Southeast industry, is expected to report earnings per share of $1.12 for the quarter ended June 2023. Click to get this free report Dime Community Bancshares, Inc. (DCOM) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that Ameris Bancorp will beat the consensus EPS estimate. | An Industry Player's Expected Results Ameris Bancorp (ABCB), another stock in the Zacks Banks - Southeast industry, is expected to report earnings per share of $1.12 for the quarter ended June 2023. Click to get this free report Dime Community Bancshares, Inc. (DCOM) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. | An Industry Player's Expected Results Ameris Bancorp (ABCB), another stock in the Zacks Banks - Southeast industry, is expected to report earnings per share of $1.12 for the quarter ended June 2023. Click to get this free report Dime Community Bancshares, Inc. (DCOM) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 28. |
27675.0 | 2023-07-20 00:00:00 UTC | Analysts Estimate Ameris Bancorp (ABCB) to Report a Decline in Earnings: What to Look Out for | ABCB | https://www.nasdaq.com/articles/analysts-estimate-ameris-bancorp-abcb-to-report-a-decline-in-earnings%3A-what-to-look-out-3 | nan | nan | The market expects Ameris Bancorp (ABCB) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on July 27, 2023, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This bank is expected to post quarterly earnings of $1.12 per share in its upcoming report, which represents a year-over-year change of -5.1%.
Revenues are expected to be $263.05 million, down 4.4% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 5.7% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Ameris Bancorp?
For Ameris Bancorp, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.89%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Ameris Bancorp will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Ameris Bancorp would post earnings of $1.20 per share when it actually produced earnings of $0.86, delivering a surprise of -28.33%.
The company has not been able to beat consensus EPS estimates in any of the last four quarters.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Ameris Bancorp doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry Player
Among the stocks in the Zacks Banks - Southeast industry, HomeTrust Bancshares (HTBI) is soon expected to post earnings of $0.90 per share for the quarter ended June 2023. This estimate indicates a year-over-year change of +130.8%. This quarter's revenue is expected to be $52.33 million, up 35.6% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for HomeTrust Bancshares has been revised 0.8% down to the current level. Nevertheless, the company now has an Earnings ESP of -5.82%, reflecting a lower Most Accurate Estimate.
This Earnings ESP, combined with its Zacks Rank #5 (Strong Sell), makes it difficult to conclusively predict that HomeTrust Bancshares will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
HomeTrust Bancshares, Inc. (HTBI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The market expects Ameris Bancorp (ABCB) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report HomeTrust Bancshares, Inc. (HTBI) : Free Stock Analysis Report To read this article on Zacks.com click here. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. | The market expects Ameris Bancorp (ABCB) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report HomeTrust Bancshares, Inc. (HTBI) : Free Stock Analysis Report To read this article on Zacks.com click here. This Earnings ESP, combined with its Zacks Rank #5 (Strong Sell), makes it difficult to conclusively predict that HomeTrust Bancshares will beat the consensus EPS estimate. | The market expects Ameris Bancorp (ABCB) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report HomeTrust Bancshares, Inc. (HTBI) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. | The market expects Ameris Bancorp (ABCB) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report HomeTrust Bancshares, Inc. (HTBI) : Free Stock Analysis Report To read this article on Zacks.com click here. The company has not been able to beat consensus EPS estimates in any of the last four quarters. |
27676.0 | 2023-07-03 00:00:00 UTC | Insiders Bullish on Certain Holdings of VTWV | ABCB | https://www.nasdaq.com/articles/insiders-bullish-on-certain-holdings-of-vtwv | nan | nan | A look at the weighted underlying holdings of the Vanguard Russell 2000 Value ETF (VTWV) shows an impressive 13.1% of holdings on a weighted basis have experienced insider buying within the past six months.
Ameris Bancorp (Symbol: ABCB), which makes up 0.20% of the Vanguard Russell 2000 Value ETF (VTWV), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,938,636 worth of ABCB, making it the #115 largest holding. The table below details the recent insider buying activity observed at ABCB:
ABCB — last trade: $34.21 — Recent Insider Buys:
PURCHASED INSIDER TITLE SHARES PRICE/SHARE VALUE
03/10/2023 William I. Bowen Jr. Director 670 $41.20 $27,604
05/01/2023 James A. Lahaise Chief Strategy Officer 10,000 $33.03 $330,287
05/10/2023 Nicole S. Stokes CFO 1,000 $29.07 $29,070
05/15/2023 James A. Lahaise Chief Strategy Officer 10,000 $29.65 $296,519
05/17/2023 William D. McKendry Chief Risk Officer 1,000 $30.14 $30,140
And Triumph Financial Inc (Symbol: TFIN), the #419 largest holding among components of the Vanguard Russell 2000 Value ETF (VTWV), shows 7 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $757,278 worth of TFIN, which represents approximately 0.08% of the ETF's total assets at last check. The recent insider buying activity observed at TFIN is detailed in the table below:
TFIN — last trade: $60.72 — Recent Insider Buys:
PURCHASED INSIDER TITLE SHARES PRICE/SHARE VALUE
01/31/2023 Michael P. Rafferty Director 1,500 $54.96 $82,440
01/31/2023 Debra A. Bradford Director 1,840 $54.19 $99,710
01/30/2023 Carlos M. Sepulveda Director 47,000 $54.47 $2,560,090
01/30/2023 Laura Easley Director 1,895 $53.19 $100,795
01/30/2023 C. Todd Sparks Director 9,500 $55.08 $523,300
01/30/2023 Charles A. Anderson Director 3,650 $54.89 $200,348
01/31/2023 Harrison B. Barnes Director 3,921 $54.79 $214,837
05/08/2023 Carlos M. Sepulveda Director 7,835 $48.86 $382,818
10 ETFs With Stocks That Insiders Are Buying »
Also see:
Ray Dalio Stock Picks
HURC Dividend History
AMG YTD Return
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ameris Bancorp (Symbol: ABCB), which makes up 0.20% of the Vanguard Russell 2000 Value ETF (VTWV), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,938,636 worth of ABCB, making it the #115 largest holding. The table below details the recent insider buying activity observed at ABCB: ABCB — last trade: $34.21 — Recent Insider Buys: | The table below details the recent insider buying activity observed at ABCB: ABCB — last trade: $34.21 — Recent Insider Buys: Ameris Bancorp (Symbol: ABCB), which makes up 0.20% of the Vanguard Russell 2000 Value ETF (VTWV), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,938,636 worth of ABCB, making it the #115 largest holding. | The table below details the recent insider buying activity observed at ABCB: ABCB — last trade: $34.21 — Recent Insider Buys: Ameris Bancorp (Symbol: ABCB), which makes up 0.20% of the Vanguard Russell 2000 Value ETF (VTWV), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,938,636 worth of ABCB, making it the #115 largest holding. | Ameris Bancorp (Symbol: ABCB), which makes up 0.20% of the Vanguard Russell 2000 Value ETF (VTWV), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,938,636 worth of ABCB, making it the #115 largest holding. The table below details the recent insider buying activity observed at ABCB: ABCB — last trade: $34.21 — Recent Insider Buys: |
27677.0 | 2023-05-25 00:00:00 UTC | Implied Volatility Surging for Ameris Bancorp (ABCB) Stock Options | ABCB | https://www.nasdaq.com/articles/implied-volatility-surging-for-ameris-bancorp-abcb-stock-options | nan | nan | Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 21, 2023 $45.00 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Ameris Bancorp shares, but what is the fundamental picture for the company? Currently, Ameris Bancorp is a Zacks Rank #5 (Strong Sell) in the Banks - Southeast industry that ranks in the Bottom 5% of our Zacks Industry Rank. Over the last 30 days, two analysts have increased their earnings estimates for the current quarter, while two have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.18 per share to $1.17 in that period.
Given the way analysts feel about Ameris Bancorp right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Looking to Trade Options?
Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk.
Click to see the trades now >>
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. | Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. | Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. | Investors in Ameris Bancorp ABCB need to pay close attention to the stock based on moves in the options market lately. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Clearly, options traders are pricing in a big move for Ameris Bancorp shares, but what is the fundamental picture for the company? |
27678.0 | 2023-05-15 00:00:00 UTC | How The Pieces Add Up: DON Targets $47 | ABCB | https://www.nasdaq.com/articles/how-the-pieces-add-up%3A-don-targets-%2447 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the WisdomTree U.S. MidCap Dividend Fund ETF (Symbol: DON), we found that the implied analyst target price for the ETF based upon its underlying holdings is $47.06 per unit.
With DON trading at a recent price near $39.55 per unit, that means that analysts see 18.98% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of DON's underlying holdings with notable upside to their analyst target prices are Ameris Bancorp (Symbol: ABCB), Comstock Resources Inc (Symbol: CRK), and Range Resources Corp (Symbol: RRC). Although ABCB has traded at a recent price of $29.06/share, the average analyst target is 44.24% higher at $41.92/share. Similarly, CRK has 34.07% upside from the recent share price of $9.79 if the average analyst target price of $13.12/share is reached, and analysts on average are expecting RRC to reach a target price of $32.27/share, which is 22.34% above the recent price of $26.38. Below is a twelve month price history chart comparing the stock performance of ABCB, CRK, and RRC:
Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
WisdomTree U.S. MidCap Dividend Fund ETF DON $39.55 $47.06 18.98%
Ameris Bancorp ABCB $29.06 $41.92 44.24%
Comstock Resources Inc CRK $9.79 $13.12 34.07%
Range Resources Corp RRC $26.38 $32.27 22.34%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
Also see:
VWE Options Chain
DGC Historical Stock Prices
Top Ten Hedge Funds Holding UDI
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | WisdomTree U.S. MidCap Dividend Fund ETF DON $39.55 $47.06 18.98% Ameris Bancorp ABCB $29.06 $41.92 44.24% Comstock Resources Inc CRK $9.79 $13.12 34.07% Range Resources Corp RRC $26.38 $32.27 22.34% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of DON's underlying holdings with notable upside to their analyst target prices are Ameris Bancorp (Symbol: ABCB), Comstock Resources Inc (Symbol: CRK), and Range Resources Corp (Symbol: RRC). Although ABCB has traded at a recent price of $29.06/share, the average analyst target is 44.24% higher at $41.92/share. | Three of DON's underlying holdings with notable upside to their analyst target prices are Ameris Bancorp (Symbol: ABCB), Comstock Resources Inc (Symbol: CRK), and Range Resources Corp (Symbol: RRC). WisdomTree U.S. MidCap Dividend Fund ETF DON $39.55 $47.06 18.98% Ameris Bancorp ABCB $29.06 $41.92 44.24% Comstock Resources Inc CRK $9.79 $13.12 34.07% Range Resources Corp RRC $26.38 $32.27 22.34% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Although ABCB has traded at a recent price of $29.06/share, the average analyst target is 44.24% higher at $41.92/share. | Three of DON's underlying holdings with notable upside to their analyst target prices are Ameris Bancorp (Symbol: ABCB), Comstock Resources Inc (Symbol: CRK), and Range Resources Corp (Symbol: RRC). Although ABCB has traded at a recent price of $29.06/share, the average analyst target is 44.24% higher at $41.92/share. Below is a twelve month price history chart comparing the stock performance of ABCB, CRK, and RRC: Below is a summary table of the current analyst target prices discussed above: | WisdomTree U.S. MidCap Dividend Fund ETF DON $39.55 $47.06 18.98% Ameris Bancorp ABCB $29.06 $41.92 44.24% Comstock Resources Inc CRK $9.79 $13.12 34.07% Range Resources Corp RRC $26.38 $32.27 22.34% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of DON's underlying holdings with notable upside to their analyst target prices are Ameris Bancorp (Symbol: ABCB), Comstock Resources Inc (Symbol: CRK), and Range Resources Corp (Symbol: RRC). Although ABCB has traded at a recent price of $29.06/share, the average analyst target is 44.24% higher at $41.92/share. |
27679.0 | 2023-05-15 00:00:00 UTC | Why Are So Many Insiders and Institutions Buying Up Regional Bank Stocks? | ABCB | https://www.nasdaq.com/articles/why-are-so-many-insiders-and-institutions-buying-up-regional-bank-stocks | nan | nan | Regional banks stocks are displaying some intriguing behavior in the last week. On one hand, the SPDR S&P Regional Banking ETF (US:KRE) extended its year-to-date decline, adding another 7.6% to that down move. The KBW Regional Banking Index is down about 30% since March 8.
On the other hand, data compiled by Fintel shows that insiders were busy buying up their individual bank shares during the week that ended on May 12.
Of course it’s not lost on us that over the last two months, there has been a great deal of concern about the outlook of U.S. regional banks and worries that their deposit outflows and balance sheet issues could cause problems for U.S. equities and for the American economy.
But maybe those insiders' purchases of several regional bank stocks could indicate that these fears are overdone.
As Bloomberg Intelligence’s Senior Industry Analyst Herman Chan and Associate Analyst Sergio Ferreira wrote last week, “perceived weakness can become reality as market dynamics pressure regional banks despite fundamentals that may not necessarily warrant such a visceral response.”
What Insiders are Buying
Three insider purchases at West Virginia-based WesBanco (US:WSBC) totaled $686,815 of the company’s shares, while two insider purchases at Indiana’s LakeLand Financial (US:LKFN) were worth $508,004. One insider at U.S. Bancorp (US:USB), one of the largest regional banks based in Minnesota, obtained $497,495 of USB stock.
Meanwhile, one insider bought $481,536 of the shares of Texas regional bank First Financial Bankshares (US:FFIN), while five insider purchases were made of shares of another Texas-based regional bank, Third Coast Bankshares (US:TCBX), worth $412,716.
Two insiders connected with Washington Federal (US:WAFD) obtained $385,206 of its stock in three deals, and there were two purchases of Georgia-based Ameris Bancorp’s (US:ABCB) by insiders for $321,580. Of note, also, is that Seattle-based WAFD stock announced a cash dividend of 25 cents per share with an ex-dividend date of May 18.
The insiders of a number of other regional banks bought less than $300,000 of their institutions’ shares last week.
Institutions Pour In
Although many institutions were selling large amounts of regional bank stocks during the end of last week, some institutions did spend significant funds on purchasing one of the most widely discussed names, PacWest (US:PACW), within the sector during that period. All of the information below is derived from Fintel data.
The State of Tennessee reported on May 12 that it had bought 74,640 shares of PacWest, while Prudential scooped up 876,444 shares and Dimensional Fund Advisors acquired 308,000 shares. Also on May 12, Charles Schwab (US:SCHW) bought 67,500 shares of PACW.
Those buys came as the West Coast regional bank revealed that customers pulled 9.5% of its total deposits after First Republic failed on May 1.
As noted above, a single insider acquired almost $500,000 worth of USB stock. They were joined by a number of institutional investors last week. On May 12, Neuberger Berman reported having bought 1.85 million shares of USB, while CIBC World Markets on the same day disclosed a purchase of 11,573 shares of the regional bank. Finally, Stifel Financial (US:SF), also on May 12, disclosed that it had acquired 478,125 shares of USB.
USB is one of the largest regional banks in the U.S., as the firm is the nation’s fifth-largest bank overall.
In March, during the beginning of the regional bank mini-crisis, the bank reported that it was “adding new accounts and new customers every day." Moreover, investment bank Stifel at the time called USB a "high-quality regional bank with little to no downside and ~50% upside over time."
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Two insiders connected with Washington Federal (US:WAFD) obtained $385,206 of its stock in three deals, and there were two purchases of Georgia-based Ameris Bancorp’s (US:ABCB) by insiders for $321,580. On the other hand, data compiled by Fintel shows that insiders were busy buying up their individual bank shares during the week that ended on May 12. Of course it’s not lost on us that over the last two months, there has been a great deal of concern about the outlook of U.S. regional banks and worries that their deposit outflows and balance sheet issues could cause problems for U.S. equities and for the American economy. | Two insiders connected with Washington Federal (US:WAFD) obtained $385,206 of its stock in three deals, and there were two purchases of Georgia-based Ameris Bancorp’s (US:ABCB) by insiders for $321,580. One insider at U.S. Bancorp (US:USB), one of the largest regional banks based in Minnesota, obtained $497,495 of USB stock. Meanwhile, one insider bought $481,536 of the shares of Texas regional bank First Financial Bankshares (US:FFIN), while five insider purchases were made of shares of another Texas-based regional bank, Third Coast Bankshares (US:TCBX), worth $412,716. | Two insiders connected with Washington Federal (US:WAFD) obtained $385,206 of its stock in three deals, and there were two purchases of Georgia-based Ameris Bancorp’s (US:ABCB) by insiders for $321,580. As Bloomberg Intelligence’s Senior Industry Analyst Herman Chan and Associate Analyst Sergio Ferreira wrote last week, “perceived weakness can become reality as market dynamics pressure regional banks despite fundamentals that may not necessarily warrant such a visceral response.” What Insiders are Buying Three insider purchases at West Virginia-based WesBanco (US:WSBC) totaled $686,815 of the company’s shares, while two insider purchases at Indiana’s LakeLand Financial (US:LKFN) were worth $508,004. Meanwhile, one insider bought $481,536 of the shares of Texas regional bank First Financial Bankshares (US:FFIN), while five insider purchases were made of shares of another Texas-based regional bank, Third Coast Bankshares (US:TCBX), worth $412,716. | Two insiders connected with Washington Federal (US:WAFD) obtained $385,206 of its stock in three deals, and there were two purchases of Georgia-based Ameris Bancorp’s (US:ABCB) by insiders for $321,580. One insider at U.S. Bancorp (US:USB), one of the largest regional banks based in Minnesota, obtained $497,495 of USB stock. The insiders of a number of other regional banks bought less than $300,000 of their institutions’ shares last week. |
27680.0 | 2023-05-11 00:00:00 UTC | RSI Alert: Ameris Bancorp Now Oversold | ABCB | https://www.nasdaq.com/articles/rsi-alert%3A-ameris-bancorp-now-oversold | nan | nan | The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Ameris Bancorp (Symbol: ABCB) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.
But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABCB entered into oversold territory, changing hands as low as $28.6293 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of Ameris Bancorp, the RSI reading has hit 29.8 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 45.0. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, ABCB's recent annualized dividend of 0.6/share (currently paid in quarterly installments) works out to an annual yield of 2.05% based upon the recent $29.23 share price.
A bullish investor could look at ABCB's 29.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABCB is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue.
Click here to find out what 9 other oversold dividend stocks you need to know about »
Also see:
DVR Options Chain
ESCA Options Chain
Institutional Holders of WTM
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A bullish investor could look at ABCB's 29.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Ameris Bancorp (Symbol: ABCB) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABCB entered into oversold territory, changing hands as low as $28.6293 per share. | Indeed, ABCB's recent annualized dividend of 0.6/share (currently paid in quarterly installments) works out to an annual yield of 2.05% based upon the recent $29.23 share price. Ameris Bancorp (Symbol: ABCB) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABCB entered into oversold territory, changing hands as low as $28.6293 per share. | Ameris Bancorp (Symbol: ABCB) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABCB entered into oversold territory, changing hands as low as $28.6293 per share. Indeed, ABCB's recent annualized dividend of 0.6/share (currently paid in quarterly installments) works out to an annual yield of 2.05% based upon the recent $29.23 share price. | Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABCB is its dividend history. Ameris Bancorp (Symbol: ABCB) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABCB entered into oversold territory, changing hands as low as $28.6293 per share. |
27681.0 | 2023-05-03 00:00:00 UTC | Wednesday 5/3 Insider Buying Report: ABCB | ABCB | https://www.nasdaq.com/articles/wednesday-5-3-insider-buying-report%3A-abcb | nan | nan | Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at one noteworthy recent insider buy.
On Monday, Chief Strategy Officer James A. Lahaise bought $330,287 worth of Ameris Bancorp, buying 10,000 shares at a cost of $33.03 each. Ameris Bancorp is trading up about 3.1% on the day Wednesday. Investors can grab ABCB at a price even lower than Lahaise did, with shares trading as low as $30.82 at last check today which is 6.7% below Lahaise's purchase price.
VIDEO: Wednesday 5/3 Insider Buying Report: ABCB
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIDEO: Wednesday 5/3 Insider Buying Report: ABCB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Investors can grab ABCB at a price even lower than Lahaise did, with shares trading as low as $30.82 at last check today which is 6.7% below Lahaise's purchase price. Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. | Investors can grab ABCB at a price even lower than Lahaise did, with shares trading as low as $30.82 at last check today which is 6.7% below Lahaise's purchase price. VIDEO: Wednesday 5/3 Insider Buying Report: ABCB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. On Monday, Chief Strategy Officer James A. Lahaise bought $330,287 worth of Ameris Bancorp, buying 10,000 shares at a cost of $33.03 each. | Investors can grab ABCB at a price even lower than Lahaise did, with shares trading as low as $30.82 at last check today which is 6.7% below Lahaise's purchase price. VIDEO: Wednesday 5/3 Insider Buying Report: ABCB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. | Investors can grab ABCB at a price even lower than Lahaise did, with shares trading as low as $30.82 at last check today which is 6.7% below Lahaise's purchase price. VIDEO: Wednesday 5/3 Insider Buying Report: ABCB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. |
27682.0 | 2023-05-03 00:00:00 UTC | Top Buys by Top Brass: Chief Strategy Officer Lahaise's $330.3K Bet on ABCB | ABCB | https://www.nasdaq.com/articles/top-buys-by-top-brass%3A-chief-strategy-officer-lahaises-%24330.3k-bet-on-abcb | nan | nan | A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both. So in this series we look at the largest insider buys by the ''top brass'' over the trailing six month period, one of which was a total of $330.3K by James A. Lahaise, Chief Strategy Officer at Ameris Bancorp (Symbol: ABCB).
PURCHASED INSIDER TITLE SHARES PRICE/SHARE VALUE
05/01/2023 James A. Lahaise Chief Strategy Officer 10,000 $33.03 $330,287.00
Lahaise's average cost works out to $33.03/share. In trading on Wednesday, bargain hunters could buy shares of Ameris Bancorp (Symbol: ABCB) and achieve a cost basis lower than Lahaise, with shares changing hands as low as $30.82 per share. Shares of Ameris Bancorp were changing hands at $31.41 at last check, trading up about 2.6% on Wednesday. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average:
Looking at the chart above, ABCB's low point in its 52 week range is $29.91 per share, with $54.24 as the 52 week high point — that compares with a last trade of $31.41.
The current annualized dividend paid by Ameris Bancorp is $0.6/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 03/30/2023. Below is a long-term dividend history chart for ABCB, which can be of good help in judging whether the most recent dividend with approx. 1.9% annualized yield is likely to continue.
Click here to find out which other top insider buys by the ''top brass'' you need to know about »
Also see:
Dividend Giants Widely Held By ETFs
Funds Holding ABNB
URGN market cap history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | So in this series we look at the largest insider buys by the ''top brass'' over the trailing six month period, one of which was a total of $330.3K by James A. Lahaise, Chief Strategy Officer at Ameris Bancorp (Symbol: ABCB). The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $29.91 per share, with $54.24 as the 52 week high point — that compares with a last trade of $31.41. In trading on Wednesday, bargain hunters could buy shares of Ameris Bancorp (Symbol: ABCB) and achieve a cost basis lower than Lahaise, with shares changing hands as low as $30.82 per share. | So in this series we look at the largest insider buys by the ''top brass'' over the trailing six month period, one of which was a total of $330.3K by James A. Lahaise, Chief Strategy Officer at Ameris Bancorp (Symbol: ABCB). In trading on Wednesday, bargain hunters could buy shares of Ameris Bancorp (Symbol: ABCB) and achieve a cost basis lower than Lahaise, with shares changing hands as low as $30.82 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $29.91 per share, with $54.24 as the 52 week high point — that compares with a last trade of $31.41. | So in this series we look at the largest insider buys by the ''top brass'' over the trailing six month period, one of which was a total of $330.3K by James A. Lahaise, Chief Strategy Officer at Ameris Bancorp (Symbol: ABCB). In trading on Wednesday, bargain hunters could buy shares of Ameris Bancorp (Symbol: ABCB) and achieve a cost basis lower than Lahaise, with shares changing hands as low as $30.82 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $29.91 per share, with $54.24 as the 52 week high point — that compares with a last trade of $31.41. | In trading on Wednesday, bargain hunters could buy shares of Ameris Bancorp (Symbol: ABCB) and achieve a cost basis lower than Lahaise, with shares changing hands as low as $30.82 per share. So in this series we look at the largest insider buys by the ''top brass'' over the trailing six month period, one of which was a total of $330.3K by James A. Lahaise, Chief Strategy Officer at Ameris Bancorp (Symbol: ABCB). The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $29.91 per share, with $54.24 as the 52 week high point — that compares with a last trade of $31.41. |
27683.0 | 2023-05-02 00:00:00 UTC | Ameris Bancorp (ABCB) Passes Through 2% Yield Mark | ABCB | https://www.nasdaq.com/articles/ameris-bancorp-abcb-passes-through-2-yield-mark | nan | nan | Looking at the universe of stocks we cover at Dividend Channel, in trading on Tuesday, shares of Ameris Bancorp (Symbol: ABCB) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.6), with the stock changing hands as low as $29.91 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. To illustrate, suppose for example you purchased shares of the iShares Russell 3000 ETF (IWV) back on 5/31/2000 — you would have paid $78.27 per share. Fast forward to 5/31/2012 and each share was worth $77.79 on that date, a loss of $0.48 or 0.6% decrease over twelve years. But now consider that you collected a whopping $10.77 per share in dividends over the same period, increasing your return to 13.15%. Even with dividends reinvested, that only amounts to an average annual total return of about 1.0%; so by comparison collecting a yield above 2% would appear considerably attractive if that yield is sustainable. Ameris Bancorp (Symbol: ABCB) is a member of the Russell 3000, giving it special status as one of the largest 3000 companies on the U.S. stock markets.
In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Ameris Bancorp, looking at the history chart for ABCB below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield.
Free Report: Top 8%+ Dividends (paid monthly)
Click here to find out which 9 other dividend stocks just recently went on sale »
Also see:
FRST Average Annual Return
Funds Holding CDXS
DFE shares outstanding history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ameris Bancorp (Symbol: ABCB) is a member of the Russell 3000, giving it special status as one of the largest 3000 companies on the U.S. stock markets. Looking at the universe of stocks we cover at Dividend Channel, in trading on Tuesday, shares of Ameris Bancorp (Symbol: ABCB) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.6), with the stock changing hands as low as $29.91 on the day. In the case of Ameris Bancorp, looking at the history chart for ABCB below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel, in trading on Tuesday, shares of Ameris Bancorp (Symbol: ABCB) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.6), with the stock changing hands as low as $29.91 on the day. Ameris Bancorp (Symbol: ABCB) is a member of the Russell 3000, giving it special status as one of the largest 3000 companies on the U.S. stock markets. In the case of Ameris Bancorp, looking at the history chart for ABCB below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel, in trading on Tuesday, shares of Ameris Bancorp (Symbol: ABCB) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.6), with the stock changing hands as low as $29.91 on the day. Ameris Bancorp (Symbol: ABCB) is a member of the Russell 3000, giving it special status as one of the largest 3000 companies on the U.S. stock markets. In the case of Ameris Bancorp, looking at the history chart for ABCB below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel, in trading on Tuesday, shares of Ameris Bancorp (Symbol: ABCB) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.6), with the stock changing hands as low as $29.91 on the day. Ameris Bancorp (Symbol: ABCB) is a member of the Russell 3000, giving it special status as one of the largest 3000 companies on the U.S. stock markets. In the case of Ameris Bancorp, looking at the history chart for ABCB below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. |
27684.0 | 2023-05-02 00:00:00 UTC | Piper Sandler Maintains Ameris Bancorp (ABCB) Overweight Recommendation | ABCB | https://www.nasdaq.com/articles/piper-sandler-maintains-ameris-bancorp-abcb-overweight-recommendation | nan | nan | Fintel reports that on May 1, 2023, Piper Sandler maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Overweight recommendation.
Analyst Price Forecast Suggests 45.26% Upside
As of April 24, 2023, the average one-year price target for Ameris Bancorp is 47.51. The forecasts range from a low of 40.90 to a high of $56.70. The average price target represents an increase of 45.26% from its latest reported closing price of 32.71.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ameris Bancorp is 1,180MM, an increase of 23.34%. The projected annual non-GAAP EPS is 5.49.
Ameris Bancorp Declares $0.15 Dividend
On March 17, 2023 the company declared a regular quarterly dividend of $0.15 per share ($0.60 annualized). Shareholders of record as of March 31, 2023 received the payment on April 10, 2023. Previously, the company paid $0.15 per share.
At the current share price of $32.71 / share, the stock's dividend yield is 1.83%.
Looking back five years and taking a sample every week, the average dividend yield has been 1.39%, the lowest has been 0.69%, and the highest has been 3.17%. The standard deviation of yields is 0.51 (n=237).
The current dividend yield is 0.86 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.13. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company has not increased its dividend in the last three years.
What is the Fund Sentiment?
There are 654 funds or institutions reporting positions in Ameris Bancorp. This is an increase of 26 owner(s) or 4.14% in the last quarter. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. Total shares owned by institutions increased in the last three months by 3.38% to 75,630K shares.
The put/call ratio of ABCB is 0.13, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 6,102K shares representing 8.80% ownership of the company. In it's prior filing, the firm reported owning 6,317K shares, representing a decrease of 3.51%. The firm decreased its portfolio allocation in ABCB by 4.11% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 4,767K shares representing 6.87% ownership of the company. In it's prior filing, the firm reported owning 4,751K shares, representing an increase of 0.34%. The firm decreased its portfolio allocation in ABCB by 3.75% over the last quarter.
Principal Financial Group holds 2,026K shares representing 2.92% ownership of the company. In it's prior filing, the firm reported owning 2,128K shares, representing a decrease of 5.05%. The firm decreased its portfolio allocation in ABCB by 48.52% over the last quarter.
American Century Companies holds 2,019K shares representing 2.91% ownership of the company. In it's prior filing, the firm reported owning 2,334K shares, representing a decrease of 15.60%. The firm decreased its portfolio allocation in ABCB by 15.33% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,996K shares representing 2.88% ownership of the company. In it's prior filing, the firm reported owning 1,991K shares, representing an increase of 0.21%. The firm decreased its portfolio allocation in ABCB by 2.43% over the last quarter.
Ameris Bancorp Background Information
(This description is provided by the company.)
Ameris Bancorp is a bank holding company headquartered in Atlanta, Georgia. The Company's banking subsidiary, Ameris Bank, had 164 locations in Georgia, Florida, South Carolina and Alabama at the end of the most recent quarter.
See all Ameris Bancorp regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on May 1, 2023, Piper Sandler maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Overweight recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. The put/call ratio of ABCB is 0.13, indicating a bullish outlook. | Fintel reports that on May 1, 2023, Piper Sandler maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Overweight recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. The put/call ratio of ABCB is 0.13, indicating a bullish outlook. | Fintel reports that on May 1, 2023, Piper Sandler maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Overweight recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. The put/call ratio of ABCB is 0.13, indicating a bullish outlook. | Fintel reports that on May 1, 2023, Piper Sandler maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Overweight recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. The put/call ratio of ABCB is 0.13, indicating a bullish outlook. |
27685.0 | 2023-05-02 00:00:00 UTC | Truist Securities Maintains Ameris Bancorp (ABCB) Buy Recommendation | ABCB | https://www.nasdaq.com/articles/truist-securities-maintains-ameris-bancorp-abcb-buy-recommendation | nan | nan | Fintel reports that on May 1, 2023, Truist Securities maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Buy recommendation.
Analyst Price Forecast Suggests 45.26% Upside
As of April 24, 2023, the average one-year price target for Ameris Bancorp is 47.51. The forecasts range from a low of 40.90 to a high of $56.70. The average price target represents an increase of 45.26% from its latest reported closing price of 32.71.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ameris Bancorp is 1,180MM, an increase of 23.34%. The projected annual non-GAAP EPS is 5.49.
Ameris Bancorp Declares $0.15 Dividend
On March 17, 2023 the company declared a regular quarterly dividend of $0.15 per share ($0.60 annualized). Shareholders of record as of March 31, 2023 received the payment on April 10, 2023. Previously, the company paid $0.15 per share.
At the current share price of $32.71 / share, the stock's dividend yield is 1.83%.
Looking back five years and taking a sample every week, the average dividend yield has been 1.39%, the lowest has been 0.69%, and the highest has been 3.17%. The standard deviation of yields is 0.51 (n=237).
The current dividend yield is 0.86 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.13. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company has not increased its dividend in the last three years.
What is the Fund Sentiment?
There are 654 funds or institutions reporting positions in Ameris Bancorp. This is an increase of 26 owner(s) or 4.14% in the last quarter. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. Total shares owned by institutions increased in the last three months by 3.38% to 75,630K shares.
The put/call ratio of ABCB is 0.13, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 6,102K shares representing 8.80% ownership of the company. In it's prior filing, the firm reported owning 6,317K shares, representing a decrease of 3.51%. The firm decreased its portfolio allocation in ABCB by 4.11% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 4,767K shares representing 6.87% ownership of the company. In it's prior filing, the firm reported owning 4,751K shares, representing an increase of 0.34%. The firm decreased its portfolio allocation in ABCB by 3.75% over the last quarter.
Principal Financial Group holds 2,026K shares representing 2.92% ownership of the company. In it's prior filing, the firm reported owning 2,128K shares, representing a decrease of 5.05%. The firm decreased its portfolio allocation in ABCB by 48.52% over the last quarter.
American Century Companies holds 2,019K shares representing 2.91% ownership of the company. In it's prior filing, the firm reported owning 2,334K shares, representing a decrease of 15.60%. The firm decreased its portfolio allocation in ABCB by 15.33% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,996K shares representing 2.88% ownership of the company. In it's prior filing, the firm reported owning 1,991K shares, representing an increase of 0.21%. The firm decreased its portfolio allocation in ABCB by 2.43% over the last quarter.
Ameris Bancorp Background Information
(This description is provided by the company.)
Ameris Bancorp is a bank holding company headquartered in Atlanta, Georgia. The Company's banking subsidiary, Ameris Bank, had 164 locations in Georgia, Florida, South Carolina and Alabama at the end of the most recent quarter.
See all Ameris Bancorp regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on May 1, 2023, Truist Securities maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. The put/call ratio of ABCB is 0.13, indicating a bullish outlook. | Fintel reports that on May 1, 2023, Truist Securities maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. The put/call ratio of ABCB is 0.13, indicating a bullish outlook. | Fintel reports that on May 1, 2023, Truist Securities maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. The put/call ratio of ABCB is 0.13, indicating a bullish outlook. | Fintel reports that on May 1, 2023, Truist Securities maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. The put/call ratio of ABCB is 0.13, indicating a bullish outlook. |
27686.0 | 2023-05-02 00:00:00 UTC | Keefe, Bruyette & Woods Maintains Ameris Bancorp (ABCB) Outperform Recommendation | ABCB | https://www.nasdaq.com/articles/keefe-bruyette-woods-maintains-ameris-bancorp-abcb-outperform-recommendation | nan | nan | Fintel reports that on May 1, 2023, Keefe, Bruyette & Woods maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Outperform recommendation.
Analyst Price Forecast Suggests 45.26% Upside
As of April 24, 2023, the average one-year price target for Ameris Bancorp is 47.51. The forecasts range from a low of 40.90 to a high of $56.70. The average price target represents an increase of 45.26% from its latest reported closing price of 32.71.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ameris Bancorp is 1,180MM, an increase of 23.34%. The projected annual non-GAAP EPS is 5.49.
Ameris Bancorp Declares $0.15 Dividend
On March 17, 2023 the company declared a regular quarterly dividend of $0.15 per share ($0.60 annualized). Shareholders of record as of March 31, 2023 received the payment on April 10, 2023. Previously, the company paid $0.15 per share.
At the current share price of $32.71 / share, the stock's dividend yield is 1.83%.
Looking back five years and taking a sample every week, the average dividend yield has been 1.39%, the lowest has been 0.69%, and the highest has been 3.17%. The standard deviation of yields is 0.51 (n=237).
The current dividend yield is 0.86 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.13. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company has not increased its dividend in the last three years.
What is the Fund Sentiment?
There are 654 funds or institutions reporting positions in Ameris Bancorp. This is an increase of 26 owner(s) or 4.14% in the last quarter. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. Total shares owned by institutions increased in the last three months by 3.38% to 75,630K shares.
The put/call ratio of ABCB is 0.13, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 6,102K shares representing 8.80% ownership of the company. In it's prior filing, the firm reported owning 6,317K shares, representing a decrease of 3.51%. The firm decreased its portfolio allocation in ABCB by 4.11% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 4,767K shares representing 6.87% ownership of the company. In it's prior filing, the firm reported owning 4,751K shares, representing an increase of 0.34%. The firm decreased its portfolio allocation in ABCB by 3.75% over the last quarter.
Principal Financial Group holds 2,026K shares representing 2.92% ownership of the company. In it's prior filing, the firm reported owning 2,128K shares, representing a decrease of 5.05%. The firm decreased its portfolio allocation in ABCB by 48.52% over the last quarter.
American Century Companies holds 2,019K shares representing 2.91% ownership of the company. In it's prior filing, the firm reported owning 2,334K shares, representing a decrease of 15.60%. The firm decreased its portfolio allocation in ABCB by 15.33% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,996K shares representing 2.88% ownership of the company. In it's prior filing, the firm reported owning 1,991K shares, representing an increase of 0.21%. The firm decreased its portfolio allocation in ABCB by 2.43% over the last quarter.
Ameris Bancorp Background Information
(This description is provided by the company.)
Ameris Bancorp is a bank holding company headquartered in Atlanta, Georgia. The Company's banking subsidiary, Ameris Bank, had 164 locations in Georgia, Florida, South Carolina and Alabama at the end of the most recent quarter.
See all Ameris Bancorp regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on May 1, 2023, Keefe, Bruyette & Woods maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Outperform recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. The put/call ratio of ABCB is 0.13, indicating a bullish outlook. | Fintel reports that on May 1, 2023, Keefe, Bruyette & Woods maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Outperform recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. The put/call ratio of ABCB is 0.13, indicating a bullish outlook. | Fintel reports that on May 1, 2023, Keefe, Bruyette & Woods maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Outperform recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. The put/call ratio of ABCB is 0.13, indicating a bullish outlook. | Fintel reports that on May 1, 2023, Keefe, Bruyette & Woods maintained coverage of Ameris Bancorp (NASDAQ:ABCB) with a Outperform recommendation. Average portfolio weight of all funds dedicated to ABCB is 0.26%, a decrease of 2.37%. The put/call ratio of ABCB is 0.13, indicating a bullish outlook. |
27687.0 | 2023-04-27 00:00:00 UTC | Ameris Bancorp (ABCB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates | ABCB | https://www.nasdaq.com/articles/ameris-bancorp-abcb-q1-earnings%3A-taking-a-look-at-key-metrics-versus-estimates | nan | nan | For the quarter ended March 2023, Ameris Bancorp (ABCB) reported revenue of $267.7 million, up 3.2% over the same period last year. EPS came in at $0.86, compared to $1.08 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $261.7 million, representing a surprise of +2.29%. The company delivered an EPS surprise of -28.33%, with the consensus EPS estimate being $1.20.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Ameris Bancorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Efficiency ratio: 52.08% versus 52.13% estimated by four analysts on average.
Net Interest Margin: 3.76% compared to the 3.93% average estimate based on four analysts.
Net charge-offs to average loans: 0.22% versus the three-analyst average estimate of 0.19%.
Total Non-Interest Income: $56.05 million versus the four-analyst average estimate of $46.98 million.
Net Interest Income(FTE): $212.59 million versus $217.91 million estimated by four analysts on average.
View all Key Company Metrics for Ameris Bancorp here>>>
Shares of Ameris Bancorp have returned -11.4% over the past month versus the Zacks S&P 500 composite's +2.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For the quarter ended March 2023, Ameris Bancorp (ABCB) reported revenue of $267.7 million, up 3.2% over the same period last year. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. | Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. For the quarter ended March 2023, Ameris Bancorp (ABCB) reported revenue of $267.7 million, up 3.2% over the same period last year. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. | For the quarter ended March 2023, Ameris Bancorp (ABCB) reported revenue of $267.7 million, up 3.2% over the same period last year. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. | For the quarter ended March 2023, Ameris Bancorp (ABCB) reported revenue of $267.7 million, up 3.2% over the same period last year. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Here is how Ameris Bancorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Efficiency ratio: 52.08% versus 52.13% estimated by four analysts on average. |
27688.0 | 2023-04-26 00:00:00 UTC | First Bancorp (FBNC) Q1 Earnings and Revenues Miss Estimates | ABCB | https://www.nasdaq.com/articles/first-bancorp-fbnc-q1-earnings-and-revenues-miss-estimates | nan | nan | First Bancorp (FBNC) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.95 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -57.95%. A quarter ago, it was expected that this bank holding company for First Bank would post earnings of $1.02 per share when it actually produced earnings of $1.08, delivering a surprise of 5.88%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
First Bancorp, which belongs to the Zacks Banks - Southeast industry, posted revenues of $106.02 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 7.32%. This compares to year-ago revenues of $96.13 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
First Bancorp shares have lost about 26% since the beginning of the year versus the S&P 500's gain of 6.1%.
What's Next for First Bancorp?
While First Bancorp has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for First Bancorp: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.01 on $115.5 million in revenues for the coming quarter and $3.77 on $464.4 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Southeast is currently in the bottom 4% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Ameris Bancorp (ABCB), has yet to report results for the quarter ended March 2023. The results are expected to be released on April 27.
This bank is expected to post quarterly earnings of $1.20 per share in its upcoming report, which represents a year-over-year change of +11.1%. The consensus EPS estimate for the quarter has been revised 6.4% lower over the last 30 days to the current level.
Ameris Bancorp's revenues are expected to be $261.7 million, up 0.9% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
First Bancorp (FBNC) : Free Stock Analysis Report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Another stock from the same industry, Ameris Bancorp (ABCB), has yet to report results for the quarter ended March 2023. Click to get this free report First Bancorp (FBNC) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | Click to get this free report First Bancorp (FBNC) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock from the same industry, Ameris Bancorp (ABCB), has yet to report results for the quarter ended March 2023. First Bancorp, which belongs to the Zacks Banks - Southeast industry, posted revenues of $106.02 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 7.32%. | Click to get this free report First Bancorp (FBNC) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock from the same industry, Ameris Bancorp (ABCB), has yet to report results for the quarter ended March 2023. First Bancorp (FBNC) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.88 per share. | Another stock from the same industry, Ameris Bancorp (ABCB), has yet to report results for the quarter ended March 2023. Click to get this free report First Bancorp (FBNC) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. First Bancorp (FBNC) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.88 per share. |
27689.0 | 2023-04-25 00:00:00 UTC | Southern First (SFST) Q1 Earnings and Revenues Lag Estimates | ABCB | https://www.nasdaq.com/articles/southern-first-sfst-q1-earnings-and-revenues-lag-estimates | nan | nan | Southern First (SFST) came out with quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.98 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -48.44%. A quarter ago, it was expected that this holding company for Southern First Bank would post earnings of $1.02 per share when it actually produced earnings of $0.68, delivering a surprise of -33.33%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Southern First, which belongs to the Zacks Banks - Southeast industry, posted revenues of $22.47 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 10.91%. This compares to year-ago revenues of $26.09 million. The company has not been able to beat consensus revenue estimates over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Southern First shares have lost about 37.1% since the beginning of the year versus the S&P 500's gain of 7.8%.
What's Next for Southern First?
While Southern First has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Southern First: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.70 on $26.1 million in revenues for the coming quarter and $2.86 on $106.45 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Southeast is currently in the bottom 5% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Ameris Bancorp (ABCB), is yet to report results for the quarter ended March 2023. The results are expected to be released on April 27.
This bank is expected to post quarterly earnings of $1.20 per share in its upcoming report, which represents a year-over-year change of +11.1%. The consensus EPS estimate for the quarter has been revised 6.4% lower over the last 30 days to the current level.
Ameris Bancorp's revenues are expected to be $261.7 million, up 0.9% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Southern First Bancshares, Inc. (SFST) : Free Stock Analysis Report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One other stock from the same industry, Ameris Bancorp (ABCB), is yet to report results for the quarter ended March 2023. Click to get this free report Southern First Bancshares, Inc. (SFST) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | Click to get this free report Southern First Bancshares, Inc. (SFST) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock from the same industry, Ameris Bancorp (ABCB), is yet to report results for the quarter ended March 2023. Southern First, which belongs to the Zacks Banks - Southeast industry, posted revenues of $22.47 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 10.91%. | One other stock from the same industry, Ameris Bancorp (ABCB), is yet to report results for the quarter ended March 2023. Click to get this free report Southern First Bancshares, Inc. (SFST) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Southern First (SFST) came out with quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.64 per share. | One other stock from the same industry, Ameris Bancorp (ABCB), is yet to report results for the quarter ended March 2023. Click to get this free report Southern First Bancshares, Inc. (SFST) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Southern First (SFST) came out with quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.64 per share. |
27690.0 | 2023-04-24 00:00:00 UTC | Capital City Bank (CCBG) Q1 Earnings and Revenues Surpass Estimates | ABCB | https://www.nasdaq.com/articles/capital-city-bank-ccbg-q1-earnings-and-revenues-surpass-estimates | nan | nan | Capital City Bank (CCBG) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.50 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 12.82%. A quarter ago, it was expected that this bank holding company would post earnings of $0.77 per share when it actually produced earnings of $0.68, delivering a surprise of -11.69%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Capital City Bank, which belongs to the Zacks Banks - Southeast industry, posted revenues of $62.64 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 5.10%. This compares to year-ago revenues of $50.51 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Capital City Bank shares have lost about 12.8% since the beginning of the year versus the S&P 500's gain of 7.7%.
What's Next for Capital City Bank?
While Capital City Bank has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Capital City Bank: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.86 on $61.5 million in revenues for the coming quarter and $3.27 on $243.9 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Southeast is currently in the bottom 4% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Ameris Bancorp (ABCB), another stock in the same industry, has yet to report results for the quarter ended March 2023. The results are expected to be released on April 27.
This bank is expected to post quarterly earnings of $1.20 per share in its upcoming report, which represents a year-over-year change of +11.1%. The consensus EPS estimate for the quarter has been revised 8% lower over the last 30 days to the current level.
Ameris Bancorp's revenues are expected to be $263.49 million, up 1.6% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Capital City Bank Group (CCBG) : Free Stock Analysis Report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ameris Bancorp (ABCB), another stock in the same industry, has yet to report results for the quarter ended March 2023. Click to get this free report Capital City Bank Group (CCBG) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | Click to get this free report Capital City Bank Group (CCBG) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Ameris Bancorp (ABCB), another stock in the same industry, has yet to report results for the quarter ended March 2023. Capital City Bank, which belongs to the Zacks Banks - Southeast industry, posted revenues of $62.64 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 5.10%. | Click to get this free report Capital City Bank Group (CCBG) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Ameris Bancorp (ABCB), another stock in the same industry, has yet to report results for the quarter ended March 2023. Capital City Bank (CCBG) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.78 per share. | Ameris Bancorp (ABCB), another stock in the same industry, has yet to report results for the quarter ended March 2023. Click to get this free report Capital City Bank Group (CCBG) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Capital City Bank (CCBG) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.78 per share. |
27691.0 | 2023-04-20 00:00:00 UTC | Ameris Bancorp (ABCB) Earnings Expected to Grow: What to Know Ahead of Next Week's Release | ABCB | https://www.nasdaq.com/articles/ameris-bancorp-abcb-earnings-expected-to-grow%3A-what-to-know-ahead-of-next-weeks-release-2 | nan | nan | The market expects Ameris Bancorp (ABCB) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on April 27, 2023, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on theearnings call it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This bank is expected to post quarterly earnings of $1.20 per share in its upcoming report, which represents a year-over-year change of +11.1%.
Revenues are expected to be $263.49 million, up 1.6% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 7.99% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Ameris Bancorp?
For Ameris Bancorp, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.
On the other hand, the stock currently carries a Zacks Rank of #4.
So, this combination makes it difficult to conclusively predict that Ameris Bancorp will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Ameris Bancorp would post earnings of $1.34 per share when it actually produced earnings of $1.17, delivering a surprise of -12.69%.
The company has not been able to beat consensus EPS estimates in any of the last four quarters.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Ameris Bancorp doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected Results
Among the stocks in the Zacks Banks - Southeast industry, Live Oak Bancshares (LOB) is soon expected to post earnings of $0.36 per share for the quarter ended March 2023. This estimate indicates a year-over-year change of -52.6%. This quarter's revenue is expected to be $111.27 million, up 0.7% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Live Oak Bancshares has been revised 11% down to the current level. Nevertheless, the company now has an Earnings ESP of 0.00%, reflecting an equal Most Accurate Estimate.
This Earnings ESP, combined with its Zacks Rank #5 (Strong Sell), makes it difficult to conclusively predict that Live Oak Bancshares will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The market expects Ameris Bancorp (ABCB) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2023. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report To read this article on Zacks.com click here. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. | The market expects Ameris Bancorp (ABCB) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2023. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report To read this article on Zacks.com click here. This Earnings ESP, combined with its Zacks Rank #5 (Strong Sell), makes it difficult to conclusively predict that Live Oak Bancshares will beat the consensus EPS estimate. | The market expects Ameris Bancorp (ABCB) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2023. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. | The market expects Ameris Bancorp (ABCB) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2023. Click to get this free report Ameris Bancorp (ABCB) : Free Stock Analysis Report Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Consensus Estimate This bank is expected to post quarterly earnings of $1.20 per share in its upcoming report, which represents a year-over-year change of +11.1%. |
27692.0 | 2023-04-05 00:00:00 UTC | Stephens & Co. Initiates Coverage of Ameris Bancorp (ABCB) with Equal-Weight Recommendation | ABCB | https://www.nasdaq.com/articles/stephens-co.-initiates-coverage-of-ameris-bancorp-abcb-with-equal-weight-recommendation | nan | nan | On April 4, 2023, Stephens & Co. initiated coverage of Ameris Bancorp with a Equal-Weight recommendation.
Analyst Price Forecast Suggests 57.35% Upside
As of March 30, 2023, the average one-year price target for Ameris Bancorp is $54.57. The forecasts range from a low of $43.43 to a high of $63.00. The average price target represents an increase of 57.35% from its latest reported closing price of $34.68.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ameris Bancorp is $1,180MM, an increase of 18.95%. The projected annual non-GAAP EPS is $5.49.
Ameris Bancorp Declares $0.15 Dividend
On March 17, 2023 the company declared a regular quarterly dividend of $0.15 per share ($0.60 annualized). Shareholders of record as of March 31, 2023 will receive the payment on April 10, 2023. Previously, the company paid $0.15 per share.
At the current share price of $34.68 / share, the stock's dividend yield is 1.73%. Looking back five years and taking a sample every week, the average dividend yield has been 1.38%, the lowest has been 0.69%, and the highest has been 3.17%. The standard deviation of yields is 0.52 (n=237).
The current dividend yield is 0.69 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.12. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company has not increased its dividend in the last three years.
What are Other Shareholders Doing?
GSSIX - Goldman Sachs Small Cap Value Fund Institutional holds 442K shares representing 0.64% ownership of the company. In it's prior filing, the firm reported owning 479K shares, representing a decrease of 8.58%. The firm increased its portfolio allocation in ABCB by 6.96% over the last quarter.
JESGX - Small Cap Stock Trust NAV holds 80K shares representing 0.12% ownership of the company. In it's prior filing, the firm reported owning 79K shares, representing an increase of 0.46%. The firm increased its portfolio allocation in ABCB by 3.57% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 4,767K shares representing 6.89% ownership of the company. In it's prior filing, the firm reported owning 4,751K shares, representing an increase of 0.34%. The firm decreased its portfolio allocation in ABCB by 3.75% over the last quarter.
JOHN HANCOCK VARIABLE INSURANCE TRUST - Small Cap Opportunities Trust NAV holds 18K shares representing 0.03% ownership of the company. In it's prior filing, the firm reported owning 18K shares, representing an increase of 1.17%. The firm decreased its portfolio allocation in ABCB by 3.60% over the last quarter.
GSSC - Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF holds 14K shares representing 0.02% ownership of the company. In it's prior filing, the firm reported owning 14K shares, representing a decrease of 4.84%. The firm increased its portfolio allocation in ABCB by 10.65% over the last quarter.
What is the Fund Sentiment?
There are 658 funds or institutions reporting positions in Ameris Bancorp. This is an increase of 38 owner(s) or 6.13% in the last quarter. Average portfolio weight of all funds dedicated to ABCB is 0.29%, an increase of 5.80%. Total shares owned by institutions increased in the last three months by 3.29% to 75,628K shares. The put/call ratio of ABCB is 0.03, indicating a bullish outlook.
Ameris Bancorp Background Information
(This description is provided by the company.)
Ameris Bancorp is a bank holding company headquartered in Atlanta, Georgia. The Company's banking subsidiary, Ameris Bank, had 164 locations in Georgia, Florida, South Carolina and Alabama at the end of the most recent quarter.
See all Ameris Bancorp regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The firm increased its portfolio allocation in ABCB by 6.96% over the last quarter. The firm increased its portfolio allocation in ABCB by 3.57% over the last quarter. The firm decreased its portfolio allocation in ABCB by 3.75% over the last quarter. | The firm increased its portfolio allocation in ABCB by 6.96% over the last quarter. The firm increased its portfolio allocation in ABCB by 3.57% over the last quarter. The firm decreased its portfolio allocation in ABCB by 3.75% over the last quarter. | The firm increased its portfolio allocation in ABCB by 6.96% over the last quarter. The firm increased its portfolio allocation in ABCB by 3.57% over the last quarter. The firm decreased its portfolio allocation in ABCB by 3.75% over the last quarter. | The firm increased its portfolio allocation in ABCB by 6.96% over the last quarter. The firm increased its portfolio allocation in ABCB by 3.57% over the last quarter. The firm decreased its portfolio allocation in ABCB by 3.75% over the last quarter. |
27693.0 | 2023-04-04 00:00:00 UTC | Ameris Bancorp Enters Oversold Territory | ABCB | https://www.nasdaq.com/articles/ameris-bancorp-enters-oversold-territory-0 | nan | nan | The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Ameris Bancorp (Symbol: ABCB) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.
But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of ABCB entered into oversold territory, changing hands as low as $34.42 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of Ameris Bancorp, the RSI reading has hit 29.1 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 46.0. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, ABCB's recent annualized dividend of 0.6/share (currently paid in quarterly installments) works out to an annual yield of 1.67% based upon the recent $35.99 share price.
A bullish investor could look at ABCB's 29.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABCB is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue.
Click here to find out what 9 other oversold dividend stocks you need to know about »
Also see:
Market Cap History
LNKB YTD Return
Top Ten Hedge Funds Holding APRE
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A bullish investor could look at ABCB's 29.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Ameris Bancorp (Symbol: ABCB) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of ABCB entered into oversold territory, changing hands as low as $34.42 per share. | Indeed, ABCB's recent annualized dividend of 0.6/share (currently paid in quarterly installments) works out to an annual yield of 1.67% based upon the recent $35.99 share price. Ameris Bancorp (Symbol: ABCB) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of ABCB entered into oversold territory, changing hands as low as $34.42 per share. | Ameris Bancorp (Symbol: ABCB) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of ABCB entered into oversold territory, changing hands as low as $34.42 per share. Indeed, ABCB's recent annualized dividend of 0.6/share (currently paid in quarterly installments) works out to an annual yield of 1.67% based upon the recent $35.99 share price. | Ameris Bancorp (Symbol: ABCB) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABCB is its dividend history. But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of ABCB entered into oversold territory, changing hands as low as $34.42 per share. |
27694.0 | 2023-04-04 00:00:00 UTC | Validea John Neff Strategy Daily Upgrade Report - 4/4/2023 | ABCB | https://www.nasdaq.com/articles/validea-john-neff-strategy-daily-upgrade-report-4-4-2023 | nan | nan | The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
METROCITY BANKSHARES INC (MCBS) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: MetroCity Bankshares, Inc. is a bank holding company. The Company operates through its banking subsidiary, Metro City Bank. Metro City Bank is a Georgia state-chartered commercial bank. The Bank offers a suite of loan and deposit products. It operates through approximately 19 branch locations across Alabama, Florida, Georgia, New York, New Jersey, Texas and Virginia. The Company offers banking products and services that are competitively priced with a focus on convenience and accessibility. The Company's offers online banking solutions, including access to account balances, online transfers, online bill payment and electronic delivery of customer statements, mobile banking solutions for iPhone and Android phones, including remote check deposit with mobile bill pay. It also offers a range of treasury management services, including balance reporting, transfers between accounts, wire transfer initiation automated clearing house (ACH) origination and stop payments.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of METROCITY BANKSHARES INC
MCBS Guru Analysis
MCBS Fundamental Analysis
PREMIER FINANCIAL CORP (OHIO) (PFC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Premier Financial Corp. is a bank holding company that conducts business through its wholly-owned subsidiaries, Premier Bank (the Bank). The Bank is primarily engaged in community banking. The Bank attracts deposits from the general public through its offices and website, and uses those and other available sources of funds to originate residential real estate loans, commercial real estate loans, commercial loans, home improvement and home equity loans and consumer loans. In addition, the Bank invests in United States Treasury and federal government agency obligations, obligations of states and political subdivisions, mortgage-backed securities that are issued by federal agencies, including real estate mortgage investment conduits (REMICs) and residential collateralized mortgage obligations (CMOs), and corporate bonds. The Bank conducts its operations through approximately 74 full-service banking center offices, 12 loan offices and two wealth offices.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of PREMIER FINANCIAL CORP (OHIO)
PFC Guru Analysis
PFC Fundamental Analysis
FS BANCORP INC (FSBW) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: FS Bancorp, Inc. is a holding company for 1st Security Bank of Washington (the Bank). The Bank operates through two segments: commercial and consumer banking and home lending. The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines (ATM), online banking platforms, mobile banking apps, and telephone banking. These products and services include deposit products; residential, consumer, business and commercial real estate lending portfolios and cash management services. The Company originates consumer loans, commercial and multi-family real estate loans, construction loans for residential and multi-family construction, and commercial business loans. The home lending segment originates from one-to-four-family residential mortgage loans primarily for sale in the secondary markets as well as loans held for investment.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of FS BANCORP INC
FSBW Guru Analysis
FSBW Fundamental Analysis
VOC ENERGY TRUST (VOC) is a small-cap value stock in the Oil & Gas Operations industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: VOC Energy Trust (the Trust) is a statutory trust formed by VOC Brazos Energy Partners, L.P. (VOC Brazos). The Trust is managed by The Bank of New York Mellon Trust Company, N.A., as trustee (the Trustee). The Trust is created to acquire and hold the net profits interest for the benefit of the trust unitholders. VOC Brazo's properties included interests in approximately 739 gross (454.6 net) producing wells and included 81,095 gross (50,310.7 net) acres. The underlying properties are interests in developing properties located in the oil and natural gas producing regions of Kansas and Texas. The fields in the Central Kansas Uplift include Fairport Field, Marcotte Field and Chase-Silica Field. The fields in Western Kansas include the Bindley, Griston SW and Rosa Northwest fields. The fields in South Central Kansas include the Gerberding, Spivey Grabs and Alford fields, which are produced primarily from the Mississippian, Simpson and Lansing Kansas City zones.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: FAIL
EPS PERSISTENCE: PASS
Detailed Analysis of VOC ENERGY TRUST
VOC Guru Analysis
VOC Fundamental Analysis
VIRGINIA NATIONAL BANKSHARES CORP (VABK) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Virginia National Bankshares Corporation is a bank holding company for Virginia National Bank (the Bank). The Bank is engaged in commercial and retail banking business. It operates through four segments: Bank, VNB Trust and Estate Services, Sturman Wealth Advisors, and Masonry Capital. Bank segment offers loans, deposits and related services to individuals, businesses and charitable organizations. It offers services, including checking accounts, NOW accounts, money market deposit accounts, certificates of deposit and various other services. VNB Trust and Estate Services segment offers corporate trustee services, trust and estate administration, IRA administration, custody service and in-house investment management services. Sturman Wealth Advisors segment offers wealth and investment advisory services. Masonry Capital segment offers investment management services for separately managed accounts and a private investment fund employing a value-based, catalyst-driven investment strategy.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: FAIL
EPS PERSISTENCE: PASS
Detailed Analysis of VIRGINIA NATIONAL BANKSHARES CORP
VABK Guru Analysis
VABK Fundamental Analysis
FIRST BANCORP INC (FNLC) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: The First Bancorp, Inc. is a bank holding company of First National Bank (the Bank). The Company, through its Bank, provides a range of banking services to individual and corporate customers from seventeen offices in coastal and eastern Maine. The Company, through First National Wealth Management, a division of the Bank, offers private banking, financial planning, investment management and trust services to individuals, businesses, non-profit organizations, and municipalities. The Company's investment securities are classified into three categories: securities available for sale, securities to be held to maturity and restricted equity securities. The Company offers a range of loans, including commercial real estate loan, commercial construction loans, commercial other loan, municipal loans, residential real estate term loan, residential real estate construction loan, and home equity line of credit, consumer loan and construction loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of FIRST BANCORP INC
FNLC Guru Analysis
FNLC Fundamental Analysis
HOME BANCORP, INC. (HBCP) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Home Bancorp, Inc. is a bank holding company for Home Bank, N.A. (the Bank), a nationally chartered bank. The Bank conducts business through approximately 43 banking offices in the Acadiana, Baton Rouge, Greater New Orleans and Northshore (of Lake Pontchartrain) regions of south Louisiana, the Natchez region of west Mississippi and Houston region of Texas. The Bank is primarily engaged in attracting deposits from the public and using those funds to invest in loans and securities. Its principal sources of funds are customer deposits, repayments of loans, repayments of investments and funds borrowed from outside sources such as the Federal Home Loan Bank (FHLB) of Dallas. These funds are primarily used for the origination of loans, including one-to four-family first mortgage loans, home equity loans and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of HOME BANCORP, INC.
HBCP Guru Analysis
HBCP Fundamental Analysis
SUNCOR ENERGY INC (USA) (SU) is a large-cap value stock in the Oil & Gas Operations industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Suncor Energy Inc. is a Canada-based integrated energy company. The Company's segments include Oil Sands, Exploration and Production (E&P), and Refining and Marketing. The Oil Sands segment includes the Company's owned operations in the Athabasca oil sands in Alberta to explore, develop and produce bitumen, synthetic crude oil and related products. The E&P segment includes offshore activity in East Coast Canada, with interests in the Hibernia, Terra Nova, White Rose and Hebron oilfields, the exploration and production of crude oil and natural gas at Buzzard and Golden Eagle Area Development in the United Kingdom, and exploration and production of crude oil and gas at Oda. The Refining and Supply operations segment includes refining crude oil and intermediate feedstock into a wide range of petroleum and petrochemical products. The Corporate and Eliminations segment includes the Company's investments in renewable energy projects and other activities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: FAIL
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of SUNCOR ENERGY INC (USA)
SU Guru Analysis
SU Fundamental Analysis
CAMBRIDGE BANCORP (CATC) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Cambridge Bancorp is a state-chartered bank holding company of Cambridge Trust Company (the Bank). The Bank operates 22 banking offices in Eastern Massachusetts and New Hampshire. The Company's core services include wealth management, commercial banking, and personal banking. The Company offers a range of services to commercial enterprises, non-profit organizations, and individuals. The Company originates commercial and industrial loans, commercial real estate loans, construction loans, consumer loans and residential real estate loans, including one-to-four family and home equity lines of credit, and accepts savings, money market, time, and demand deposits. In addition, it offers a range of commercial and personal banking services, which include cash management, online banking, mobile banking, and global payments. The Bank's clients consist primarily of consumers and small-and medium-sized businesses in these communities and surrounding areas throughout Massachusetts and New Hampshire.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of CAMBRIDGE BANCORP
CATC Guru Analysis
CATC Fundamental Analysis
CENOVUS ENERGY INC (US) (CVE) is a large-cap value stock in the Oil & Gas Operations industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Cenovus Energy Inc. is a Canada-based integrated energy company. The Company has oil and natural gas production operations in Canada and the Asia Pacific region, and upgrading, refining and marketing operations in Canada and the United States. The Company's segments include Upstream, Downstream, and Corporate and Eliminations. Its Upstream segment includes Oil Sands, Conventional, and Offshore. Its Downstream segment consists of Canadian Manufacturing, United States Manufacturing, and Retail. The Company's upstream operations include oil sands projects in northern Alberta, thermal and conventional crude oil, natural gas and natural gas liquids (NGLs) projects across Western Canada, crude oil production offshore Newfoundland and Labrador and natural gas and NGLs production offshore China and Indonesia. The Company's downstream operations include upgrading and refining operations in Canada and the United States, and commercial fuel operations across Canada.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of CENOVUS ENERGY INC (US)
CVE Guru Analysis
CVE Fundamental Analysis
CITIZENS FINANCIAL GROUP INC (CFG) is a large-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Citizens Financial Group, Inc. offers a range of retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations and institutions. The Company operates through two segments: Consumer Banking and Commercial Banking. Consumer Banking segment serves retail customers and small businesses, with products and services that include deposit products, mortgage and home equity lending, credit cards, business loans, wealth management and investment services across its 14-state traditional banking footprint. Its network includes specialists covering lending, savings and investment needs as well as small business products and services. Commercial Banking segment primarily serves companies and institutions. The segment offers a complement of financial products and solutions, including lending and leasing, deposit and treasury management services, foreign exchange, and interest rate and commodity risk management solutions, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of CITIZENS FINANCIAL GROUP INC
CFG Guru Analysis
CFG Fundamental Analysis
BLACK STONE MINERALS LP (BSM) is a mid-cap value stock in the Oil & Gas Operations industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Black Stone Minerals, L.P. is an owner and manager of oil and natural gas mineral interests in the United States. The Company's principal business is maximizing the value of its existing mineral and royalty assets through active management and expanding its asset base through acquisitions of additional mineral and royalty interests. The Company owns mineral interests in approximately 16.8 million gross acres. It also owns nonparticipating royalty interests (NPRIs) in 1.8 million gross acres and overriding royalty interests (ORRIs) in 1.6 million gross acres. The Company's mineral and royalty interests are located in 41 states in the continental United States, including all of the onshore producing basins. Many of these interests are in active resource plays, including the Haynesville/Bossier shales in East Texas/Western Louisiana, the Wolfcamp/Spraberry/Bone Springs in the Permian Basin, the Bakken/Three Forks in the Williston Basin, and the Eagle Ford shale in South Texas.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of BLACK STONE MINERALS LP
BSM Guru Analysis
BSM Fundamental Analysis
SISECAM RESOURCES LP (SIRE) is a small-cap value stock in the Non-Metallic Mining industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Sisecam Resources LP, formerly Ciner Resources LP, is a producer of natural soda ash with its facility in the Green River Basin of Wyoming. The Company, through its, subsidiary Sisecam Wyoming LLC (Sisecam Wyoming) is engaged in the business of mining trona ore to produce soda ash. It processes trona ore into soda ash, which is an essential raw material in flat glass, container glass, detergents, chemicals, paper and other consumer and industrial products. The Company's Green River Basin surface operations are situated on approximately 2,360 acres in Wyoming. The Company's mining operations consist of approximately 23,500 acres of leased and licensed subsurface mining area. The Company's mining leases, and licenses are located in two mining beds, designated by the United States Geological Survey as beds 24 and 25, at depths of 800 to 1100 feet, respectively, below the surface. The Company's soda ash is shipped by rail or truck from its Green River Basin operations.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of SISECAM RESOURCES LP
SIRE Guru Analysis
SIRE Fundamental Analysis
BAYCOM CORP (BCML) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: BayCom Corp is a bank holding company. The Company operates through its wholly owned subsidiary, United Business Bank (the Bank). The Bank provides a range of financial services to businesses and business owners as well as individuals. The Bank provides a range of loans, including small business administration (SBA), farm service agency (FSA) and United States Department of Agriculture (USDA) guaranteed loans, and deposit products and services to businesses and its affiliates in California, Washington, New Mexico and Colorado. The Bank provides services to small and medium-sized businesses, professional firms, real estate professionals, non-profit businesses, labor unions and related non-profit entities, and businesses and individual consumers. The Bank operates approximately 33 full-service banking branches consisting of branch offices in Northern and Southern California; Denver, Colorado, and Custer, Delta, and Grand counties, Colorado; Seattle, Washington and Central New Mexico.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of BAYCOM CORP
BCML Guru Analysis
BCML Fundamental Analysis
BUSINESS FIRST BANCSHARES INC (BFST) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Business First Bancshares, Inc. is a financial holding company. The Company operates through its banking subsidiary, b1BANK (the Bank). The Bank is a Louisiana state banking association and community-based financial institution that offers a range of banking products and services. It operates throughout the state of Louisiana, in the Dallas/Fort Worth metroplex and Houston, from a network of banking centers and loan production offices. It offers checking, savings and money market accounts, certificates of deposit, commercial and consumer loans, mortgage loans, real estate loans, and other installment and term loans. In addition, it offers its customers wealth management products, drive-through banking facilities, ATMs, night depository, credit cards, debit cards, Internet banking, electronic funds transfers through ACH services, domestic and foreign wire transfers, traveler's checks, cash management, vault services, loan and deposit sweep accounts, and lock box services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of BUSINESS FIRST BANCSHARES INC
BFST Guru Analysis
BFST Fundamental Analysis
UNIVEST FINANCIAL CORP (UVSP) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Univest Financial Corporation is the bank holding company of Univest Bank and Trust Co. (the Bank). The Bank is a state-chartered bank that offers domestic banking services. It operates through three segments: Banking, Wealth Management and Insurance. The Banking segment provides financial services to individuals, businesses, municipalities and non-profit organizations. These services include a range of banking services, such as deposit taking, loan origination and servicing, mortgage banking, other general banking services and equipment lease financing. The Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, which serves a client base of private families and individuals, municipal pension plans, retirement plans, trusts and guardianships. The Insurance segment includes an insurance brokerage agency offering commercial property and casualty insurance, employee benefit solutions, personal insurance lines and human resources consulting.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of UNIVEST FINANCIAL CORP
UVSP Guru Analysis
UVSP Fundamental Analysis
VALLEY NATIONAL BANCORP (VLY) is a mid-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Valley National Bancorp is a bank holding company and financial holding company. The Company's principal subsidiary includes Valley National Bank (the Bank). It offers a full suite of national and regional banking solutions through various commercial, retail, insurance and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. Its solutions include, but are not limited to, traditional consumer and commercial deposit and lending products, commercial real estate financing, small business loans, equipment financings, insurance and wealth management financial services products, cash management solutions, and personal financing solutions, such as residential mortgages, home equity loans and automobile financing. It also offers niche financial services, including loan and deposit products for homeowners' associations, insurance premium financing and cannabis-related business banking.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of VALLEY NATIONAL BANCORP
VLY Guru Analysis
VLY Fundamental Analysis
OCEANFIRST FINANCIAL CORP. (OCFC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: OceanFirst Financial Corp. is a holding company for OceanFirst Bank N.A. (the Bank). The Bank is a full-service regional bank delivering financial products and services, which include commercial and consumer financing, deposit services, and wealth management products and services, throughout New Jersey and the metropolitan markets of Philadelphia, New York, Baltimore, Washington D.C., and Boston. The Bank's commercial loans include multi-family and commercial real estate loans, commercial construction loans, and commercial and industrial loans. The Bank also offers investment products for sale through its retail branch network. The Bank is focused on growth opportunities in areas, including derivative contracts, trust and asset management, digital product offerings, and equity investments in non-bank finance companies. It operates approximately 37 branch offices, and deposit production facilities located throughout New Jersey and metropolitan area of New York City and Philadelphia.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of OCEANFIRST FINANCIAL CORP.
OCFC Guru Analysis
OCFC Fundamental Analysis
NORWOOD FINANCIAL CORP (NWFL) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Norwood Financial Corp is a holding company for Wayne Bank (the Bank). The Bank is an independent community bank with about 14 offices in Northeastern Pennsylvania and 15 offices in Delaware, Sullivan, Ontario, Otsego and Yates Counties, New York. The Bank offers a variety of personal and business credit services and trust and investment products, and real estate settlement services to the consumers, businesses, nonprofit organizations, and municipalities in each of the communities that the Bank serves. The Bank primarily serves the northeastern Pennsylvania counties of Wayne, Pike, Monroe, Lackawanna, and Luzerne and, to a much lesser extent, Susquehanna County in addition to the New York counties of Delaware and others. In addition, it operates automated teller machines at about 29 branch facilities plus one machine at an off-site location. It operates a Wealth Management/Trust Department, which provides estate planning, investment management, and financial planning to customers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of NORWOOD FINANCIAL CORP
NWFL Guru Analysis
NWFL Fundamental Analysis
GUARANTY BANCSHARES, INC. (GNTY) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Guaranty Bancshares, Inc. is a bank holding company. The Company, through its wholly owned subsidiary, Guaranty Bank & Trust (the Bank), offers a range of commercial and consumer banking, as well as trust and wealth management, products and services that meet the needs of small- and medium-sized businesses, professionals and individuals. Its lending activities provide a range of loans, including commercial lines of credit, working capital loans, commercial real estate-backed loans, term loans, equipment financing, acquisition, expansion and development loans, and borrowing base loans. It also offers various consumer loans to individuals and professionals, including residential real estate loans, home equity loans, installment loans, unsecured and secured personal lines of credit, and standby letters of credit. The Bank operates approximately 32 full-service banking locations in East Texas, Central Texas, the Dallas/Fort Worth metropolitan statistical area (MSA) and the Houston MSA.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of GUARANTY BANCSHARES, INC.
GNTY Guru Analysis
GNTY Fundamental Analysis
PEAPACK-GLADSTONE FINANCIAL CORP (PGC) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Peapack-Gladstone Financial Corporation is a bank holding company. The Company's principal subsidiary is Peapack-Gladstone Bank (the Bank), which is a state chartered commercial bank. Its segments include Banking and Peapack Private. Its Banking segment includes commercial (includes corporate and industrial (C&I) and equipment financing), commercial real estate, multifamily, residential and consumer lending activities; treasury management services; C&I advisory services; escrow management; deposit generation; operation of ATMs; telephone and Internet banking services; merchant credit card services and customer support sales. Its Peapack Private segment includes investment management services for individuals and institutions; personal trust services, including services as executor, trustee, administrator, custodian; and other financial planning and advisory services. This segment also includes the activity of the Delaware subsidiary, PGB Trust and Investments of Delaware.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of PEAPACK-GLADSTONE FINANCIAL CORP
PGC Guru Analysis
PGC Fundamental Analysis
PINNACLE FINANCIAL PARTNERS INC (PNFP) is a mid-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Pinnacle Financial Partners, Inc. is a financial holding company. The Company operates through its wholly owned subsidiary, Pinnacle Bank (the Bank). The Bank is a Tennessee state-chartered bank. The Bank offers a full range of lending products, including commercial, real estate and consumer loans to individuals, businesses and professional entities. The Bank is also focused on offering core deposits, including savings, noninterest-bearing checking, interest-bearing checking, money market and certificate of deposit accounts, including access to products offered through various IntraFi Network Deposit programs. It also offers a range of treasury management and remote deposit services, including online wire origination, zero balance and sweep accounts, automated bill pay services, and lockbox processing. It operates approximately 123 offices, including 51 in Tennessee, 38 in North Carolina, 20 in South Carolina, 10 in Virginia, two in Georgia and two in Alabama.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of PINNACLE FINANCIAL PARTNERS INC
PNFP Guru Analysis
PNFP Fundamental Analysis
FARMERS NATIONAL BANC CORP (FMNB) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Farmers National Banc Corp. is a diversified financial services company. The Company provides full banking services through its nationally chartered subsidiary, The Farmers National Bank of Canfield (Bank). The Company's segment includes Bank segment and the Trust segment. The Company provides trust and retirement consulting services through its subsidiary, Farmers Trust Company (Trust), and insurance services through the Bank's subsidiary, Farmers National Insurance, LLC. Farmers National Captive, Inc. (Captive) is a wholly owned insurance subsidiary of the Company that provides property and casualty insurance coverage to the Company and its subsidiaries. The Company's wholly owned subsidiaries are comprised of Bank, a full-service national bank engaged in commercial and retail banking with 65 banking locations throughout Ohio and Pennsylvania; Trust, which operates five trust offices and offers services in the same geographic markets; and Farmers National Insurance, LLC.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of FARMERS NATIONAL BANC CORP
FMNB Guru Analysis
FMNB Fundamental Analysis
HEARTLAND FINANCIAL USA INC (HTLF) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Heartland Financial USA, Inc.is a multi-bank holding company. The Company conducts its banking business through multiple community banks operating as either independent entities or independently branded divisions. Its Banks provide a range of commercial, small business, and consumer banking services to businesses, including public sector and non-profit entities. It provides traditional and non-traditional service channels, including online banking, mobile banking, and telephone banking. Its Banks provide a suite of banking services comprised of deposit and credit offerings, with treasury management and retirement plan services. Its primary lines of business include commercial banking, small business banking, agricultural loans, residential real estate mortgage lending, retail banking and wealth management, investment and insurance, and retirement plan services. It serves communities in Arizona, California, Colorado, Illinois, Iowa, Kansas, Minnesota, New Mexico, Texas, and Wisconsin.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of HEARTLAND FINANCIAL USA INC
HTLF Guru Analysis
HTLF Fundamental Analysis
PACIFIC PREMIER BANCORP, INC. (PPBI) is a mid-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Pacific Premier Bancorp, Inc. is a bank holding company. The Company operates through its wholly owned subsidiary, Pacific Premier Bank (the Bank). The Bank's loan portfolio includes commercial and industrial (C&I) and franchise lending, commercial owner-occupied business lending, commercial non-owner-occupied real estate lending, multifamily residential lending, construction lending, one-to-four family real estate lending, and consumer loans. It offers a range of deposit products and services, including checking, money market and savings accounts, electronic banking services, treasury management services, and online bill payment. It conducts business throughout the Western Region of the United States from its 59 full-service depository branches located in Arizona, California, Nevada, and Washington. It also provides commercial escrow and exchange services, which provides a variety of real-property and non-real property escrow services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of PACIFIC PREMIER BANCORP, INC.
PPBI Guru Analysis
PPBI Fundamental Analysis
PROVIDENT FINANCIAL SERVICES, INC. (PFS) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Provident Financial Services, Inc. is a holding company for The Provident Bank (the Bank). The Bank is a New Jersey-chartered capital stock savings bank operating full-service branch offices throughout northern and central New Jersey, as well as Bucks, Lehigh and Northampton counties in Pennsylvania and Queens County, New York. The Bank provides a range of financial products and services through its network of branches. The Bank originates commercial real estate loans, commercial business loans, fixed-rate and adjustable-rate mortgage loans collateralized by one-to four-family residential real estate and other consumer loans, for borrowers generally located within its primary market area. The Bank invests in mortgage-backed securities and other permissible investments. It provides fiduciary and wealth management services through its wholly owned subsidiary, Beacon Trust Company, and insurance brokerage services through its subsidiary, SB One Insurance Agency, Inc.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of PROVIDENT FINANCIAL SERVICES, INC.
PFS Guru Analysis
PFS Fundamental Analysis
PLUMAS BANCORP (PLBC) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Plumas Bancorp is a bank holding company, which operates through, Plumas Bank (the Bank). The Bank is a state-chartered bank, which primary service in the Northeastern portion of California, with Lake Tahoe to the south and the Oregon border to the north, and the Northwestern portion of Nevada. The Bank primarily is engaged in providing loans and investment securities. The Banks principal commercial lending services include term real estate, commercial and industrial term loans. In addition, the Bank provides agricultural loans, as well as credit lines. The Banks principal retail lending services include consumer, automobile and home equity loans. The Bank provides land development and construction loans on a limited basis. The Bank has 14 branch networks and 18 automated teller machines. In addition to its branch network, the Bank operates a lending office in Auburn, California and commercial/agricultural lending offices located in Chico, California and Klamath Falls, Oregon.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of PLUMAS BANCORP
PLBC Guru Analysis
PLBC Fundamental Analysis
TECK RESOURCES LTD (USA) (TECK) is a large-cap value stock in the Coal industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Teck Resources Limited is a Canada-based mining company that operates in copper, zinc, steelmaking coal and energy segment. The Company's operations and projects include Antamina, Cardinal River, Carmen de Andacollo, Elkview, Fording River, Fording River Extension, Fort Hills, Galore Creek Project, Greenhills, Highland Valley Copper, HVC 2040, Line Creek, NewRange Copper Nickel, NuevaUnion, Quebrada Blanca, Quebrada Blanca Phase II, Quintette Project, Red Dog, Sullivan Mine and Trail Operations. The Antamina mine is a large copper and zinc mine, located in the Andes Mountain range of Peru. Its Carmen de Andacollo is located in the Coquimbo Region of central Chile. The Fording River Extension Project is located adjacent and to the south of Teck's existing Fording River Operations. Its Galore Creek is located within the territory of the Tahltan in northwestern British Columbia, approximately 150 kilometers northwest of Stewart.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of TECK RESOURCES LTD (USA)
TECK Guru Analysis
TECK Fundamental Analysis
AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ameris Bancorp is a bank holding company of Ameris Bank (the Bank). The Bank provides a full range of banking services to its retail and commercial customers in approximately 165 locations in Georgia, Alabama, Florida, North Carolina and South Carolina. It has five segments. The Banking Division provides full financial services, including commercial loans, consumer loans and deposit accounts. The Retail Mortgage Division is engaged in origination, sales and servicing of one-to-four family residential mortgage loans. The Warehouse Lending Division is engaged in the origination and servicing of warehouse lines to other businesses, which are secured by underlying one-to-four family residential mortgage loans and residential mortgage servicing rights. The SBA Division is engaged in the origination, sales and servicing of small business administration loans. The Premium Finance Division is engaged in the origination and servicing of commercial insurance premium finance loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of AMERIS BANCORP
ABCB Guru Analysis
ABCB Fundamental Analysis
ROCKY BRANDS INC (RCKY) is a small-cap value stock in the Footwear industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Rocky Brands, Inc. is a designer, manufacturer and marketer of footwear and apparel. It markets its products under a portfolio of brand names, including Rocky, Georgia Boot, Durango, Lehigh, The Original Muck Boot Company, XTRATUF, Servus, Ranger and the licensed brand Michelin. It operates through three segments: Wholesale, Retail and Contract Manufacturing. Its Wholesale segment distributes products through a range of distribution channels representing over 10,000 retail store locations in the United States, Canada and others. Its Retail segment markets directly to consumers through its Lehigh business-to-business, including direct sales and through its CustomFit Websites, consumer e-commerce Websites, third-party marketplaces, and Rocky outlet stores. Its Contract Manufacturing segment includes sales to the United States Military, private label sales and any sales to customers in which it is contracted to manufacture or source a specific footwear product for a customer.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of ROCKY BRANDS INC
RCKY Guru Analysis
RCKY Fundamental Analysis
BANK OF MARIN BANCORP (BMRC) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Bank of Marin Bancorp is the holding company for Bank of Marin (the Bank). Its business banking focus is on small to medium-sized businesses, not-for-profit organizations, and commercial real estate investors. It offers a suite of business and personal financial products designed to meet the needs of its customers. Its lending categories include commercial real estate loans, commercial and industrial loans, including small business loans, construction financing, consumer loans, and home equity lines of credit. It offers a variety of personal and business checking and savings accounts, and a number of time deposit alternatives, including time certificates of deposit, Individual Retirement Accounts, Health Savings Accounts, Certificate of Deposit Account Registry Service, Insured Cash Sweep, and Demand Deposit Marketplace accounts. It offers deposit options, including mobile deposit, remote deposit capture, Automated Clearing House services, wire transfers, and image lockbox services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of BANK OF MARIN BANCORP
BMRC Guru Analysis
BMRC Fundamental Analysis
SCHNITZER STEEL INDUSTRIES INC (SCHN) is a small-cap value stock in the Waste Management Services industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Schnitzer Steel Industries, Inc. are the manufacturers and exporters of recycled metal products in North America, with operating facilities located in 25 states, Puerto Rico, and Western Canada. The Company operates at the intersection of metals recovery, reuse, recycling, and manufacturing. Its nonferrous products include mixed metal joint products recovered from the shredding process, as well as aluminum, copper, stainless steel, nickel, brass, titanium, lead, and high temperature alloys. It also sells catalytic converters to specialty processors that extract the nonferrous precious metals. Its steel mill produces semi-finished goods (billets) and finished goods, consisting of rebar, coiled rebar, wire rod, merchant bar, and other specialty products, using recycled ferrous metal. It offers a range of products and services through its network that includes about 51 retail self-service auto parts stores, 54 metals recycling facilities, and an electric arc furnace (EAF) steel mill.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of SCHNITZER STEEL INDUSTRIES INC
SCHN Guru Analysis
SCHN Fundamental Analysis
SOUTHERN MISSOURI BANCORP, INC. (SMBC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Southern Missouri Bancorp, Inc. is a bank holding company for Southern Bank (Bank). The principal business of the Bank consists primarily of retail deposits from the general public and using its deposits along with wholesale funding from the Federal Home Loan Bank of Des Moines (FHLB), lesser extent, brokered deposits, mortgage loans and commercial non-mortgage business loans. The Bank offers a range of deposit instruments, including interest-bearing and noninterest-bearing transaction accounts, money market deposit accounts, saving accounts, certificates of deposit and retirement savings plans. The Bank's lending activities consist of originating loans secured by mortgages on one- to four-family and multi-family residential real estate, commercial and agricultural real estate, construction loans on residential and commercial properties, commercial and agricultural business loans and consumer loans.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of SOUTHERN MISSOURI BANCORP, INC.
SMBC Guru Analysis
SMBC Fundamental Analysis
ARROW FINANCIAL CORPORATION (AROW) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 58% to 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Arrow Financial Corporation (Arrow) is a bank holding company. Arrow is engaged in a range of lending activities, including commercial and industrial lending primarily to small and mid-sized companies; mortgage lending for residential and commercial properties; and consumer installment and home equity financing. Arrow provides services, such as trust administration, retirement plan administration, advice to its proprietary mutual funds and insurance products. The Company offers a range of commercial and consumer banking and financial products. The deposit base consists of deposits derived principally from the communities served. Arrow targets lending activities to consumers and small- and mid-sized companies in Arrow's regional geographic area. The Company provides retirement planning, trust and estate administration. Arrow's subsidiaries include Glens Falls National Bank and Trust Company (Glens Falls National) and Saratoga National Bank and Trust Company (Saratoga National).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: FAIL
EPS PERSISTENCE: FAIL
Detailed Analysis of ARROW FINANCIAL CORPORATION
AROW Guru Analysis
AROW Fundamental Analysis
FIRST MERCHANTS CORP (FRME) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: First Merchants Corporation is a financial holding company. The Company operates banking operations through its wholly owned subsidiary, First Merchants Bank (the Bank). The Bank also operates First Merchants Private Wealth Advisors, which is a division of the Bank. The Bank includes approximately 122 banking locations in Indiana, Ohio, Michigan and Illinois. In addition to its branch network, the Company offers comprehensive electronic and mobile delivery channels to its customers. The Company operates through a community banking segment. Through the Bank, the Company offers a range of financial services, including accepting time, savings and demand deposits; making consumer, commercial, agri-business and real estate mortgage loans; providing personal and corporate trust services; offering full-service brokerage and private wealth management, and providing letters of credit, repurchase agreements, and other corporate services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of FIRST MERCHANTS CORP
FRME Guru Analysis
FRME Fundamental Analysis
PEOPLES BANCORP INC. (PEBO) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Peoples Bancorp Inc. is a financial holding company. It operates principally through its subsidiary, Peoples Bank, an Ohio state-chartered bank. Its other subsidiaries include Peoples Investment Company and Peoples Risk Management, Inc., a captive insurance subsidiary. It provides commercial and consumer banking, trust and investment, insurance, premium financing solutions, equipment leases and equipment financing agreements through its financial subsidiaries. Its financial products and services are primarily offered through its financial service offices and automated teller machines (ATMs) in Ohio, West Virginia, Kentucky, Virginia, Washington, D.C. and Maryland, as well as through online resources that are web-based and mobile-based. Its Brokerage services are offered through an unaffiliated registered broker-dealer located at Peoples Bank's offices. The Peoples Bank's credit card and merchant processing services are provided through joint marketing arrangements with third parties.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of PEOPLES BANCORP INC.
PEBO Guru Analysis
PEBO Fundamental Analysis
CEDAR FAIR, L.P. (FUN) is a mid-cap value stock in the Recreational Activities industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Cedar Fair, L.P. is a regional amusement park operator with approximately 13 properties in its portfolio consisting of amusement parks, water parks and complementary resort facilities. The Company's parks are family-oriented, with recreational facilities for people of all ages, and provide clean and attractive environments with rides and immersive entertainment. The Company's parks operate seasonally except for Knott's Berry Farm, which is typically open daily on a year-round basis. Its seasonal parks are generally open daily from Memorial Day until Labor Day. In addition to daily operations, its seasonal parks are open during select weekends, including at various properties in the fourth quarter for Halloween and winter events. Its flagship park, Cedar Point, is located on a peninsula in Sandusky, Ohio. Cedar Point serves a six-state region, which includes Ohio and Michigan, western Pennsylvania and New York, northern West Virginia and Indiana, as well as southwestern Ontario, Canada.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of CEDAR FAIR, L.P.
FUN Guru Analysis
FUN Fundamental Analysis
NATIONAL FUEL GAS CO. (NFG) is a mid-cap value stock in the Oil & Gas Operations industry. The rating according to our strategy based on John Neff changed from 60% to 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: National Fuel Gas Company is a holding company. The Company is a diversified energy company engaged principally in the production, gathering, transportation, storage and distribution of natural gas. Its segments include Exploration and Production, Pipeline and Storage, Gathering, and Utility. The Exploration and Production segment is engaged in the exploration for, and the development and production of, primarily natural gas in the Appalachian region of the United States. The Pipeline and Storage segment provides interstate natural gas transportation services for affiliated and nonaffiliated companies through integrated gas pipeline systems in Pennsylvania and New York. The Gathering segment builds, owns, and operates natural gas processing and pipeline gathering facilities in the Appalachian region. The Utility segment provides natural gas utility services to approximately 754,000 customers through a local distribution system located in western New York and northwestern Pennsylvania.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: FAIL
EPS PERSISTENCE: PASS
Detailed Analysis of NATIONAL FUEL GAS CO.
NFG Guru Analysis
NFG Fundamental Analysis
ACNB CORPORATION (ACNB) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on John Neff changed from 62% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: ACNB Corporation is a financial holding company. The Company's banking operations are conducted through its subsidiary, ACNB Bank (the Bank). The ACNB Bank serves its marketplace with banking and wealth management services, including trust and retail brokerage with a network of approximately 26 community banking offices and three loan offices located in the Pennsylvania counties of Adams, Cumberland, Franklin, Lancaster and York, and the Maryland counties of Baltimore, Carroll, and Frederick. The Company operates through two segments: Banking and Insurance. Its Banking segment includes the Bank and related financial services that the Corporation offers through its banking subsidiary. The Company's subsidiary, ACNB Insurance Services, Inc., is a full-service agency, which offers a range of property, casualty, health, life, and disability insurance serving personal and commercial clients through office locations in Westminster and Jarrettsville, Maryland, and Gettysburg, Pennsylvania.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: PASS
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of ACNB CORPORATION
ACNB Guru Analysis
ACNB Fundamental Analysis
John Neff Portfolio
About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. He was mild-mannered and low-key, and the same might be said of the Windsor Fund that he managed for more than three decades. In fact, Neff himself described the fund as "relatively prosaic, dull, [and] conservative." There was nothing dull about his results, however. From 1964 to 1995, Neff guided Windsor to a 13.7 percent average annual return, easily outpacing the S&P 500's 10.6 percent return during that time. That 3.1 percentage point difference is huge over time -- a $10,000 investment in Windsor (with dividends reinvested) at the start of Neff's tenure would have ended up as more than $564,000 by the time he retired, more than twice what the same investment in the S&P would have yielded (about $233,000). Considering the length of his tenure, that track record may be the best ever for a manager of such a large fund.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of TECK RESOURCES LTD (USA) TECK Guru Analysis TECK Fundamental Analysis AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis ROCKY BRANDS INC (RCKY) is a small-cap value stock in the Footwear industry. Company Description: Schnitzer Steel Industries, Inc. are the manufacturers and exporters of recycled metal products in North America, with operating facilities located in 25 states, Puerto Rico, and Western Canada. | Detailed Analysis of TECK RESOURCES LTD (USA) TECK Guru Analysis TECK Fundamental Analysis AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis ROCKY BRANDS INC (RCKY) is a small-cap value stock in the Footwear industry. The Company offers a range of loans, including commercial real estate loan, commercial construction loans, commercial other loan, municipal loans, residential real estate term loan, residential real estate construction loan, and home equity line of credit, consumer loan and construction loans. | Detailed Analysis of TECK RESOURCES LTD (USA) TECK Guru Analysis TECK Fundamental Analysis AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis ROCKY BRANDS INC (RCKY) is a small-cap value stock in the Footwear industry. The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines (ATM), online banking platforms, mobile banking apps, and telephone banking. | Detailed Analysis of TECK RESOURCES LTD (USA) TECK Guru Analysis TECK Fundamental Analysis AMERIS BANCORP (ABCB) is a mid-cap value stock in the Money Center Banks industry. Detailed Analysis of AMERIS BANCORP ABCB Guru Analysis ABCB Fundamental Analysis ROCKY BRANDS INC (RCKY) is a small-cap value stock in the Footwear industry. The Company operates through two segments: Consumer Banking and Commercial Banking. |
27695.0 | 2023-03-28 00:00:00 UTC | Ex-Dividend Reminder: Franklin BSP Realty Trust, Kilroy Realty and Ameris Bancorp | ABCB | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-franklin-bsp-realty-trust-kilroy-realty-and-ameris-bancorp | nan | nan | Looking at the universe of stocks we cover at Dividend Channel, on 3/30/23, Franklin BSP Realty Trust Inc (Symbol: FBRT), Kilroy Realty Corp (Symbol: KRC), and Ameris Bancorp (Symbol: ABCB) will all trade ex-dividend for their respective upcoming dividends. Franklin BSP Realty Trust Inc will pay its quarterly dividend of $0.355 on 4/10/23, Kilroy Realty Corp will pay its quarterly dividend of $0.54 on 4/12/23, and Ameris Bancorp will pay its quarterly dividend of $0.15 on 4/10/23. As a percentage of FBRT's recent stock price of $11.72, this dividend works out to approximately 3.03%, so look for shares of Franklin BSP Realty Trust Inc to trade 3.03% lower — all else being equal — when FBRT shares open for trading on 3/30/23. Similarly, investors should look for KRC to open 1.84% lower in price and for ABCB to open 0.41% lower, all else being equal.
Below are dividend history charts for FBRT, KRC, and ABCB, showing historical dividends prior to the most recent ones declared.
Franklin BSP Realty Trust Inc (Symbol: FBRT):
Kilroy Realty Corp (Symbol: KRC):
Ameris Bancorp (Symbol: ABCB):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 12.12% for Franklin BSP Realty Trust Inc, 7.37% for Kilroy Realty Corp, and 1.64% for Ameris Bancorp.
Free Report: Top 8%+ Dividends (paid monthly)
In Tuesday trading, Franklin BSP Realty Trust Inc shares are currently up about 1%, Kilroy Realty Corp shares are off about 1.7%, and Ameris Bancorp shares are down about 0.8% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
Also see:
Top Ten Hedge Funds Holding MGEN
Institutional Holders of TX
ISAA market cap history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel, on 3/30/23, Franklin BSP Realty Trust Inc (Symbol: FBRT), Kilroy Realty Corp (Symbol: KRC), and Ameris Bancorp (Symbol: ABCB) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for KRC to open 1.84% lower in price and for ABCB to open 0.41% lower, all else being equal. Below are dividend history charts for FBRT, KRC, and ABCB, showing historical dividends prior to the most recent ones declared. | Looking at the universe of stocks we cover at Dividend Channel, on 3/30/23, Franklin BSP Realty Trust Inc (Symbol: FBRT), Kilroy Realty Corp (Symbol: KRC), and Ameris Bancorp (Symbol: ABCB) will all trade ex-dividend for their respective upcoming dividends. Franklin BSP Realty Trust Inc (Symbol: FBRT): Kilroy Realty Corp (Symbol: KRC): Ameris Bancorp (Symbol: ABCB): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for KRC to open 1.84% lower in price and for ABCB to open 0.41% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel, on 3/30/23, Franklin BSP Realty Trust Inc (Symbol: FBRT), Kilroy Realty Corp (Symbol: KRC), and Ameris Bancorp (Symbol: ABCB) will all trade ex-dividend for their respective upcoming dividends. Franklin BSP Realty Trust Inc (Symbol: FBRT): Kilroy Realty Corp (Symbol: KRC): Ameris Bancorp (Symbol: ABCB): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for KRC to open 1.84% lower in price and for ABCB to open 0.41% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel, on 3/30/23, Franklin BSP Realty Trust Inc (Symbol: FBRT), Kilroy Realty Corp (Symbol: KRC), and Ameris Bancorp (Symbol: ABCB) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for KRC to open 1.84% lower in price and for ABCB to open 0.41% lower, all else being equal. Below are dividend history charts for FBRT, KRC, and ABCB, showing historical dividends prior to the most recent ones declared. |
27696.0 | 2023-03-21 00:00:00 UTC | Ameris Bancorp (ABCB) Declares $0.15 Dividend | ABCB | https://www.nasdaq.com/articles/ameris-bancorp-abcb-declares-%240.15-dividend | nan | nan | Ameris Bancorp said on March 17, 2023 that its board of directors declared a regular quarterly dividend of $0.15 per share ($0.60 annualized). Previously, the company paid $0.15 per share.
Shares must be purchased before the ex-div date of March 30, 2023 to qualify for the dividend. Shareholders of record as of March 31, 2023 will receive the payment on April 10, 2023.
At the current share price of $36.04 / share, the stock's dividend yield is 1.66%. Looking back five years and taking a sample every week, the average dividend yield has been 1.37%, the lowest has been 0.69%, and the highest has been 3.17%. The standard deviation of yields is 0.52 (n=237).
The current dividend yield is 0.57 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.12. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company has not increased its dividend in the last three years.
Learn to Harvest Dividends
Buy Stock. Capture Dividend. Sell Stock. Repeat. This is the essence of dividend harvesting and you can do it easily with Fintel's Dividend Capture Calendar.
Analyst Price Forecast Suggests 56.51% Upside
As of March 19, 2023, the average one-year price target for Ameris Bancorp is $56.41. The forecasts range from a low of $52.52 to a high of $63.00. The average price target represents an increase of 56.51% from its latest reported closing price of $36.04.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ameris Bancorp is $1,180MM, an increase of 18.95%. The projected annual non-GAAP EPS is $5.49.
What is the Fund Sentiment?
There are 657 funds or institutions reporting positions in Ameris Bancorp. This is an increase of 33 owner(s) or 5.29% in the last quarter. Average portfolio weight of all funds dedicated to ABCB is 0.28%, an increase of 6.94%. Total shares owned by institutions increased in the last three months by 2.87% to 75,414K shares. The put/call ratio of ABCB is 0.06, indicating a bullish outlook.
What are Large Shareholders Doing?
Wellington Management Group Llp holds 6,102K shares representing 8.82% ownership of the company. In it's prior filing, the firm reported owning 6,317K shares, representing a decrease of 3.51%. The firm decreased its portfolio allocation in ABCB by 99.99% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 4,767K shares representing 6.89% ownership of the company. In it's prior filing, the firm reported owning 4,751K shares, representing an increase of 0.34%. The firm decreased its portfolio allocation in ABCB by 3.75% over the last quarter.
Principal Financial Group holds 2,026K shares representing 2.93% ownership of the company. In it's prior filing, the firm reported owning 2,128K shares, representing a decrease of 5.05%. The firm decreased its portfolio allocation in ABCB by 48.52% over the last quarter.
American Century Companies holds 2,019K shares representing 2.92% ownership of the company. In it's prior filing, the firm reported owning 2,334K shares, representing a decrease of 15.60%. The firm decreased its portfolio allocation in ABCB by 15.33% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,996K shares representing 2.89% ownership of the company. In it's prior filing, the firm reported owning 1,991K shares, representing an increase of 0.21%. The firm decreased its portfolio allocation in ABCB by 2.43% over the last quarter.
Ameris Bancorp Background Information
(This description is provided by the company.)
Ameris Bancorp is a bank holding company headquartered in Atlanta, Georgia. The Company's banking subsidiary, Ameris Bank, had 164 locations in Georgia, Florida, South Carolina and Alabama at the end of the most recent quarter.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Average portfolio weight of all funds dedicated to ABCB is 0.28%, an increase of 6.94%. The put/call ratio of ABCB is 0.06, indicating a bullish outlook. The firm decreased its portfolio allocation in ABCB by 99.99% over the last quarter. | Average portfolio weight of all funds dedicated to ABCB is 0.28%, an increase of 6.94%. The put/call ratio of ABCB is 0.06, indicating a bullish outlook. The firm decreased its portfolio allocation in ABCB by 99.99% over the last quarter. | Average portfolio weight of all funds dedicated to ABCB is 0.28%, an increase of 6.94%. The put/call ratio of ABCB is 0.06, indicating a bullish outlook. The firm decreased its portfolio allocation in ABCB by 99.99% over the last quarter. | Average portfolio weight of all funds dedicated to ABCB is 0.28%, an increase of 6.94%. The put/call ratio of ABCB is 0.06, indicating a bullish outlook. The firm decreased its portfolio allocation in ABCB by 99.99% over the last quarter. |
27697.0 | 2023-03-16 00:00:00 UTC | Bargain Bin Stocks: ABCB Now 13.3% Cheaper Than Director Bowen Jr.'s Buy | ABCB | https://www.nasdaq.com/articles/bargain-bin-stocks%3A-abcb-now-13.3-cheaper-than-director-bowen-jr.s-buy | nan | nan | There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on March 10, Ameris Bancorp's Director, William I. Bowen Jr., invested $27,604.00 into 670 shares of ABCB, for a cost per share of $41.20. Bargain hunters tend to pay particular attention to insider buys like this one, because presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money. In trading on Thursday, bargain hunters could buy shares of Ameris Bancorp (Symbol: ABCB) and achieve a cost basis 13.3% cheaper than Bowen Jr., with shares changing hands as low as $35.70 per share. Ameris Bancorp shares are currently trading off about 1.2% on the day. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average:
Looking at the chart above, ABCB's low point in its 52 week range is $34.28 per share, with $54.24 as the 52 week high point — that compares with a last trade of $36.44. By comparison, below is a table showing the prices at which ABCB insider buying was recorded over the last six months:
PURCHASED INSIDER TITLE SHARES PRICE/SHARE VALUE
03/10/2023 William I. Bowen Jr. Director 670 $41.20 $27,604.00
The current annualized dividend paid by Ameris Bancorp is $0.6/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 12/29/2022. Below is a long-term dividend history chart for ABCB, which can be of good help in judging whether the most recent dividend with approx. 1.6% annualized yield is likely to continue.
Free Report: Top 8%+ Dividends (paid monthly)
Click here to find out which 9 other dividend bargains you can buy cheaper than insiders »
Also see:
MBND Historical Stock Prices
LRAD market cap history
VISL shares outstanding history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $34.28 per share, with $54.24 as the 52 week high point — that compares with a last trade of $36.44. By comparison, below is a table showing the prices at which ABCB insider buying was recorded over the last six months: Back on March 10, Ameris Bancorp's Director, William I. Bowen Jr., invested $27,604.00 into 670 shares of ABCB, for a cost per share of $41.20. | Back on March 10, Ameris Bancorp's Director, William I. Bowen Jr., invested $27,604.00 into 670 shares of ABCB, for a cost per share of $41.20. In trading on Thursday, bargain hunters could buy shares of Ameris Bancorp (Symbol: ABCB) and achieve a cost basis 13.3% cheaper than Bowen Jr., with shares changing hands as low as $35.70 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $34.28 per share, with $54.24 as the 52 week high point — that compares with a last trade of $36.44. | In trading on Thursday, bargain hunters could buy shares of Ameris Bancorp (Symbol: ABCB) and achieve a cost basis 13.3% cheaper than Bowen Jr., with shares changing hands as low as $35.70 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $34.28 per share, with $54.24 as the 52 week high point — that compares with a last trade of $36.44. Back on March 10, Ameris Bancorp's Director, William I. Bowen Jr., invested $27,604.00 into 670 shares of ABCB, for a cost per share of $41.20. | Back on March 10, Ameris Bancorp's Director, William I. Bowen Jr., invested $27,604.00 into 670 shares of ABCB, for a cost per share of $41.20. In trading on Thursday, bargain hunters could buy shares of Ameris Bancorp (Symbol: ABCB) and achieve a cost basis 13.3% cheaper than Bowen Jr., with shares changing hands as low as $35.70 per share. The chart below shows the one year performance of ABCB shares, versus its 200 day moving average: Looking at the chart above, ABCB's low point in its 52 week range is $34.28 per share, with $54.24 as the 52 week high point — that compares with a last trade of $36.44. |
27698.0 | 2023-03-16 00:00:00 UTC | Live Oak Bancshares (LOB) Surges 8.5%: Is This an Indication of Further Gains? | ABCB | https://www.nasdaq.com/articles/live-oak-bancshares-lob-surges-8.5%3A-is-this-an-indication-of-further-gains | nan | nan | Live Oak Bancshares (LOB) shares ended the last trading session 8.5% higher at $25.93. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 32.2% loss over the past four weeks.
After stumbling significantly over the past few trading day, the trend reversed. Following the fall out from the collapse of two S&P 500 banks, the investors regained some confidence in the sector amid the steps taken by the regulators to avert a full-blown bank run. Moreover, inflation numbers came out as expected, which further reinforced investor optimism. These developments drove the LOB stock higher.
This bank holding company is expected to post quarterly earnings of $0.41 per share in its upcoming report, which represents a year-over-year change of -46.1%. Revenues are expected to be $112.84 million, up 2.2% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Live Oak Bancshares, the consensus EPS estimate for the quarter has been revised 1.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on LOB going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Live Oak Bancshares is part of the Zacks Banks - Southeast industry. Ameris Bancorp (ABCB), another stock in the same industry, closed the last trading session 0.1% higher at $36.79. ABCB has returned -24.2% in the past month.
For Ameris Bancorp, the consensus EPS estimate for the upcoming report has changed +0.4% over the past month to $1.26. This represents a change of +16.7% from what the company reported a year ago. Ameris Bancorp currently has a Zacks Rank of #3 (Hold).
Is THIS the Ultimate New Clean Energy Source? (4 Ways to Profit)
The world is increasingly focused on eliminating fossil fuels and ramping up use of renewable, clean energy sources. Hydrogen fuel cells, powered by the most abundant substance in the universe, could provide an unlimited amount of ultra-clean energy for multiple industries.
Our urgent special report reveals 4 hydrogen stocks primed for big gains - plus our other top clean energy stocks.
See Stocks Now
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report
Ameris Bancorp (ABCB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ameris Bancorp (ABCB), another stock in the same industry, closed the last trading session 0.1% higher at $36.79. ABCB has returned -24.2% in the past month. Click to get this free report Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Ameris Bancorp (ABCB), another stock in the same industry, closed the last trading session 0.1% higher at $36.79. ABCB has returned -24.2% in the past month. | Click to get this free report Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. Ameris Bancorp (ABCB), another stock in the same industry, closed the last trading session 0.1% higher at $36.79. ABCB has returned -24.2% in the past month. | Ameris Bancorp (ABCB), another stock in the same industry, closed the last trading session 0.1% higher at $36.79. ABCB has returned -24.2% in the past month. Click to get this free report Live Oak Bancshares, Inc. (LOB) : Free Stock Analysis Report Ameris Bancorp (ABCB) : Free Stock Analysis Report To read this article on Zacks.com click here. |
27699.0 | 2023-03-09 00:00:00 UTC | Ameris Bancorp is Oversold | ABCB | https://www.nasdaq.com/articles/ameris-bancorp-is-oversold-0 | nan | nan | The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Ameris Bancorp (Symbol: ABCB) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.
But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABCB entered into oversold territory, changing hands as low as $43.19 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of Ameris Bancorp, the RSI reading has hit 28.1 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 43.8. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, ABCB's recent annualized dividend of 0.6/share (currently paid in quarterly installments) works out to an annual yield of 1.34% based upon the recent $44.92 share price.
A bullish investor could look at ABCB's 28.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABCB is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue.
Click here to find out what 9 other oversold dividend stocks you need to know about »
Also see:
MFC Average Annual Return
Top Ten Hedge Funds Holding FC
Funds Holding VNSE
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A bullish investor could look at ABCB's 28.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Ameris Bancorp (Symbol: ABCB) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABCB entered into oversold territory, changing hands as low as $43.19 per share. | Indeed, ABCB's recent annualized dividend of 0.6/share (currently paid in quarterly installments) works out to an annual yield of 1.34% based upon the recent $44.92 share price. Ameris Bancorp (Symbol: ABCB) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABCB entered into oversold territory, changing hands as low as $43.19 per share. | Ameris Bancorp (Symbol: ABCB) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABCB entered into oversold territory, changing hands as low as $43.19 per share. Indeed, ABCB's recent annualized dividend of 0.6/share (currently paid in quarterly installments) works out to an annual yield of 1.34% based upon the recent $44.92 share price. | Ameris Bancorp (Symbol: ABCB) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. Indeed, ABCB's recent annualized dividend of 0.6/share (currently paid in quarterly installments) works out to an annual yield of 1.34% based upon the recent $44.92 share price. But making Ameris Bancorp an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABCB entered into oversold territory, changing hands as low as $43.19 per share. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.